Functional analysis of metallothionein-2A isoform in Breast Cancer by LIM DAINA
 FUNCTIONAL ANALYSIS OF METALLOTHIONEIN-2A ISOFORM 





[B.Appl.Sc. (Hons.), NUS] 
 
 
A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF ANATOMY 
YONG LOO LIN FACULTY OF MEDICINE 






I will like to thank the people that has been involved and contributed to this project. 
First and foremost, I will like to express my heartfelt gratitude to my supervisor and head of 
department, Prof Bay Boon Huat, for providing me an opportunity to pursue my PhD degree in the 
Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore (NUS). 
His dedicated guidance, support and encouragement have played an important part in making this 
project a successful one. Next, I will like to thank my co-supervisor, Dr. Yip George Wai Cheong, for 
his helpful suggestions and guidance in this project.  
I am grateful to my friends, Ms Koo Chuay Yeng for her encouragements, invaluable 
discussions and help on the analysis of the breast cancer clinicopathological data; Ms Alice Zin Mar 
Lwin for support and technical assistance during my pregnancy; Mr Lai Yiyang, Ms Yu Yingnan, Ms 
Yvonne Teng Huifang, Ms Grace Leong Shuxian, Ms Li Yinghui and all the present and former 
members from Prof Bay Boon Huat’s and Dr. Yip George Wai Cheong’s groups for their valuable 
discussion and friendship.  
My special thanks go to Dr. Liu Yang for his contribution on the structural modelling of the 
MT-2A protein mutant. I will like to express my appreciation to collaborators in the Department of 
Microbiology, Prof Sim Tiow Suan and Dr. Maurice Chan for the technical assistance rendered in the 
construction of the MT-2A overexpression vectors.   
I will like to thank the Department of Pathology, Singapore General Hospital for providing the 
breast cancer tissues sections and breast cancer TMAs. In particular, I am grateful to our collaborator, 
Assoc Prof Tan Puay Hoon (Department of Pathology, SGH) for the collaboration in this project and 
ACKNOWLEDGEMENTS 
 
    ii 
her guidance on the morphology of various breast pathology specimens; and Dr. Aye (Department of 
Pathology, SGH) for her guidance and verification on the MT immunostaining in breast TMAs.  
I will like to express my gratitude to the staff, with special thanks to Ms June Koh, in the core 
facilities of the teaching laboratory in the Department of Microbiology (NUS) for the use of the 
ABI7000 real-time PCR machine; Department of Pharmacology (NUS) for the use of Tecan2000 
absorbance plate reader with special appreciation to Mr Wong Yong Jie (Department of Pharmacology, 
NUS) for his help. 
My apologies to those whom I have not mentioned by name I am indebted to them in many 
ways they have helped me.  
I will like to pay tribute to my husband, son and my immediate family members whose 
immense love and tremendous support has made this work possible. 
Last but not least, I will like to show my appreciation to National University of Singapore for 
providing me the research scholarship to pursue my PhD degree.
TABLE OF CONTENTS 
 
    ii 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS....................................................................................................................... i 
SUMMARY.............................................................................................................................................. vi 
PUBLICATIONS .................................................................................................................................... ix 
LIST OF ABBREVIATIONS................................................................................................................... x 
LIST OF FIGURES.............................................................................................................................. xiii 
LIST OF TABLES................................................................................................................................. xvi 
CHAPTER 1 INTRODUCTION ............................................................................................................. 1 
1.1 Breast anatomy and development...................................................................................................... 2 
1.2. Breast cancer..................................................................................................................................... 4 
1.2.1. Classification of breast lesions ............................................................................................................... 4 
1.2.1.1. Benign breast disorders .......................................................................................................................................5 
1.2.1.2. Non-invasive breast cancer .................................................................................................................................6 
1.2.1.3. Invasive breast cancer .........................................................................................................................................7 
1.2.2. Epidemiology of breast cancer ..............................................................................................................11 
1.2.3. Breast cancer symptoms and treatment .............................................................................................. 13 
1.2.3.1. Surgery ..............................................................................................................................................................13 
1.2.3.2. Radiotherapy .....................................................................................................................................................14 
1.2.3.3. Chemotherapy ...................................................................................................................................................17 
1.2.3.4. Hormonal therapy..............................................................................................................................................18 
1.2.3.5. Targeted therapies..............................................................................................................................................20 
1.2.4. Risk factors of breast cancer ................................................................................................................ 20 
1.3. Cancer progression ......................................................................................................................... 22 
1.3.1. Cell proliferation ................................................................................................................................... 22 
1.3.2. Cell migration and invasion ................................................................................................................. 24 
1.3.3. Cell death ............................................................................................................................................... 25 
1.4. Biomarkers in breast cancer........................................................................................................... 30 
1.5. Metallothionein ............................................................................................................................... 31 
1.5.1 Biology of Metallothionein .................................................................................................................... 31 
1.5.2 Structure of MT...................................................................................................................................... 32 
1.5.3. Protective effects of MT........................................................................................................................ 34 
1.5.3.1 Oxidative stress ..................................................................................................................................................34 
1.5.3.2 Radiation ............................................................................................................................................................35 
1.5.3.3 Infections............................................................................................................................................................35 
1.5.3.4 Alkylating agents................................................................................................................................................36 
1.5.4. MT isoforms........................................................................................................................................... 37 
1.5.5. MT and cancer....................................................................................................................................... 38 
TABLE OF CONTENTS 
 
    iii 
1.6. Gene silencing ................................................................................................................................. 39 
1.6.1. Overview of gene silencing ................................................................................................................... 39 
1.6.2. Mechanism of RNA interference.......................................................................................................... 40 
1.6.3. RNAi as a tool for gene analysis........................................................................................................... 42 
1.7. Scope of study.................................................................................................................................. 44 
CHAPTER 2 MATERIALS AND METHODS ..................................................................................... 46 
2.1. Antibodies and reagents .................................................................................................................. 47 
2.2. Cell culture ...................................................................................................................................... 47 
2.2.1. Maintenance of cell lines....................................................................................................................... 47 
2.2.2. Cryopreservation of cells ...................................................................................................................... 48 
2.3. Downregulation using siRNA transfection .................................................................................... 49 
2.3.1. Optimization of siRNA transfection .................................................................................................... 49 
2.3.2. Silencing in MCF-7 breast cancer cells ............................................................................................... 49 
2.4. Cloning and overexpression of MT-2A .......................................................................................... 50 
2.5. Quantitative real-time PCR............................................................................................................. 51 
2.5.1 Extraction of total RNA..................................................................................................................... 51 
2.5.2 cDNA synthesis ................................................................................................................................... 52 
2.5.3 Quantitative real-time PCR .............................................................................................................. 52 
2.6. Automated Flow Cell Sorting (FACS)............................................................................................ 54 
2.7. Immunocytochemistry..................................................................................................................... 55 
2.8. Growth curve analysis..................................................................................................................... 55 
2.9. Cell proliferation assay ................................................................................................................... 56 
2.10. Cell adhesion assay ....................................................................................................................... 56 
2.11. Cell cycle analysis.......................................................................................................................... 57 
2.12. Cell migration assay...................................................................................................................... 58 
2.13. Invasion assay ............................................................................................................................... 59 
2.14. Superarray analysis....................................................................................................................... 60 
2.15. Immunoblot analysis..................................................................................................................... 62 
2.15.1. Protein extraction................................................................................................................................ 62 
2.15.2 Preparation of protein sample ............................................................................................................ 62 
2.15.3. Preparation of resolving and stacking gel ......................................................................................... 63 
2.15.4. SDS-PAGE ........................................................................................................................................... 64 
2.15.5. Transfer of proteins............................................................................................................................. 64 
TABLE OF CONTENTS 
 
    iv 
2.16. Electron microscopy...................................................................................................................... 65 
2.16.1 Transmission electron microscopy...................................................................................................... 65 
2.16.2. Scanning electron microscopy............................................................................................................ 66 
2.17. Scanning transmission ion micro-tomography (STIM) .............................................................. 66 
2.18. Statistical analysis ......................................................................................................................... 66 
2.19. MT staining in invasive ductal breast carcinoma tissues ............................................................ 67 
2.19.1. Patients and tissues ............................................................................................................................. 67 
2.19.2. Tissue microarrays .............................................................................................................................. 67 
2.19.3. Clinicopathological parameters of patients of invasive ductal carcinomas ................................... 68 
2.19.4. Immunohistochemical staining .......................................................................................................... 71 
2.19.5. Scoring system ..................................................................................................................................... 71 
2.19.6. Statistical analysis ............................................................................................................................... 72 
CHAPTER 3  RESULTS ..................................................................................................................... 73 
3.1. Morphology of breast cell lines....................................................................................................... 74 
3.2. Expression of MT in breast cell lines ............................................................................................. 76 
3.3. Transfection in MCF-7 ................................................................................................................... 78 
3.4. Down-regulation of MT-2A ............................................................................................................ 81 
3.5. Morphological changes after down-regulation of MT-2A............................................................. 85 
3.6. Specificity of MT isoforms.............................................................................................................. 88 
3.6.1. Down-regulation of MT-1F................................................................................................................... 88 
3.7. Effect of down-regulation of MT-2A on cell proliferation ............................................................ 90 
3.8. Effect of down-regulation of MT-2A on cell adhesion of breast cancer cells............................... 94 
3.9. Effect of down-regulation of MT-2A on migration of breast cancer cells .................................... 95 
3.10. Invasion of MCF-7 cells ............................................................................................................... 98 
3.11. Cloning and expression of MT-2A plasmids................................................................................. 98 
3.12. Overexpression of MT-2A in MCF-7 cells.................................................................................. 100 
3.13. Structure of MT-2A and MT-2A’................................................................................................. 102 
3.14. Effect of overexpression of MT-2A on cell proliferation ........................................................... 103 
3.15. Differential effects of overexpression of MT-2A and MT-2A’ on cell migration ...................... 105 
3.16. Differential expression of cancer related genes......................................................................... 107 
3.17. Differential expression of cell cycle related genes ......................................................................111 
3.18. Differential expression of cell cycle related proteins ..................................................................116 
TABLE OF CONTENTS 
 
    v 
3.19. Differential expression of metastasis related proteins ................................................................119 
3.21. Expression of MT in invasive ductal breast carcinoma tissues................................................. 121 
3.22. Association of MT cytoplasmic staining with clinicopathological parameters......................... 126 
CHAPTER 4  DISCUSSION............................................................................................................. 137 
4.1. General discussion ........................................................................................................................ 138 
4.2. MT-2A and cell proliferation in breast cancer cells..................................................................... 139 
4.2.1. General overview of cell proliferation............................................................................................... 139 
4.2.2. Role of MT-2A in cell proliferation.................................................................................................... 141 
4.2.2.1. In vitro studies.................................................................................................................................................141 
4.2.2.2. Clinicopathological associations of MT with cell proliferation ......................................................................147 
4.3. MT-2A and breast cancer metastasis ............................................................................................ 151 
4.3.1. General overview of cancer metastasis.............................................................................................. 151 
4.3.2. Role of MT-2A in cancer metastasis .................................................................................................. 152 
4.3.2.1. In vitro assay ...................................................................................................................................................152 
4.3.2.2. Associations of MT-2A with lymph node metastasis in breast cancer patients ...............................................155 
CHAPTER 5  CONCLUSIONS  AND  FUTURE STUDIES ...................................................... 156 
5.1. Conclusions ................................................................................................................................... 157 
5.2. Future studies................................................................................................................................ 159 
References ............................................................................................................................................ 161 
SUMMARY 
 
    vi 
SUMMARY 
Breast cancer is one of the most prevalent cancers in women worldwide. The rate of breast cancer 
has been increasing rapidly. Invasive ductal carcinoma makes up the bulk of all breast cancer cases. 
There has been a surge in the research on biomarkers in breast cancer for better evaluation and 
management of the disease. Metallothionein (MT) is a cysteine rich, low molecular weight protein that 
has a protective function against heavy metal detoxification, oxidative stress, radiation, infections and 
alkylating agents. MT has also been found to be associated with cell proliferation and apoptosis which 
has lead to the implication of MT in carcinogenesis.  
MT expression has been shown to be associated with a higher grade, more aggressive breast cancer 
and poorer prognosis. Despite so, the exact mechanism by which MT has had an impact on breast 
cancer has not been elucidated. Furthermore, there are ten functional isoforms in human, with MT-2A 
being the most abundant isoform in breast cancer. The exact roles of the individual MT isoforms in 
cancer progression have yet to be identified. This study aims to examine the functional roles of the 
most abundant MT isoform, MT-2A, in breast cancer progression.  
The results in this study showed that MT-2A has an effect on cell proliferation, cell death and 
metastasis in breast cancer. The data demonstrated that down-regulation of MT-2A in breast cancer 
cells led to an increase in cell death and a decrease in cell proliferation (with a rise in the sub G1 and 
G1 phase of the cell-cycle), while overexpression of MT-2A led to a significant increase in the G2/M 
phase of the cell cycle. Analysis of the expression of several cancer pathway-related and cell cycle-
related genes has shown significant altered regulation of several genes at both mRNA and protein level. 
MT-2A is postulated to affect the cell-cycle and cell proliferation via the ATM/Chk2/Cdc25a pathway. 
The gene expression results also indicated that another possible pathway by which MT-2A regulates 
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cell proliferation is via the cyclin G1 or cyclin C/cdk8 pathway. Down-regulation of MT-2A also 
affected cell death as there was an apoptotic peak at the sub-G1 phase and SEM pictures had shown an 
increase in apoptotic bodies. Gene analysis revealed that this effect may be mediated via an increase in 
Bax or Cyclin G1 expression. In addition, it was also observed that cells, in which MT was down-
regulated, exhibited signs of entosis (a cell-eat-cell phenomenon) under TEM.  
The data has shown for the first time that MT-2A has an effect on metastasis. Down-regulation of 
MT-2A resulted in a significant decrease in the number of cells migrating through the transwell 
membrane while overexpression of MT-2A produced an opposite effect. It was shown that this 
phenomenon was specific to MT-2A isoform alone as down-regulation of MT-1F isoform was shown to 
have no significant effect on cell migration. From the gene expression analysis results, it is posited that 
MT-2A expression influences cell migration via differential regulation of the uPAR protein, through c-
Met. The uPA system is involved in metastasis and angiogenesis with uPAR being the primary 
modulator of the system.  
Moreover, cloning of the MT-2A gene has led to identification of a naturally occurring deletion 
mutant of the MT-2A gene, MT-2A’. The deletion mutant was found to have 8 amino acids lacking in 
the amino terminus. Through reconstruction of MT-2A’ protein structure, the folding of the amino 
terminus was found to be affected. The deletion mutant was shown to have no difference to the native 
protein with regard to cell-cycle progression but was found to have a lesser potency in cell migration. 
Perhaps, cell migration via MT-2A mediation is dependent on the number of divalent ions MT-2A 
carries. 
MT expression was also examined in breast cancer tissues in a TMA format using general MT 
antibodies which recognises all MT isoforms. MT staining was observed to be present in both the 
cytoplasm and nucleus of the tumour cells. MT was documented to be expressed in the cytoplasm of 
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the cancer cells in 122 cases (87.1 %), with only 18 cases (12.9 %) exhibiting no staining in the 
cytoplasm of the tumour cells. The percentage of MT staining in the nucleus was found to be relatively 
similar to the cytoplasm with 118 cases (84.3 %) showing positive MT staining and only 22 cases (15.7 
%) showing absence of MT staining in the nucleus. The staining of MT was classified into two groups; 
presence or absence of MT staining and low and high MT staining for both cytoplasmic and nuclear 
staining. A significant relationship was found between MT staining with higher grade tumour; higher 
lymph node stage; absence of ER and closely related to PCNA staining. This verifies that MT 
expression is closely related to proliferation and metastasis. Hence from the in vitro and 
clinicopathological studies, it is concluded that MT-2A expression has an intimate relationship with cell 
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1.1 Breast anatomy and development 
The mammary glands are situated in the anterior part of the chest wall and are responsible for 
secreting milk to provide nourishment for the young. The external features of a normal breast consist of 
the nipple, areola, tubercles and some glands (Gray 1918). The internal structure of the breast is a 
secretory organ which includes lobules which are milk producing glandular structures that are 
supported by fibrovascular and adipose tissue for nutrition (Figure 1).  
 
Figure 1. Anatomical representation of the adult female breast. Enlargement shows the arrangement of 
the ductal cells in a normal duct.  
 
The glandular tissue includes an assembly of ducts that is responsible for transporting milk from 
the glands to the nipple. The ducts consist of an inner layer of secretary epithelial cells lining the lumen 
and an external layer of myoepithelial cells around a basal membrane. The outer layer of myoepithelial 
INTRODUCTION 
 
    3 
cells has the ability to contract to facilitate the transport of milk. Mammary glands are situated at the 
other terminal of the ducts. Each lobule consists of about twenty small glandular acini which open into 
terminal duct. The ducts and lobules are surrounded by connective tissues which include fibrous and 
adipose tissue, nerves and blood and lymphatic vessels for support and nutrients (Cooper 1840). The 
anatomical representation of the breast is shown in Figure 1.  
The female breast undergoes numerous development stages throughout life. These stages are 
generally classified as during fetal development, adolescence and child-bearing years (Townsend et al. 
2007). The relative proportion of glandular, fibrous and adipose tissue varies with the age, menstrual 
cycle, pregnancy and nutritional status of the individual.   
Histologically, the initial stage of breast development starts around 4 weeks in the fetus during 
gestation with the thickening of the mammary ridge and at 6 weeks the fetus will have developed the 
milk line all the way from the armpit to the groin on both sides (Dawson 1954). However usually the 
breast will only develop in the chest region and the remaining of the milk line will regress (Howard and 
Gusterson 2000). At around 16 weeks of gestation, the formation of hollow milk ducts from mammary 
buds takes place with each breast having a separate duct to the nipple. At birth, the newborn mammary 
tissue contains milk ducts and the nipple (McKiernan et al. 1988).  
In a female, during puberty at around 8 to 13 years of age, estrogen will trigger changes in the 
mammary glands. With ample fat accumulation, the breasts enlarge. The ductal system in the breast 
also develops with tiny groups of cells form at the ductal openings. These groups of cells will form the 
alveoli cells, which are responsible for secreting and storing milk during lactation. With each menstrual 
cycle, the maturation and growth of the ductal tissue takes place (Anderson et al. 1982). The breast 
epithelium between puberty and the first pregnancy is immature and does not respond fully to 
circulating progesterones (Drife 1984). 
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The breasts are only fully developed when a woman has given birth and produced milk (Drife 
1986). During pregnancy, there is rapid growth of the mammary gland and the epithelial cells are able 
to differentiate into milk producing alveoli (Lochter 1998). This is governed by the surge in estrogen to 
produce more ducts and progesterone to produce more lobules. In addition, there are many other 
hormones such as follicle stimulating hormone, luteinizing hormone, prolactin, oxytocin and human 
placental lactogen that play vital roles in milk production.  
  During menopause, the level of estrogen in a women’s body starts to decline dramatically. This 
results in the connective tissues of the breast becoming inelastic and dehydrated, with an eventual loss 
of shape and shrinking of the breasts.  
 
1.2. Breast cancer 
1.2.1. Classification of breast lesions 
As the pathological examination of the diseased breast requires morphological study, detailed 
histological assessment is important in the diagnosis and treatment of the disease. Breast lesions 
include benign disorders, simple hyperplasia, atypical hyperplasia, in situ carcinoma to invasive 
carcinoma (Polyak 2001; Seow et al. 2004). The distinction between benign and malignant stages is not 
always definite as it is a morphological manifestation of the disease progression. The stages of cancer 
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Figure 2. Breast cancer progression – in a normal duct.  
 
1.2.1.1. Benign breast disorders 
Benign breast disorder includes a heterogeneous group of breast lesions that is presented as an 
abnormal mass. Benign breast lesions are also known as fibrocystic disease. Benign breast lesions are 
categorized into three categories: non-proliferative lesions, proliferative lesions without atypical 
hyperplasia and proliferative lesions with atypical hyperplasia (Harris et al. 2004).  
Non-proliferative lesions include cysts, fibroadenomas, intraductal papilloma, fibrosis and 
mastitis. Such lesions have no increased risk for breast cancer. Proliferative lesions without atypical 
hyperplasia include complex fibroadenoma, sclerosing adenosis or solitary papilloma without atypical 
hyperplasia. The excessive proliferation of the epithelial layer surrounding the lumen is the main cause 
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for hyperplasia. This can occur in the ducts (ductal hyperplasia) or lobules (lobular hyperplasia). 
Hyperplasia is usually non-cancerous and occurs as the breast changes or ages. Moderate and severe 
hyperplasia has an increased risk of breast carcinoma by 1.5 - 2 folds (Dupont and Page 1985). 
Proliferative lesions with atypical hyperplasia include atypical ductal hyperplasia and atypical lobular 
hyperplasia. Atypical hyperplasia is a category in which the lesion is abnormal and has a malignant 
risk. Atypical hyperplasia shows features of both simple hyperplasia and carcinoma in situ. These 
include cytological and histopathological features in the lesions. Proliferative lesions with atypical 
hyperplasia result in a moderately elevated risk for breast cancer (Rosens 2008).  
 
1.2.1.2. Non-invasive breast cancer 
Non-invasive breast cancer is also known as breast cancer in situ. There are two forms of such 
breast cancer: ductal cancer in situ (DCIS) or lobular cancer in situ (LCIS). DCIS accounts for most of 
the non-invasive cancers (Polyak 2001). DCIS is the pre-invasive malignant proliferation of the breast 
epithelial cells which consists of an uncontrolled mass of epithelial cells that have undergone malignant 
changes but still contained within the mammary epithelial structures. There is absence in the invasion 
of basement membrane and no visible infiltration of breast stroma. The inner luminar cells are 
cancerous in nature but are contained within the duct (Rosens 2008). However it may affect just one 
area of the breast or may affect different areas of the breast at the same time. This is also known as the 
pre-cancer stage of breast cancer. However, if left untreated for a period of years, it may continue 
developing. Classification of DCIS is based on its morphological growth pattern and the cytological 
abnormalities or grade. Once it breaks through the ducts to invade into normal surrounding tissues, it 
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will be classified as invasive cancer. There are three grades of DCIS: low, intermediate and high. The 
grade shows how the cells look under microscope and gives an idea of how quickly the cells may 
develop into invasive cancer or the recurrence of the cancerous cells after excision. With proper 
treatment, DCIS is unlikely to develop into invasive cancer.  
 
1.2.1.3. Invasive breast cancer 
Invasive ductal breast cancer is the most common form of invasive breast cancer accounting for 
most of the invasive breast cancer. This occurs when the cancerous cells that originate from the ductal 
cells infiltrate into the surrounding normal tissues of the duct. Other forms of invasive breast cancer 
include lobular breast cancer, which as the term suggests, derives from the lobules of the breast. Breast 
cancer is a heterogeneous disease accompanied by varying phenotypes such as growth, invasion and 
angiogenesis in different patients. Clinically, parameters that are examined to better understand the 
status of the disease in each patient include tumour size, tumour stage, histological grade, nuclear 
grade, hormone receptor status and proliferation capactity (Harris, et al. 2004). A new classification of 
breast cancer has been developed as the previous TNM categorization was no longer applicable with 
the evolution of the medical practice in the last decade. The latest revision to the American Joint 
Committee on Cancer (AJCC) staging system for breast cancer has been has been reviewed (Singletary 
and Connolly 2006; Thor 2004). The new system together with several of the parameters that are used 
in the analysis of the clinicopathological data will be discussed. Similar to the old system, staging 
comprises of pathological and clinical staging; where pathological staging includes all information 
from physical examination, imaging, and histological details from biopsies while clinical staging 
includes the information from the excised tumour and further examinations for the presence of 
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metastasis. The new staging classification has also included guidelines for management of 
microinvasion, multiple carcinomas and inflammatory carcinomas (Thor 2004). 
Tumour staging refers to the extent of much the tumour has spread. It usually employs the TNM 
classification of malignant tumors where the tumour size (T), axillary lymph node status (N) and the 
degree of metastasis (M). This is able to show the extent of the cancer in the patient’s body. 
Most of the amendments for the new classification were based on the measurement and size of 
the tumour. Tumour size is the measurement of the gross size of a mammary carcinoma. As most 
tumors are asymmetrical shapes, the measurement is based on the greatest diameter. In the old system, 
this was usually an approximation as benign tissue embedded between the invasive tumour may 
constitute to the size of the tumour as well but in the revised system, this measurement should be 
recalculated and increased accordingly if a significant portion of the tissue has been removed 
previously for prior diagnostics (Thor 2004). In addition, the revised tumour size system involves the 
measurement of the largest focus of the invasive tumour and does not require a separate classification 
for smaller adjacent tumors. For tumour size, scoring is ranges from T0, Tis to T1 – 4, T0 depicts no 
evidence of primary tumour; Tis means presence of cancer in situ, T1 for tumour less than 2 cm in size; 
T2 for tumors between 2 – 5 cm in size; T3 for tumors larger than 5 cm in size and T4 for tumors of 
any size that extend into the chest or skin. Most of the revision for the invasive tumor staging involves 
T1 category, where it has been further subdivided into size to include microinvasion (T1mic). T1 
category has been subdivided into T1mic (microinvasion less than 0.1 cm); T1a (0.1 - 0.5 cm); T1b 
(0.5 – 1.0 cm); T1c (1.0 – 2.0 cm). As for microinvasion, the measurement involves that of the largest 
focus instead of the sum of each focus. Some amendments had also been made to the T4 category to 
include several subcategories to include edema and inflammatory carcinoma. The new staging system 
also provided guidelines for stimultaneous bilateral breast cancer to be separately staged as individual 
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cancers.  
The new staging system involves further subcategorization and an inclusion for sentinel lymph 
node examination (Ozmen and Cabioglu 2006). In general, the examination of nodal status requires 
either at least six level 1 lymph nodes examined or mapping of a sentinel node. For nodal status, 
scoring ranges from X, 0 – 3, NX depicts that metastasis cannot be assessed; N0 is no regional lymph 
node metastasis; N1 is metastasis to one to three axillary lymph node(s) or in internal mammary nodes 
with microscopic disease detected by sentinel lymph node dissection; N2 is metastasis to four to nine 
axillary lymph nodes or in clinically apparent lymph nodes in the absence of axillary lymph node 
metastasis; N3 is metastasis to ipsilateral internal mammary lymph node(s) and supraclavicular nodes. 
Furthermore, the size of the spread of cancer to the regional nodes is also required to be included in 
pathology reports. As sentinel lymph node examination has been the norm for node-negative cases, the 
new AJCC guidelines have also included a section on it. A separate identifier “sn” is added to the TNM 
classification if sentinel lymph node examination has been done. This category is divided into pN0(i-) 
where no regional lymph node metastasis found histologically, negative by immunohistochemistry; 
pN0(i+) where no regional lymph node metastasis found histologically, positive by 
immunohistochemistry but no larger than 0.2 mm; pN0(mol-) where no regional lymph node metastasis 
histologically and negative molecular findings; pN0(mol+) where no regional lymph node metastasis 
histologically and positive molecular findings (Pugliese et al. 2008). For metastasis, scoring is either 0 
or 1, 0 depicts no distant metastasis while 1 depicts distant metastasis detected. The new staging system 
had reclassified supraclavicular lymph node metastasis to N3 category (Thor 2004). 
After examination of these three factors (tumor size, axillary lymph node status and metastasis), 
the pathologist can then assign the overall stage of the cancer as 0, I, II, III or IV (Escobar et al. 2007): 
In the new tumor staging system, all invasive carcinoma except medullary carcinoma should be 
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graded (Thor 2004). Grading of the tumor is the estimation of differentiation. Grading of the cancer is 
only limited to the invasive part of the tumor. Histological grading describes the microscopic growth 
and cytological features of differentiation of the invasive ductal carcinoma. The Nottingham Combined 
Histological Grading System was recommended by the new cancer staging manual (Thor 2004). This 
involves the degree of tubule or gland formation, mitotic index and nuclear pleomorphism of the cancer 
cells or otherwise also known as nuclear grade. There is a scale of 1 – 3 for each of these criteria. For 
tumor tubule formation, the presence of more than 75 % of the tumor cells arranged in tubule has a 
score of 1; 10 – 75 % has a score of 2 and less than 10 % has a score of 3. Tumour mitotic activity is 
examined at low scanning power of 100X to identify the area with the highest mitotic activity before 
proceeding to high magnification of 400X magnification. A total of 10 power fields are examined for 
each cancer patient. Less than 10 mitosis was given a score of 1, 10 – 20 mitosis a score 2 and more 
than 20 a score 3. For nuclear pleomorphism, score 1 refers to relatively small, uniformly sized and 
shaped nuclei with dispersed chromatin patterns and without a prominent nuclei; score 2 refers to 
intermediate sized nuclei with nucleoli and pleomorphism to some extent; score 3 refers to relatively 
large nuclei that contain prominent nucleoli or multiple nucleoli and varying size and shape with coarse 
chromatin patterns. The sum of the three scores from tubule formation, tumour mitotic activity and 
nuclear pleomorphism gives the Bloom-Richardson’s score. A Bloom-Richardson score of 3 – 5 shows 
the tumour is well differentiated and has a low grade (grade 1), a score of 6, 7 shows the tumour is 
moderately differentiated and has a intermediate grade (grade 2) and a score of 8, 9 shows the tumour 
is poorly differentiated and has a high grade (grade 3). Furthermore, there is a new subcategory that 
allocates cases where therapies have been administered prior to surgery as these will alter the 
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1.2.2. Epidemiology of breast cancer 
Breast cancer has been rated one of the most prevalent cancer in women. Its incidence and 
death rate is modified by countless of environmental, reproductive, hereditary and dietary influences. 
Its rate is increasing rapidly every year (Seow, et al. 2004), with the highest incidence rate among all 
the cancers in females in Singapore (Figure 3).  
 
Figure 3. Ten most frequent cancers in females (Adapted with permission from Seow et al, 2004)  
 
Breast cancer also has the highest incidence rate compared to other forms of cancer in females 
of 26 % (178,480 cases) in the United States (Jemal et al. 2007). In the United States, there was a total 
of 394,891 cases of invasive breast cancer and 59,837 cases of in situ breast cancer from 1975 to 2003 
in women 40 years old and above in the nine oldest SEER cancer registry areas of the U.S. (Jemal, et 
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al. 2007). The rising incidence is reflected by the increased use of mammography screening for women 
above 45 years of age and decreased use of postmenopausal hormone replacement therapy (HRT) in 
peri and/or postmenopausal women 50-69 years old.  
The death rate due to breast cancer has been declining through the years in developed countries 
such as United States from 32.69 per 100,000 in 1991 to 25.19 per 100,000 in 2003 (Jemal, et al. 
2007). This may be due to more effective therapies available for women who develop breast cancer. 
Women who are diagnosed with breast cancer in stage 1 have a higher survival rate than those 
diagnosed with stage 2 or stage 3 cancers.  
This has led to the identification of biomarkers in breast cancer to indicate the risk, presence, 
status, or future behavior of cancers, as well as in the management of tumours. With this, the molecular 
mechanisms of the cancers and their treatment can be better understood. Several biomarkers in breast 
cancer, including oestrogen receptor, progesterone receptor, bcl-2, E-cadherin and metallothionein, 
have been identified as potential biomarkers (Cherian et al. 2003; Esteva and Hortobagyi 2004; 
Giancotti 2006; Nicolini et al. 2006).  
Breast cancer is the most common form of cancer in Singaporean women, accounting for 
around 29.4 % of all the cancer cases in 2001 - 2005. This is followed by colorectal cancer, which 
accounts for less than half of that in breast cancer (14.4 % of the total cancer cases). Breast cancer 
remains as the highest ranking cancer in the three major ethnic groups. The age standardized rates were 
highest in the Chinese female, followed by the Malay and Indian females. Breast cancer has the highest 
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1.2.3. Breast cancer symptoms and treatment 
Breast cancer in its early stage is usually painless. The typical first symptom of breast cancer is 
a lump in the breast (Bullough 1980). However 90 % of breast lumps are benign and include cysts and 
fibroadenoma. Tell-tale signs of breast cancer other than presence of lumps include thickening in an 
area of the breast, change in the size or shape of the breast, dimpling of the skin, change in shape of the 
nipple, abnormal discharges from the nipple, rash on the nipple or surrounding area or a lump in the 
armpit area (Mahoney et al. 1977). Despite so, there are many breast cancers in the early stages which 
go undetected as they do not produce any symptoms and cannot be felt by examination. Most of the 
time, these cancers can only be detected by a mammogram. 
 There are several treatment methods for breast cancer patients. The treatment options include 
surgery, chemotherapy, radiation therapy, hormonal therapy and targeted therapies. These different 




Surgery is a form of local control of cancer. The two major types of surgeries for breast cancer 
are lumpectomy and mastectomy. Lumpectomy is also known as “breast conserving” or “breast 
preservation” surgery. In this surgery, only the tumour and some normal surrounding tissues are 
removed. However the amount of tissues to be removed varies greatly from patient to patient. 
Radiation is usually given after lumpectomy (Poortmans et al. 2008). 
 Mastectomy is the surgery to remove the whole breast. There are five different types of 
mastectomy: total mastectomy, modified radial mastectomy, radial mastectomy, partial mastectomy and 
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subcutaneous mastectomy.  
 Total mastectomy includes removal of the whole breast. This usually does not involve removal 
of lymph nodes unless they are embedded in the breast tissue. The surgical perocedure does not include 
the muscles beneath the breast. Such a procedure is usually applicable to patients with multiple or large 
DCIS or who require prophylactic mastectomies to prevent the recurrence of the disease (Roses et al. 
1981).  
 Modified radial mastectomy is the removal of the whole breast together with the lymph nodes. 
In this case, the axillary lymph nodes at level I and II are excised from the underarm on the side of the 
affected breast. In this procedure, the muscles beneath the breast are not affected. Such a procedure is 
usually carried out on women with invasive breast cancer. Examination can then be carried out on the 
lymph nodes to determine if the cancer cells have spread beyond the breast (Cajucom et al. 1993; 
Hermann and Steiger 1978).  
 Radical mastectomy is the most extensive form of breast surgery where the whole breast and 
level I, II and III lymph nodes beneath the armpits are removed. The chest wall muscles beneath the 
breast are also removed (Handley and Thackray 1969). This form of surgery was common in the past 
for women diagnosed with breast cancer. Today, this type of surgery is only performed in women who 
have the cancer spread to the chest muscles beneath the breast, as it is a massive procedure and can 
result in disfigurement.  
 
1.2.3.2. Radiotherapy 
Radiation is a form of localised treatment for breast cancer which makes use of ionizing 
radiation to destroy cancer cells. The high energy beams damages the DNA of the cells, making it hard 
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for the cells to continue growing or dividing. Radiotherapy only affects the cells that are in the range of 
the beam. Although these beams damage both normal and cancer cells, most cancer cells will recover 
from the injury and function properly. This is not so for cancer cells as the DNA repair machinery in 
cancer cells has been inhibited. The areas that are treated with radiation in breast cancer can be the 
breast tissue, lymph nodes or another neighbouring part of the breast. Radiotherapy is usually used 
after lumpectomy or mastectomy in some cases. Radiotherapy is essential as it reduces the recurrence 
of the cancer by eliminating any cancer cell from the surrounding tissue and increases survival of the 
patients (Clarke et al. 2005). Radiation is shown to reduce the risk of recurrence after lumpectomy 
(Fisher et al. 1989; Poortmans, et al. 2008). Furthermore, radiation was shown to lower the risk of 
cancer recurrence in patients with small tumour size. Other than use after lumpectomy or mastectomy, 
radiotherapy can also be used in metastatic breast cancer patients at the site of metastasis to shrink the 
tumour. This will relieve the symptoms and control the spread of cancer.  
There are two methods to deliver radiation to the targeted site: external radiation (from outside 
the body) and internal radiation (from inside the body).  
External radiation is the most common form of radiation (Moore-Higgs 2006). In this method, a 
large machine known as the linear accelerator aims a beam of high energy radiation at the affected area. 
In this case, the whole breast is being treated. Other forms of external radiation include external beam 
partial-breast radiation and intraoperative radiation. External beam partial-breast radiation is a 
technique where only a localized section of the breast is exposed to the high energy beam. 
Intraoperative radiation is used after surgery where a single high dose of high energy radiation is given 
to the original site of cancer. Intraoperative radiation is usually used after lumpectomy.  
Internal radiation or brachytherapy is a new technique that is still being studied by researchers. 
This method is specially designed for the patients who have undergone lumpectomy. This involves the 
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use of radiation from within the body by placing some radioactive materials, known as seeds, in the 
area of the cancer. These will emit radiation into the surrounding tissue. The radioactive seeds will then 
emit radiation to the surrounding tissue to remove any remaining cancer cells. These radioactive seeds 
can be injected directly into the tumour, a body cavity, an area where the cancer has been removed, 
intravenously or orally (Keller et al. 2005). Internal radiation is most commonly delivered using multi-
catheter or a balloon catheter device (Moore-Higgs 2006). Multiple catheters are sewn underneath the 
skin at the site of cancer where the end of the tube sticks out through the skin for delivery of 
radioactive seeds. For balloon catheter, a special tube with a balloon at one end positioned above the 
cancer site is inserted, with MammoSite being the most widely used method (Streeter et al. 2003). The 
balloon is filled with fluid to hold it in place. A radioactive seed is then inserted to the center of the 
balloon. The use of internal radiation has several benefits over external radiation. The treatment 
duration for internal radiation is much shorter as compared to external radiation. Radiation is only 
applied to the region where cancer recurrence is the highest. The other areas are not affected by 
radiation and hence lowering of side effects is experienced.  
Side effects from radiotherapy are a result of damaging the surrounding normal tissue during 
the process of killing the cancer cells. The side effects experienced with radiotherapy varies with each 
individual. Some patients do not experience any side effects at all. Most of these side effects are short 
lived and usually disappear few months following the completion of the radiotherapy. One of the 
common side effects experienced include skin changes such as drying, itching and blistering. This is 
especially so in external radiation where the high energy beam may damage the outermost layer of 
skin. Such symptoms can be easily relieved by the use of creams and lotions to soothe the skin. 
Another common side effect is experience of fatigue. Other side effects include increased skin 
sensitivity, skin discoloration, chest pain, heart problems, lung problems and lowered white blood cell 
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counts (Wengstrom et al. 2000).   
 
1.2.3.3. Chemotherapy 
Chemotherapy is the term for the use of chemical agents to stop the cancer cells from growing. 
Chemotherapy is used in breast cancer patients to destroy cancer cells and reduce the tumour size. One 
of the main advantages of chemotherapy is that it is able to destroy cancer cells that are far away from 
the original site of cancer. Chemotherapy can be administered intravenously or orally depending on the 
drug used (Findlay et al. 2008; O'Neill and Twelves 2002). The type of drug to be used differs with 
every cancer patient. This is because every cancer patient has different cancer factors such as tumour 
size, lymph node involvement, histological grade, hormone receptor status and various oncogene 
expressions and also the overall health of the patient has to be considered (McArthur and Hudis 2007). 
Research has shown that the use of chemotherapy is more common in patients with a larger tumour size, 
higher grade, human epidermal growth factor receptor-2 overexpression and younger age (Hassett et al. 
2008). Chemotherapy basically works by targeting the cancerous cells which grow in an uncontrollable 
fashion. It kills these cells by affecting the multiplication of these cells.  
The main disadvantage of chemotherapy is that it not only targets cancer cells as it generally 
targets rapidly growing cells in the body. Other cells with a high proliferation rate such as cells in the 
blood, mouth, intestinal tract and hair will be affected as well. Hence, this will give rise to several side 
effects experienced by the patients. These side effects include low red and white blood cell count, low 
platelet count, fatigue, hair loss, loss of bone matter, memory loss, neuropathy, nausea and vomiting 
(Kayl and Meyers 2006). Some of these side effects may be just temporary or causes discomfort in the 
patients while other side effects may cause delay in treatment and be detrimental to the patient’s health 
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(Partridge et al. 2001). One of the more serious side effects is low white blood cell count. This can 
delay the treatment process as the patients’ immunity to infections is being lowered (Dykes et al. 1985; 
Nobbenhuis and Cleton 1992). Several research groups have identified this problem and drugs that 
specifically target the cancer cells but not the normal proliferating cells are being explored (Chen et al. 
2000; Hartwell and Kastan 1994).  
Chemotherapy is usually also used after surgery to eliminate any clusters of cells that may have 
metastasize from the original site of cancer. This systemic approach is able to target any cancerous cells 
that are still present in body. Moreover the cells that have metastasized from the original site usually 
have a higher proliferation rate due to the higher availability of nutrients from the new site as compared 
to the initial crowded tumour site (McArthur and Hudis 2007). 
  
1.2.3.4. Hormonal therapy 
Hormonal therapy is a form of systemic treatment with the use of drugs to interfere with the 
activity of a hormone or to stop its production. This form of therapy is only applicable to breast cancer 
patients with hormone receptor positive (Bush 2007). Estrogen and progesterone are responsible for 
inducing growth in ducts and lobules in normal breast (Weinberg et al. 2005). In most of the cancer 
patients, the status of the progesterone receptors usually coincides with the status of the oestrogen 
receptors. Clinically, the presence of estrogen receptors is more important than progesterone receptors. 
Estrogen plays an important role in triggering the growth of the cancer cells with estrogen receptor site 
throughout the body and in some breast cancer cells (Bush 2007). Hence in hormonal therapy, the 
hormone antagonists used will block the receptors to disable further stimulation of cancer cells by 
estrogen. Further examination of the cancer is required to determine if hormone therapy is applicable or 
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the types of hormone therapy to be given. In such case, a hormone receptor test is carried out, where 
the amount of hormone receptors are determined in the patients cancer tissue. The more estrogen or 
progresterone receptors are present on the cancer cells; the tumour will be more responsive to the 
hormonal therapy.  
 Hormonal therapy can be given to patients with non-invasive cancer such as DCIS to prevent 
recurrence of the disease (Boughey et al. 2007). Hormonal therapy is usually used together with other 
forms of treatments for patients with invasive breast cancer. In some cases, hormonal therapy can be 
even more efficient than chemotherapy. When hormonal therapy is used prior to other treatment, it is 
known as neoadjuvant treatment. Neoadjuvant treatment is used to shrink the tumour and improve the 
effectiveness of the cancer treatment (Yuyama et al. 2000). If the hormonal therapy is given after a 
primary treatment, it is known as adjuvant therapy. Such a treatment is usually given to improve the 
chance of recovery and reduce the chance of recurrence. Furthermore, hormonal therapy can be used to 
reduce the risk in women with high risk of breast cancer.  
There are four types of hormonal therapy; namely aromatase inhibitors, SERMs (selective 
estrogen-receptor modulator), ERDs (estrogen-receptor downregulators) and ovarian shutdown or 
removal (Weinberg, et al. 2005). The type of hormonal therapy used depends on several factors which 
include status of the hormone receptors, age, tumour size and tumour staging and also whether if the 
patient is pre-menopausal or post-menopausal. These treatments may either involve prevention of the 
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1.2.3.5. Targeted therapies 
Targeted therapies are treatments that are directed at certain characteristics of cancer cells. 
Some of such characteristics include certain proteins or mutant proteins that promote the growth of the 
cancer cells. There are currently three targeted therapies for breast cancer. These are herceptin, tykerb 
and avastin (Fischgrabe and Wulfing 2008). Herceptin is a Her-2 antibody that is effective for patients 
with Her-2 positive breast cancer. Tykerb also works against Her-2 positive breast cancer in the 
advanced stage by interfering with the kinases that are responsible in the signal transduction cascade 
from the Her-2 receptor in the cancer cells. Avastin is also used in metastatic Her-2 positive breast 
cancer before chemotherapy as an immune therapy using antibodies targeted to vascular endothelial 
growth factor (VEGF). This works by blocking angiogenesis in cancer cells by binding to VEGF, as 
VEGF is responsible for the generation of new blood vessels.  
 
1.2.4. Risk factors of breast cancer  
A risk factor is a variable that associates with an increased risk of a disease such as breast 
cancer. However possessing one or more risk factors are not necessary causal to a disease. Several 
factors that are known to affect breast cancer include age and gender (Conner et al. 2008).  
Female has a much higher risk of breast cancer as compared to males. Males only constitute 
less than 1 % of all breast cancer patients (Brinton et al. 2008; Parker et al. 1997). The main reason for 
this is that the breast cells in women are constantly exposed to growth regulating hormones such as 
oestrogen and progesterone.  
Another factor that is found to affect the risk of breast cancer is race. Although white women 
are at the highest risk to develop breast cancer, African-American women are more likely to die from 
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this disease than white women. This is because they seem to develop more aggressive forms of breast 
cancer. Asian, Hispanic and Native-American have the lowest risk of developing and dying from breast 
cancer (Smigal et al. 2006).  
Many studies have also shown a high correlation of breast cancer with pregnancy. Women who 
do not have children or have children when they are more than 30 years of age have a slightly higher 
risk of breast cancer. On the contrary, women with multiple pregnancies or pregnant at a young age 
have a low risk of breast cancer. This increased risk is more pronounced in women that are more than 
30 years of age at the time of their first delivery (Li and Daling 2007; Schedin 2006). These parity 
beneficial effects were confined to oestrogen positive/progesterone positive breast cancer (Ma et al. 
2006). In addition, breast feeding is found to slightly decrease risk of breast cancer in women if 
continued for 1.5 to 2 years (Conner, et al. 2008).   
In addition, the use of hormone replacement therapy was also found to increase the risk of 
breast cancer (Cuzick 2008). Women who are undergoing menopause are usually prescribed with 
postmenstrual hormone therapy, also known as HRT. This was primarily used to relieve the symptoms 
of menopause. HRT seems to provide additional benefits such as preventing other age related illnesses, 
osteoporosis, heart disease and type II diabetes (Kirschstein 2003). However, research has shown that 
long term use of HRT results in an increase in mammographic density (Persson et al. 1997). This will 
result in lowering the efficiency in detecting breast tumours with mammography. A higher 
mammographic density is also found to be positively associated with breast cancer (Vachon et al. 
2007).     
Hereditary breast cancer accounts for 10 % of all breast cancers, while 15-20 % has a positive 
family history of this disease (Margolin and Lindblom 2006). Genetic factors that affect breast cancer 
include BRCA1 and BRCA2 (Claus et al. 1998; Frank et al. 1999; Loman et al. 2001; Narod et al. 
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1993), ATM (Chenevix-Trench et al. 2002), p53 (Glebov et al. 1994) and CHEK2 (CHEK2-Breast-
Cancer-Case-Control-Consortium. 2004; Vahteristo et al. 2002). Of these genetic risk factors, BRCA1 
and BRCA2 are found to be the most highly mutated and this mutation is present in 45 % of all 
germline mutation breast cancer cases (Kell and Burke 2007). CHEK2 and p53 mutations account for 5 
% and 1 % of all the breast cancer (Walsh et al. 2006). 
Women possessing proliferative lesions with no atypia which involves excessive outgrowth of 
breast tissue (including ductal hyperplasia, complex fibroadenoma, sclerosing adenosis and several 
papillomas) have an increased risk of 2 times as compared to normal women (Dupont and Page 1985). 
Lastly, there is a five times higher risk than normal in proliferative lesions with atypia which include 
atypical ductal hyperplasia and atypical lobular hyperplasia (Conner, et al. 2008; Dupont and Page 
1987).  
Women who start their menstrual periods at an early year of age, before 12 years (Kato et al. 
1988; Kelsey et al. 1993; Li and Daling 2007), or have menopause at a late age (after 55 years) (Kato, 
et al. 1988; Kelsey, et al. 1993) have a higher risk of developing breast cancer. This is due to longer 
exposure time to oestrogen and progesterone hormones.  
 
1.3. Cancer progression 
1.3.1. Cell proliferation 
Cell proliferation which involves the intimately linked processes of cell growth and division is a 
fundamental attribute of all life forms. The regulation of cell proliferation is usually in response to 
development, tissue repair and evolutionary fitness. A dysfunction in cell proliferation is usually the 
primary initiator and promoter in the development of cancer (Vermeulen et al. 2003). The first step of 
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the development of cancer consists of mutation of the DNA that does not undergo repair or undergoes 
faulty DNA repair. Such mutations can occur spontaneously or be brought about by carcinogens 
(Preston and Williams 2005). Carcinogens include chemicals, UV and viruses. Usually multiple 
mutations to susceptible genes are necessary before the onset of cancer. If such a mutation lies on a 
gene that is responsible for growth and proliferation, uncontrolled cell proliferation may be resulted, 
leading to the growth of an abnormal mass of cells.  
The control of cell proliferation in a normal mammary gland is a result of steroid hormone 
dependent, interaction with other hormones and cytokines. It is intimately regulated by the different 
phases in cell cycle progression. These different phases of cell cycle start with the G1 phase, also 
known as the first growth phase where the cell undergoes growth and normal metabolic roles. 
Following so, the cell will enter the synthesis phase (S phase), where DNA replication takes place. In 
between DNA synthesis and mitosis, the cell will continue to grow and synthesis new protein for 
preparation of mitosis in the second growth phase (G2 phase). At the end of this phase is the G2 
checkpoint to determine if the cell can proceed to enter the mitosis phase (M phase) for division. There 
is also another phase, the quiescence phase (sub-G1 phase), where cells are able re-enter the cell cycle 
to under go DNA replication and mitosis. Transitions out of G1 or G2 phases are regulated by specific 
cyclins and cyclin dependent kinases (CDK) which include a series of protein phosphorylation. 
Cdk1/Cdk2 and Cdk2/Cdk4/Cdk6 are responsible for transition out of G1 and G2 phases respectively 
(Vermeulen, et al. 2003). Although the levels of CDKs remain unchanged throughout the cell cycle, the 
levels of their binding partners (which include cyclins, phosphatases and kinases) fluctuate through the 
cell cycle. The accumulation of different cyclins results in the formation of different cyclin-CDK 
complexes that is essential in targeting the transition between the phases. The predominant cyclin-CDK 
complexes for the G1 phase are cyclin D–Cdk4/Cdk6 and cyclin E–Cdk2; S phase is cyclin A–Cdk2; 
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G2 phase are cyclin A–Cdk2 and cyclin B–Cdk1 (Caldon et al. 2006). There are also a set of 
checkpoints to monitor the completion of critical events and delay progression to the next stage if 
necessary. These checkpoints sense flaws in the critical events such as DNA replication and 
chromosome segregation and will delay cell cycle progression until the flaw has been repaired.  
Cell cycle machinery controls the proliferation of the cells while cancer is a condition where 
there is uncontrolled cell proliferation, allowing the presence of too many cells. This excess in cell 
number will reduce the sensitivity to external stimuli for the cell to differentiate, adhere or die. 
Although the G2/M phase of the cell cycle is important in cancer as a result of chromosomal 
aberrations, most of the alterations for breast cancer belong to the G1/S phase (Schwartz and Shah 
2005).  
Several cyclins and CDKs were found to be deregulated in breast cancer. Some markers of 
therapeutic importance include cyclin D1 and E1, CDK inhibitors such as p27, p21, p16 (Caldon, et al. 
2006) and c-Myc (Jamerson et al. 2004). Cyclin D1 is one of the most commonly overexpressed 
oncogenes in breast cancer and has been found to be overexpressed in up to 50 % of the breast cancers 
(Arnold and Papanikolaou 2005; Sutherland and Musgrove 2004). Such an overexpression is more 
common in ER positive breast cancer. On the contrary, cyclin E is found to be overexpressed in ER-
negative breast cancer and is associated with truncated isoforms (Sutherland and Musgrove 2004).   
 
1.3.2. Cell migration and invasion 
Due to the shortage of space and nutrients, these cells may develop malignant characteristics, 
such as the ability to migrate and invade into the neighboring tissues from its original location as a 
primary tumour. These migratory cancer cells are capable of establishing new tumours remote from the 
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site of origin. In order to metastasize, the tumour cells have to first break off from its primary tumour 
and migrate via the circulatory or lymphatic system to a new location (Pluijm et al. 2000; Stacker et al. 
2002). The body has many defenses to prevent this from happening but the cancer cells have various 
mutations to enable them to overcome these barriers. Once metastasis to the lymph or blood system has 
occurred, the prognosis of the disease will be poor. In order to move to another location, a malignant 
cell has to first detach from the cancerous tumour. In a normal tissue, the cells are packed regularly 
where each cell is strongly adhered to one another by cell-cell adhesion molecules in the extra-cellular 
matrices (ECM). This adhesion allows interaction of the numerous proteins on the cell surface.  
One family of proteins known as the cadherins plays an important part in holding the epithelial 
cells together and cell motility. E-cadherin, when absent or dysfunctional is found to be associated with 
tumour aggressiveness and poor patient prognosis (Christofori and Semb 1999; Oka et al. 1993; Umbas 
et al. 1994). E-cadherin is found to be associated with metastasis in cancers (Derksen et al. 2006; 
Frixen et al. 1991; Perl et al. 1998). N-cadherin is found to promote neurite outgrowth and cell 
migration (Bixby and Jhabvala 1990; Hazan et al. 2000; Li et al. 2001). Migration also plays an 
important role in cancer invasion and metastasis. The motility of the cells in vitro has an association 
with the invasive behavior in vivo (Shaw 2005). Cell motility is a complex process that involves 
polarization, extension of pseudopodia-like structures, attachment and detachment. Proteins such as 
CD44 (Herrera-Gayol and Jothy 1999), EGFR and c-erbB2 (Verbeek et al. 1998) and uPAR (Madsen et 
al. 2007) are reported to have an important implication in tumour metastasis.  
 
1.3.3. Cell death 
 There are several mechanisms of cell death. The most commonly known forms of cell deaths 
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are apoptosis (Type I), autophagy (Type II) and necrosis (Type III) (Edinger and Thompson 2004) 
The most well studied form of cell death is apoptosis. This is an active regulatory mechanism 
where cells are programmed to die. Apoptosis is an essential part of development and morphogenesis. 
Morphological characteristics of this form of cell death include shrinkage of cells, condensation of 
nucleus and fragmentation of DNA, slight or undetectable shrinkage in cell organelles, rounding and 
blebbing of the cells (de Bruin and Medema 2008). The dead cells are then packaged into apoptotic 
bodies without rupture of the cell surface membrane, which are eventually removed by phagocytes. 
There are no signs of inflammation around the dying cells in apoptosis. In this form of cell death, ATP 
is also depleted. Apoptosis is typically hallmarked by caspase activation by extrinsic death receptors 
such as the FADD or intrinsic mitochondria depolarization leading to the release of cytochrome C (Li 
and Yuan 2008). Although multicellular organisms primarily use caspase dependant apoptosis, there are 
also cases of caspase independent apoptosis, where there are no signs of chromatin condensation and 
DNA fragmentation but other features of apoptosis such as cell shrinkage and membrane blebbing are 
still observed (McCarthy et al. 1997).  
Upstream of caspase activation, there are several groups of proteins that regulate a pivotal role 
in deciding if a cell will undergo survival or apoptosis. One of such is the Bcl-2 family. There are three 
subgroups of Bcl-2 family proteins; the Bcl-2 subfamily (anti-apoptotic proteins), the Bax subfamily 
(pro-apoptotic proteins) and BH-3 subfamily (pro-apoptotic proteins). The anti-apoptotic proteins are 
responsible for preventing the cells from programmed cell death when exposed to cellular insults such 
as DNA damage and growth deprivation. This group of proteins contains four well conserved Bcl-2 
homology (BH) domains; BH1, BH2, BH3 and BH4, which are alpha helixes in structure (Adams and 
Cory 1998; Kelekar and Thompson 1998; Matsuyama et al. 1998). Members of this subfamily include 
Bcl-2, Bcl-XL and Boo. Next is the Bax subfamily which contains pro-apoptotic proteins that promote 
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cell death when cells are exposed to cellular insults. These proteins have a very similar structure to the 
anti-apoptotic proteins such as Bcl-2, consisting entirely of alpha helixes (Petros et al. 2004). This 
group of proteins includes Bax, Bak and Bok. The last set is the BH-3 only subfamily of proteins 
consists of pro-apoptotic proteins such as Bid, Bim, Puma and Nova. These are of a separate group 
from the pro-apoptotic group as they only consists a single BH3 domain. The ratio of the pro-apoptotic 
and anti-apoptotic members are essential in determining a cell’s susceptibility to cell death (Oltvai et al. 
1993). Members of the Bcl-2 family can homo- or heterodimerize with each other. The BH1, BH2 and 
BH3 domains of the Bcl-2 subfamily can bind with the BH3 domain of the BH-3 subfamily. This 
interaction is essential for the pro-apoptotic activity of the BH-3 subfamily. The pro-survival proteins 
are able to either directly or indirectly regulate the release of cytochrome c from the mitochondria 
(Yang et al. 1997). For example, the Bcl-2 and Bcl-XL are able to bind to the Apaf-1 receptor on the 
mitochondria and preventing Caspase-9 from associating with Apaf-1, thus preventing cell death (Hu et 
al. 1998; Huang et al. 1998; Pan et al. 1998). 
There are distinctively three sub-groups of caspases, catergorized by their structural and 
functional properties; caspase-1 subfamily includes caspase 1, 4, 5 and 11, caspase-2 subfamily 
includes caspase 2 and 9 and caspase-3 subfamily includes caspase 3, 6, 7 and 8. These caspases are 
usually present in inactive forms that are activated by proteolytic cleavage at Asp residues to remove 
the N-terminal prodomain. Caspases which are proteases in nature are responsible for the proteolytic 
cleavage responsible for the activation of death promoting proteins or inactivation of structural or 
survival promoting proteins. Most of the proteins are substrates of one or more caspases, hence 
resulting in the ultimate degradation of the cell. Upon activation of death receptos such as Fas or TNF 
receptors, initiator caspases such as procaspase-1 and procaspase-8 will be recruited to the death 
receptors (Boldin et al. 1996; Muzio et al. 1998). Oligomerization of these initiator caspases at the 
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death receptors result in the self-activation of these caspases by proteolytic cleavage of the prodomain 
(Martin et al. 1998; Muzio, et al. 1998; Yang et al. 1998). Similiarly in mitochondria activated cell 
death; procaspases are also activated by adaptor protein oligomerization. On the other hand, the 
effector caspases are activated by other proteases, most likely the initiator caspases. Examples of such 
effector caspases are caspase 3 and caspase 7 (Fernandes-Alnemri et al. 1996; Li et al. 1997; Muzio, et 
al. 1998; Orth et al. 1996; Stennicke et al. 1998; Yang, et al. 1998). Some initiator and effector caspases 
were found to be activated by Granzyme B (GZMB), an Asp specific protease with no structural 
similarities to the caspase family (Yang, et al. 1998; Zhou and Salvesen 1997).  
There is second form of programmed cell death known as autophagy (Yu et al. 2008). This form 
of cell death involves the lysosomal compartment. There is formation of a double membrane vesicle in 
the cytosol that encapsulates organelles and bulk cytoplasm, known as the autophagosome. This 
process is under the control of GTPases (Klionsky and Emr 2000), phosphatidylinositol kinases (Ogier-
Denis et al. 1996) and novel ubiquitin-like systems (Ohsumi 2001). After formation, the 
autophagosome will fuse with the lysosome for degradation and recycle of the contents. There has been 
some controversy on whether autophagy is a means of cell death of cell protection. This phenomenon 
has been described in cells that experience famine or hormone deprivation, to reduce metabolic 
demands and enabling turnover of damaged organelles and long-lived proteins. This is usually typical 
in cells with large, cytoplasm rich, post mitotic or slowly mitotic cells. Autophagy is a means of 
reducing cell mass prior to apoptosis in many tissues (Bursch et al. 2000; Lockshin and Zakeri 2004a). 
Even then, autophagy does not necessarily lead to cell death as cells that undergo autophagy can 
survive when appropriately resuscitated. Autophagy was not only found to be a physiological process 
in the routine renewal of cell constituents (Yoshimori 2004). Autophagy has been well described in 
development and may be an evolutionary process that has been well conserved from simple organisms 
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such as yeast (Bursch, et al. 2000; Klionsky and Emr 2000). In some cases, the nucleus will eventually 
collapse, leading to cell death. Cell death from autophagy can be a result of activation of apoptosis 
(Scott et al. 2007) or due to uncontrolled cytoplasm degradation such as overexpression of autophagy 
protein, Beclin 1 in mammalian cells (Pattingre et al. 2005). The regulation of autophagy and apoptosis 
is governed by common factors such as the anti-apoptotic Bcl-2 family members (Pattingre, et al. 2005) 
and BH3-only proteins (Maiuri et al. 2007).  
 Necrosis is also known as Type III cell death. The morphology of cell death is poorly defined 
and cell death that does not have characteristics of either apoptosis or autophagy is often characterized 
as necrosis. The cells usually die an accidental death due to a environmental perturbations. 
Characteristically, the cells undergoing necrosis loses their osmotic pressure and swell, hence resulting 
in dilation of cytoplasmic organelles. The cells will also experience a premature rupture of the cell 
membrane and lysis. The intracellular proteins will often precipitate at high ionic concentration or 
acidic pH. The liberation of certain proteins will elicit an inflammatory response (Edinger and 
Thompson 2004; Festjens et al. 2006; Zitvogel et al. 2004). The necrotic cells are then internalized by a 
macropinocytotic mechanism where only parts of the cells are taken up by phagocytes (Krysko et al. 
2006). The molecular signaling cascade prior to necrosis has not been well studied. However several 
studies have documented an increase in cytoplasmic calcium ions (Harriman et al. 2002; Xu et al. 
2001), swelling of mitochondria (Niquet et al. 2005), presence of reactive oxygen species (ROS) in the 
mitochondria (Goossens et al. 1995), involvement of calpain (Harriman, et al. 2002; Liu et al. 2001; 
Syntichaki et al. 2002) and some lysosomal alterations (Artal-Sanz et al. 2006) in the cells that are 
undergoing necrosis. Each of these events does not constitute to necrosis alone and the relationship 
between each of these events is complex. However it is possible that the accumulation of these events 
eventually lead to cell death by necrosis. Several studies have shown that necrosis is programmable 
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where necrosis occurs when apoptosis or autophagy is blocked. Necrosis was observed in the presence 
of caspase inhibitors such as zVAD-fmk or in the presence of anti-apoptotic molecules such as Bcl-XL 
when cells are triggered by an apoptotic stimulus (Jaattela et al. 2004; Lockshin and Zakeri 2004b). 
Similarly, a knock out of autophagy protein, Beclin-1 has also shown to result in a necrotic cell death 
(Degenhardt et al. 2006). Programmed necrosis has been shown to be present in a physiological setting. 
Necrosis instead of apoptosis occurs in virally infected cells in the presence of inflammatory cytokine, 
TNF (Chan et al. 2003). This provides a possibility of programming necrosis for cancer cells which 
have sustained DNA damage. In proliferating cells such as cancer, programmed necrosis is found to 
occur when initiated by the DNA damage repair protein, PARP. This is because PARP activation results 
in the rapid depletion of nuclear and cytoplasmic NAD, which inhibits glycolysis (Herceg and Wang 
1999) and eventally leads to cell death by necrosis when the cells are depleted of ATP. A recent study 
showed that programmed necrosis upon DNA damage by alkylating agents result in PARP-1 mediated 
release of AIF from the mitochondria result in necrosis through a mechanism involving calpains 
(Moubarak et al. 2007).   
 
1.4. Biomarkers in breast cancer 
Biomarkers are proteins or protein fragments that are important in assessing the condition of an 
illness. In cancer, biomarkers are used in detection and the chance of recurrence. In addition, cancer 
biomarkers are used in the accurate evaluation and management of the disease in different stages. They 
are useful in predicting throughout the course of the disease which includes early detection, prognosis 
of the disease, prediction of how the disease will respond to drug treatment and detection of recurrence 
of the disease. In the last two decades, oestrogen receptor (ER) and Her2 has become standard markers 
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in the management of breast cancer (Jordan et al. 2007; Jordan and Brodie 2007; Slamon et al. 1987). 
Carcinoembryonic antigen (CEA) (Cove et al. 1979; Waalkes et al. 1978), human chorionic 
gonadotrophin (hCG) (Waalkes, et al. 1978) and ferretin (Jacobs et al. 1976) were examined as markers 
of metastasis in breast cancer from the serum of the patients.  
 
1.5. Metallothionein 
1.5.1 Biology of Metallothionein 
MT was first isolated in equine renal cortex (Kagi and Valee 1960) and was further 
characterized as a low molecular weight, water soluble, cysteine rich (30 % cysteine composition) and 
a cadmium, zinc and copper binding protein by Kagi and Vallee (Kagi and Vallee 1961). These 
characteristics resulted in the name of this protein “metallothionein”. MTs are also found to be 
involved in metal detoxification as increasing level of this protein has been found to accumulate in the 
liver and kidneys of rabbits that were exposed to increasing levels of cadmium (Piotrowski et al. 1973). 
Hence MTs have been implicated in defense mechanisms, especially in low level chronic cadmium 
exposure. It has also been found that other metals such as copper and zinc can also induce the 
expression of metallothionein. Thus the primary role of MT seems to be in the homeostasis of these 
elements (Richards and Cousins 1975). Several groups have linked the synthesis of metallothionein to 
the concentration of cytosolic zinc in the liver (Bremner and Davies 1975; Cousins 1979). Cytosolic 
zinc levels are regulated by the level of zinc in the plasma and this will eventually lead to the increase 
in expression of metallothionein mRNA and subsequently metallothionein protein. MT is found to be 
also differentially regulated in a variety of stress conditions where there are profound changes in zinc. 
These include physiological stress conditions such as cold and exercise (Oh et al. 1978), food 
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restriction (Bremner and Davies 1975), and bacterial infection (Sobocinski et al. 1978). Various 
glucocorticoids are found to increase the expression of zinc uptake and zinc-thionein formation (Failla 
and Cousins 1978; Karin et al. 1980; Karin and Herschman 1981), by increasing the synthesis of 
thionein, a metal free apoprotein which actively binds to zinc, thus stimulating it’s uptake. 
Dexamethasone is found to be the most effective glucocorticoid for this function. The binding of 
dexamethasone to the receptor sites in the nucleus preceding the synthesis of MT indicates a direct 
effect of glucocorticoids on the production of MT mRNA (Karin and Herschman 1981). Other 
glucocorticoids such as progesterone and aldosterone that can induce MT synthesis bind to the 
dexamethasone binding site at different affinities (Hernandez et al. 2000).  
The apo-metallothionein was found to be more reactive as compared to the zinc bound form, 
suggesting that it is the principal regulator in cellular processes (Petering et al. 2006). One function of 
the zinc bound form of MT is that it is able to donate its bound cations to other apoproteins of various 
zinc-dependant enzymes and restore their activity (Li et al. 1980; Udom and Brady 1980). Several 
studies have also documented a similar role for copper-thioneins.  
 
1.5.2 Structure of MT 
Data has shown that MT possesses independent metal binding sites, each containing three 
cysteinyl residues that bind with the divalent metal ion (Carpene et al. 2007; Kagi and Vallee 1961). 
The first amino acid sequence of MT was deduced by Kojima et al. (Kojima et al. 1976). The primary 
sequence show interesting features of clustering of the 20 cysteine residues into 7 groups separated by 
other amino acids. The metal ions are bounded at cysteinyl residues at the cysteine clusters. Within the 
clusters, the cysteine residues were organized 7 times in alternating Cys-X-Cys sequences and 3 times 
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in Cys-Cys and Cys-X-X-Cys sequences, where X is a variable residue (Kojima, et al. 1976). Analysis 
of amino acid sequences of various isoforms of mammalian MTs showed a similar fashion of 61 amino 
acid chain with consisting of 38 invariant residues including 20 cysteine residues and ten of these 
cysteine residues are present in Cys-X-Cys motif (Boulanger et al. 1982). Other than high content of 
cysteine residues, MTs are found to be rich in lysine and serine and total lack of aromatic and histidine 
residues (Boulanger, et al. 1982). Circular dichroism spectrometry shows that all the 20 cysteine 
residues are involved in the ligation of 7 mol of metal ions per mol of metallothionein and MT has 
differential binding stability in decreasing order of Cu greater than Cd greater than Zinc (Rupp and 
Weser 1978). Metallothioneins possess a well defined tertiary structure when induced with zinc and 
copper ions while the apoprotein thionein was found to exist in an essentially random coil 
conformation (Vasak et al. 1980). The main amino acids involved in metal binding were found to be the 
cysteine residues. Winge and Miklossy found that MT consist of 3 metal cysteine domains in the amino 
terminal (residues 1-29) and 4-metal cysteine domains in the carboxyl terminal (residues 30-61) 
(Winge and Miklossy 1982). The crystal structure of MT-II from the rat liver also shows that the amino 
terminal is coordinated by six terminal cysteine thiolate ligands and three cysteine thiolates while the 
carboxyl terminal is coordinated by six terminal and five bridging cysteine thiolates, with each metal 
site with tetrahedral coordination geometry (Furey et al. 1986; Jin et al. 2002). The reconstructed figure 
of MT-2 is shown in Figure 4.  
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Figure 4. Structure of MT-2 isoform from the rat liver showing the protein backbone in blue with the 
alpha domain labelled as N and the carboxyl terminal labelled as C. The red and green spheres indicate 
zinc and cadmium ions respectively. The figure was generated using PyMol . PDB code: 4MT2. 
 
1.5.3. Protective effects of MT 
1.5.3.1 Oxidative stress 
Other than being involved in previously mentioned heavy metal detoxification, MT has been 
found to be implicated with other protective functions. MT is also found to be involved in protecting 
the cells from oxidative stress by actively scavenging free radicals such as superoxide or free hydroxyl 
radicals (Klimczak et al. 1984). Study has shown that this reversible process involves all the 20 
cysteine residues in the ROS quenching process resulting in metal ion loss and this damage of the free 
hydroxyl radicals to the MT protein can be repaired by reduced glutathione. This provides a sacrificial 
but renewable source of cellular target for free hydroxyl-mediated cellular damage (Thornalley and 
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Vasak 1985). As a result, MT has been reported to inhibit hydroxyl-radical induced DNA damage (Abel 
and de Ruiter 1989). MT was also found to be involved in protection of lysosomal destabilization as a 
result from oxidative stress (Baird et al. 2006). This protective effect is believed to be a result of the 
release of zinc ions triggered by oxidative stress (Feng et al. 2006). A recent study has also shown that 
MT also plays an important role in the protection from oxidative damage in when the mitochondria 
activity is being limited (Futakawa et al. 2006).  
 
1.5.3.2 Radiation 
MT overexpressing cells were also found to have a protective effect against ionizing radiation 
against cytotoxicity (Bakka et al. 1982). Mice that were subjected to pretreatments so as to induce 
metallothionein production were shown to be more resistant to radiation by a steady increase of body 
weight after irradiation while the control mice have a typical loss of body weight and increased 
mortility (Matsubara et al. 1986; Matsubara et al. 1987a). This protective effect of metallothionein may 
be a result of scavenging radiation induced ROS (Matsubara et al. 1987b), hence conferring resistance 
against DNA damage. A recent study has shown that MT protects against radiation induced 
carcinogenesis (Shibuya et al. 2008) and this effect has been proposed to be due to the protective effect 
of zinc-metallothionein against DNA damage (Cai and Cherian 2003).  
 
1.5.3.3 Infections 
Metallothioneins levels were also found to increase in response to infections to protect the cells 
from the lethal effects and inflammation (Ilback et al. 2004; Mita et al. 2008; Patierno et al. 1983; Tran 
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et al. 2003). MTs were also demonstrated to be intimately involved in the zinc distribution during the 
acute stage of infections (Sobocinski, et al. 1978). Overexpression of MT was shown to be beneficial in 
hepatitis B infection (Quaife et al. 1999) and influenza virus infection (Geiss et al. 2001). The up-
regulation of MTs may be a possible protective response to virus-induced oxidative stress. MT may 
also play a role in inflammation as pro-inflammatory factors such as IL-1 was found to up-regulate MT 
synthesis via zinc metabolism upon infection (Cousins and Leinart 1988). 
 
1.5.3.4 Alkylating agents 
Furthermore, MT was found to have a protective effect against alkylating agent cytotoxicity. 
Alkylating agents involves the transfer of an alkyl groups and these can be electrophilic or nucleophilic 
in nature. A relevant example of alkylating agents is alkylating antineoplatic agents used in anticancer 
treatments. These agents are able to alkylate DNA leading in inability of the DNA to coil properly. This 
ultimately results in inhibition of cell growth or cell death. Studies have shown that overexpression of 
human MT resulted in resistance to alkylating agents such as cis-diamminedichloroplatinum(II), 
chlorambucil, melphalan (Kelley et al. 1988; Yap et al. 2008), N'-nitro-N'-nitrosoguanidine (MNNG) 
(Kaina et al. 1990) and mitomycin C (MMC) (Lohrer and Robson 1989). Endresen was the first to 
associate metallothioneins with conferring protection to cancerous cells as tumours with high content 
of metallothioneins were found to be resistant against several chemotherapeutic drugs such as cisplatin 
and chlorambucil (Endresen and Rugstad 1987; Endresen et al. 1984).  Several other studies have also 
substantiated this finding in several other cancers including ovarian, lung, liver and bladder (Endo et al. 
2004; Kasahara et al. 1991; Schilder et al. 1990; Wood et al. 1993). Cancer patients undergoing 
chemotherapy were found to have a lower survival rate if they have MT-positive cancer. Bladder cancer 
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patients with MT-positive tumours undergoing cisplatin chemotherapy have a significantly poorer 
survival rate as compared to MT-negative tumours (Wulfing et al. 2007).  
MT has been postulated to function as a cofactor or regulatory factor in the repair or tolerance 
of toxic alkylating agents (Kaina, et al. 1990). Studies has shown that this resistance is a result of 
covalent sequestration of the alkylating agent by metallothionein at two cysteine residues that co-
chelate a zinc cation in the carboxyl terminal, eventually resulting in trypsin cleavage of the alkylating 
agent bounded metallothionein between the amino and carboxyl domains (Antoine et al. 1998; He et al. 
2000; Yu et al. 1995). Hence, this prevents the alkylating agent from reaching the DNA of cancer cells. 
As for MNNG, metallothionein was found to confer resistance by serving as a sink for the ROS derived 
from its metabolism (Moffatt and Denizeau 1997). In addition to sequestering electrophilic anti-cancer 
drugs, metallothionein can also regulate the activities of zinc-requiring metalloenzymes or scavenging 
radical species, altering the therapeutic efficacy of anticancer drugs (Ebadi and Iversen 1994). 
Furthermore, the increase of MT levels could provide a zinc cofactor reserve that increases the cell's 
reparative potential when faced by DNA damage by cytotoxic agents (Doz et al. 1993). 
 
1.5.4. MT isoforms 
In humans, there are ten functional isoforms, viz. MT-1A, 1B, 1E, 1F, 1G, 1H, 1X, 2A, 3 and 4 
which encode for 4 MT proteins, MT-1, 2, 3 and 4. MT-3 isoform is specifically located in the brain 
and has involvement in Alzheimer’s disease (Palmiter et al. 1992; Uchida et al. 1991) while MT-4 is 
found to be involved in the differentiation of certain stratified epithelia (Quaife et al. 1994). MT-1 and 
MT-2 isoforms are expressed co-ordinately in most organs but the precise role of these MT isoforms 
has not been well elucidated. MT-2A has been found to be positively related to the cell proliferation in 
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livers (Nagamine et al. 2005). In addition, the MT-2A isoform has been reported to be the most 
abundant MT isoform in breast cancer cell lines and tissues (Jin, et al. 2002). Hence it would be of 
great interest to examine the roles of MT-2A in breast cancer progression.  
 
1.5.5. MT and cancer 
MTs are also reported to be involved in cell proliferation. The level of MT was found to be 
increased in rapidly proliferating cells in various parts of the body (Bakka and Webb 1981; Nishimura 
et al. 1989a; Nishimura et al. 1990; Nishimura et al. 1989b; Panemangalore et al. 1983), hyperplastic 
epidermis (Karasawa et al. 1991) and various tumours (Murphy et al. 1991; Nartey et al. 1987). MT 
was shown to peak at late G1 and G1/S transition (Nagel and Vallee 1995) indicating its specific role in 
cell cycle progression. It was shown that MT nuclear localization is involved in cell proliferation as 
MT nuclear staining was observed in hepatocytes in the S and G2/M phases and not G1 phase of the 
cell cycle (Tsujikawa et al. 1994). The role of MT in cell proliferation has been postulated to be in the 
detoxification and/or transfer of copper ions from the cytoplasm to the nucleus at the G1/S phase 
(Wlostowski 1993).  
Other than facilitating cell proliferation in cancer, MT was also found to have an influence on 
DNA damage. Studies have found opposite functions for intra-cellular and extra-cellular MT; intra-
cellular MT has protective functions (Goncharova and Rossman 1994) while extracellular MT bound 
with cadmium/zinc resulted in increase in random DNA breaks (Muller et al. 1994).  
There are varying studies on the level of MT in different cancer. In liver cancer, a lower amount 
of MT was detected in malignant as compared to normal livers (Ebadi and Swanson 1988). On the 
contrary, epithelial cells which are more proliferative in breast and colon cancer show a higher 
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immunoreactivity with MT antibodies (Meskel et al. 1993). These studies indicate a use of MT as an 
epithelial proliferative marker, which can be an index of malignancy in certain cancers.  
MT was also observed to be associated with apoptosis (Abdel-Mageed and Agrawal 1997; Jin, 
et al. 2002). MT null cells showed increased sensitivity to apoptosis when challenged with DNA 
damaging agents (Kondo et al. 1997). Moreover, Ostrakhovitch et al. has reported that the p53 tumour 
suppressor protein interacts with MT and this interaction may be involved in regulating apoptosis in 
breast cancer cells (Ostrakhovitch et al. 2006). The same group of investigators also found that 
activation of p53 is critical in stimulating MT synthesis (Ostrakhovitch et al. 2007). Furthermore, MT 
has been reported to modulate p53 conformation and transcriptional activity by zinc chelation (Meplan 
et al. 2000). Hence altered levels of this protein can be expected in abnormal cell growth such as 
cancer. Studies have documented a relationship between higher aggressiveness and poorer prognosis of 
breast cancer with increased MT protein expression (Bay et al. 2006; Goulding et al. 1995; Jin, et al. 
2002; Oyama et al. 1996; Sens et al. 2001).The exact mechanism by which MT has an impact on breast 
cancer has not been elucidated.  
 
1.6. Gene silencing 
1.6.1. Overview of gene silencing 
RNA silencing regulatory mechanism operates on two levels: transcriptional gene silencing 
(TGS) and post-transcriptional gene silencing (PTGS), which is generally known as RNA interference 
(RNAi) (Grishok 2005; Montgomery and Fire 1998). TGS is typically associated with DNA 
methylation within the promoter regions (Mette et al. 2000; Sijen et al. 2001) while RNAi involves the 
specific degradation of a target gene. PTGS was initially known as “co-suppression” in plants. This 
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was discovered in the study conducted by Napoli and his co-workers on increasing coloured pigment 
production in petunia plants using a sense chalcone synthase transgene. The introduction of a transgene 
surprisingly resulted in co-suppression of both the transgene and endogenous chalcone synthase gene 
in petunia plants (Napoli et al. 1990). The phenomenon of RNAi was first discovered in the nematode 
worm Caenorhabditis elegans, as a result of introducing antisense or sense RNA constructs into 
embryos (Guo S et al., 1995). The observation that double stranded RNAs (dsRNAs) are much more 
effective in silencing a gene in Caenorhabditis elegans as compared to the traditionally used antisense 
strand (Hannon 2002) has led to the revolution of using dsRNA as a preferred method to knock down a 
gene. To date, RNAi has been shown in many organisms from plants to vertebrates (Montgomery and 
Fire 1998). 
The natural function of RNAi mechanism and its related processes is to protect the genome by 
silencing repetitive or transposable genetic elements (Ketting et al. 1999; Wu-Scharf et al. 2000). RNAi 
also acts as a defense mechanism against viral infections by knocking down the viral transcripts 
(Voinnet 2001). With the discovery of naturally occurring miRNA, RNAi is also shown to be involved 
in endogenous gene expression (Voinnet 2002) and help to regulate growth and development (Lee and 
Ambros 2001).  
 
1.6.2. Mechanism of RNA interference 
The RNAi pathway can be dissected into two main phases, each involving ribonuclease activity 
(Boisvert and Simard 2008; Collins and Cheng 2006; Sen and Blau 2006). The initiator stage is 
triggered by the presence of a long dsRNA molecule, which can be exogenously or endogenously 
introduced. This dsRNA molecule is then processed into double stranded small interfering RNA 
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(siRNA) molecules of 21-25 nucleotides long (Zamore et al. 2000) by an RNaseIII containing enzyme, 
Dicer (Bernstein et al. 2001; Macrae et al. 2006). In the effector stage, the RNA induced silencing 
complex (RISC) guided by the siRNA binds to the target mRNA molecule (Martinez et al. 2002) and 




Figure 5. Mechanism of RNAi 
 
RNaseIII enzymes can be classified into three classes (Mian 1997). Class I enzymes containing 
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a single RNaseIII domain are found in prokaryotes. Class II and III enzymes contain two RNaseIII 
domains (Mian 1997; Rotondo and Frendewey 1996). Class III ribonucleases are further distinguished 
by the presence of a PAZ (Piwi/Agronaute/Zwille) domain (Cerutti et al. 2000). The congruent model 
for the activity of Dicer is where the two RNaseIII domains associate intramolecularly to form a 
pseudo-dimer encompassing an active site between them (Blaszczyk et al. 2004). Each domain then 
cleaves a single strand of the dsRNA molecule. Generation of the two nucleotide overhang is based on 
the pseudo-dimer alignment of the RNaseIII domains. The siRNA product length of 21-25 nucleotides 
is determined by the distance between the PAZ domain and the active site. The variation in siRNA 
length is due to the less efficient terminal binding of the dsRNA molecule (Blaszczyk, et al. 2004).  
 RISC, the effector nuclease of RNAi, is a multiprotein complex with an Agronaute family 
member central to this complex (Hammond et al. 2001). Several members of this family have nuclease 
activity. Although the Drosophila genome encodes for at least four Agronaute family members - AGO1, 
AGO2, Piwi, and Sting, only AGO2 is found to be a component of the RISC in Drosophila cells 
(Meister et al. 2004). Ago2 is characterized to contain the PAZ and PIWI domain. Ago2 is the catalytic 
engine of mammalian RNA interference as it mediates RNA cleavage (Liu et al. 2004; Song et al. 
2004). The revelation of a RNaseH fold in the PIWI domain of Ago2 from it’s crystal structure further 
ascertain the nuclease activity of Ago2 in the RISC complex (Mourelatos et al. 2002). 
1.6.3. RNAi as a tool for gene analysis  
With more complete genome sequences available, the discovery of RNAi offers the power of 
silencing specific genes in various organisms. This specific gene knockdown technology is able to 
provide us with the understanding of the functions of specific genes through phenotypic analysis. Gene 
knockdown can also provide information on the interacting partners of the particular silenced gene. 
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Analysis of gene functions can also be carried out in a functional genomics approach. Kiger et al. used 
large scale RNAi to determine the set of genes that are responsible for cell morphology and 
cytoskeletal organization for cell shape maintenance (Kiger et al. 2003). Some other groups have also 
utilize the ease of RNAi in conducting large scale RNAi analysis to determine the fat regulatory genes 
and the genes involved in early embrogenesis in C. elegans (Ashrafi et al. 2003; Sonnichsen et al. 
2005). The use of RNAi accomplished with the use of siRNA duplexes coupled with genome-wide 
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1.7. Scope of study 
MTs were found to have an effect on cell proliferation and have been identified as one of the 
potential biomarkers alongside estrogen receptors, progesterone receptors, E-cadherin and bcl-2 in 
breast cancer (Bay, et al. 2006; Cherian, et al. 2003; Esteva and Hortobagyi 2004; Giancotti 2006; 
Nicolini, et al. 2006). Studies have documented a relationship between higher aggressiveness and 
poorer prognosis of breast cancer with increased MT protein expression (Bay, et al. 2006; Jin, et al. 
2002; Oyama, et al. 1996; Sens, et al. 2001). The exact mechanism by which MT, including MT-2A 
(the most abundant isoform) affects breast carcinogenesis has not been elucidated.  
 
Hypothesis: The hypothesis in this study is that MT-2A, the most abundant MT-isoform 
detected in breast cancer, plays important functional roles in breast cancer progression by affecting cell 
proliferation and metastasis. As such, a dual approach of silencing and overexpressing the MT-2A gene 
was adopted to study the effects on proliferation, adhesion, migration and invasion. The relationship of 
MT and breast cancer was further validated by a clinicopathologic study in breast cancer tissues. 
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The objectives of the present study are to: 
1. Down-regulate MT-2A expression in the MCF-7 breast cancer cell line using siRNA duplexes and 
examine the consequent phenotypic and functional effects in vitro. 
2. Over-express MT-2A in the MCF-7 breast cancer cell line using plasmids encoding for MT-2A or 
its deletion mutant MT-2A’ and validate the phenotypic and functional effects 
3. Investigate the differential gene expression in the various cancer related pathways using 
Superarray technology for both sets of MT-2A silenced cells and MT-2A over-expressing cells, and 
validate the expression of several related genes at protein level. 
4. Examine the relationship of MT expression in breast cancer tissues with clinicopathological data 
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2.1. Antibodies and reagents 
 MT monoclonal antibody (E9) (Dako Corp, Carpinteria, CA, USA) was used for the detection 
of MT proteins by immunocytochemistry and immunohistochemistry. This antibody detects all MT-1 
and MT-2 isoforms. Monoclonal antibodies employed for western blotting are mouse anti-cdc25A 
(Santa Cruz, CA, USA) and mouse anti-uPAR (MAB 807) (R&D Systems, Minneapolis, MN, USA), 
anti c-Met (Santa Cruz, CA, USA) and anti-ATM (Santa Cruz). The two siRNAs against MT-2A and 
MT-1F were specially designed and manufactured by Qiagen (Qiagen, Hilden, Germany). Transfection 
reagent for overexpression, Lipofectaime2000 was from Invitrogen (Invitrogen, Carlsbad, CA, USA). 
Other reagents were purchased from Sigma-aldrich (Sigma Aldrich, Saint Louis, MI, USA).  
 
2.2. Cell culture 
2.2.1. Maintenance of cell lines  
 MCF-12A (CRL-10782), MCF-7 (HTB-22), MDA-MB-231 (HTB-26), T47D (HTB-133) and 
ZR-75-1 (CRL-1500) cell lines were obtained from American Tissue Culture Collection (ATCC, 
Rockville, MD, USA). MCF-12A cell line is a non-tumorigenic epithelial cell line established from 
tissue extracted at reduction mammoplasty from a nulliparous patient with fibrocystic breast disease 
with focal areas of intraductal hyperplasia (Paine et al. 1992; Pauley et al. 1993). MCF-12A cells were 
cultured in a 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM) and Ham's F12 medium 
supplemented with 5 % FBS, 20 ng/ml Human epidermal growth factor, 100 ng/ml cholera toxin, 0.01 
mg/ml bovine insulin, 500 ng/ml hydrocortisone and 40 μg/ml gentamicin (Invitrogen, Carlsbad, CA, 
USA). The main breast cancer cell line used in this study, MCF-7, is comprised of epithelial cells from 
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an adenocarcinoma derived from 69 year old Caucasian woman who had undergone two mastectomies 
in a five year span (Dickson et al. 1986). The woman was found to suffer from benign tumour in the 
first mastectomy, malignant adenocarcinoma in the second mastectomy and pleural effusion with the 
subsequent removal of lobules in the chest wall. This cell line was obtained from the pleural fluid of 
the patient in 1970 (Dickson, et al. 1986). MDA-MB-231 epithelial cells are derived from 
adenocarcinoma of the breast while ZR-75-1 and T47D are epithelial cells derived from ductal 
carcinoma of the breast. MCF-7 cells were cultured in DMEM medium supplemented with 10 % FBS. 
T47D, MDA-MB-231 and ZR-75-1 cells were cultured in RPMI medium supplemented with 10 % 
FBS. The cells were constantly visualized under light microscope to ensure that there were no 
morphological changes during cell culture. 
The cell cultures were passaged at subconfluency and maintained at 5 % carbon dioxide at 
37ºC. The cell monolayers were dispersed with 1 % trypsin-EDTA in PBS. For seeding, the cells were 
centrifuged before resuspension in complete medium and counted with a hemocytometer to determine 
the cell concentration for seeding. 
 
2.2.2. Cryopreservation of cells 
For cryopreservation of the cell lines, the cells were centrifuged at 900 rpm for 5 min at 4ºC to 
remove any traces of trypsin before suspension in the respective culture medium containing 20 % FBS 
and 10 % DMSO. The cells were then kept overnight in 5100 Cryo 1ºC freezing container (Nalgene, 
Rochester, USA) before transferring to liquid nitrogen for long term storage.  
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2.3. Downregulation using siRNA transfection 
2.3.1. Optimization of siRNA transfection 
MCF-7 cells were transfected using RNAiFect transfection reagent (Qiagen, Hilden, Germany). 
Transfection efficiency of the transfection reagent was first analyzed using a Cy3 labeled siNegative 
(Ambion, Austin, TX, USA). Optimization of the silencing efficiency was conducted using a positive 
siRNA, AAC TGG ACT TCC AGA AGA ACA (siAClamin). Optimization of the silencing efficiency 
was examined by varying the following factors: seeding density in a 24-well plate; the medium used to 
dilute the siRNA for transfection (complete medium of DMEM supplemented with 10 % FBS or 
Optimem1 (Invitrogen, Carlsbad, CA, USA)); amount of siRNA used per well and the ratio of 
transfection reagent to amount of siRNA used. The expression of A/C lamin gene was then examined 
using real-time PCR with A/C lamin gene specific primers as follows:  
AClam Fwd: 5’-CAA GAA GGA GGG TGA CCT GA-3’ 
AClam Rev: 5’-GCA TCT CAT CCT GAA GTT GCT T-3’ 
 
2.3.2. Silencing in MCF-7 breast cancer cells  
The siRNA sequences were purchased from Qiagen. The human MT-2A siRNA sequences used 
were as follows; CGC CGG TTC CTG CAA ATG CAA (siMT2A_1) and CCC GCT CCC AGA TGT 
AAA GAA (siMT2A_2). The human MT-1F siRNA sequences used were as follows; AAC CTT TCT 
CCC AGA TGT AAA (siMT1F_1) and CAC CTT GAC CCA TTT GCT ACA (siMT1F_3). A negative 
siRNA sequence AAT TCT CCG AAC GTG TCA CGT that does not target any human genes was used 
as a negative control. Cells were seeded at 6 X 104 in a 24-well plate with a total volume of 24 h prior 
to siRNA transfection. On the day of transfection, 1 ug of siRNA was diluted with Optimem1 
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(Invitrogen, Carlsbad, CA, USA) to a total volume of 100 μl and mixed by pipetting. Following which, 
6 μl of RNAiFect transfection reagent was added to the diluted siRNA and mixed by pipetting. The 
samples were then incubated for 10-15 minutes at room temperature to allow siRNA-complex 
formation. Subsequently, the culture medium of the cells was changed to 300 μl of fresh culture 
medium containing DMEM supplemented with 10 % FBS. The siRNA-complexes were then added 
dropwise into the cells and the plates were swirled to ensure uniform distribution. The cells were 
incubated under their normal growth conditions. Gene expression in the transfected cells was examined 
at 48 h post-transfection while protein expression was examined at 72 h post-transfection after 
optimization.  
 
2.4. Cloning and overexpression of MT-2A  
Total RNA was isolated from the cells using RNEasy Mini Kit (Qiagen, Hilden, Germany) and 
the mRNA was purified from the total RNA using the Oligotex Mini kit (Qiagen, Hilden, Germany). 
Sensiscript two-step RT-PCR (Qiagen, Hilden, Germany) was employed to amplify the MT-2A gene 
using the designed primers; 5' GGA TCC GAT CCC AAC TGC TCC TGC GCC 3' and 5' CTC GAG 
TCA GGC GCA GCA GCT GCA CTT 3'. MT-2A gene was then cloned into the pXJ40 vector 9 (a gift 
from Dr Ed Manser, Institute of Molecular & Cell Biology, Singapore) which is capable of expressing 
recombinant protein as an N-terminal GFP fusion protein, driven by a strong CMV promoter. The 
empty vector coding for GFP alone was used as the negative control. Four μg of the plasmids were 
transfected into MCF-7 cells using Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA) at a ratio of 
1:3 of DNA (μg) to Lipofectamine (μl) and the transfection efficiency was determined using the 
fluorescence of GFP. Gene expression of MT-2A was determined at mRNA level using real-time RT-
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PCR.  
 
2.5. Quantitative real-time PCR  
2.5.1 Extraction of total RNA 
Total RNA was extracted from the cells using RNEasy Mini kit. Briefly, the cells growing in a 
monolayer were first washed with PBS to remove any traces of culture medium. The cells were then 
harvested using trypsin-EDTA method and pelleted down at 300 x g for 5 min. The pelleted cells were 
disrupted with freshly prepared RLT buffer with 1 % β-ME and mixed by vortexing. After which, the 
cell lysate was homogenized using QiaShredder (Qiagen, Hilden, Germany) and the homogenized 
lysate is mixed with one volume of 70 % ethanol by pipetting. The mixture was then transferred to a 
RNEasy spin column and centrifuged for 15 s at maximum speed. The column was washed with 350 μl 
of buffer RW1 and centrifuged at maximum speed for 15 s before adding the DNase 1 incubation mix 
of 10 μl of DNase 1 (2.7 Kunitz units/ ul, Qiagen, Hilden, Germany) with 70 μl of RDD buffer and 
incubating for 15 min at room temperature to remove any traces of genomic DNA contamination. 350 
μl of RW1 buffer was added to the spin column before centrifuging for 15 s maximum speed. The spin 
column was then washed twice with buffer RPE at 15 s and 2 min respectively at maximum speed. The 
RNA was eluted by pipetting 30 μl of RNase-free water to the middle of the silica gel and centrifuging 
for 1 min at maximum speed. The quantity and quality of the RNA was measured by a 
spectrophotometer (Eppendorf, Hamburg, Germany). All the RNA obtained had an OD260:OD280 
ratio between 1.8 and 2.1. The RNA extracted were either used immediately or stored at -80ºC.   
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2.5.2 cDNA synthesis  
cDNA was synthesized from 2 μg of RNA using SuperScript III 1st-Strand Synthesis System 
(Invitrogen, Carlsbad, CA, USA). Briefly, the RNA / primer mixture for each reaction included: 2 μg of 
total RNA, 50 ng of random hexamer primers, 10 mM of dNTP mix and DEPC treated water to a total 
volume of 10 μl. The RNA / primer samples were then incubated at 65°C for 5 min before placing on 
ice for at least 1 min. The cDNA synthesis mix for each sample was prepared as follows: 
z 2 μl of 10X RT buffer,  
z 4 μl of 25 mM MgCl2,  
z 2 μl of 0.1 M DTT 
z 1 μl of RNaseOut (40 U / μl) 
z 1 μl of Superscript III (200 U/ μl)  
The cDNA synthesis mix was combined with the RNA / primer mix before incubation at 25ºC 
for 10 min, followed by 50ºC for 50 min. The activity of the enzyme was terminated at 85ºC for 5 min 
before storing the samples on ice. Any remaining RNA in the sample was removed by the incubation of 
1 μl of RNaseH for 20 min at 37ºC. The cDNA sample twas used immediately for PCR or stored at -
20ºC. 
 
2.5.3 Quantitative real-time PCR 
The primers specific for the individual MT isoforms were adapted from Mididoddi et al 
(Mididoddi et al. 1996) while the primers employed for amplification of the MT-2A gene, described in 
the ‘Cloning and overexpression of MT-2A’ section, were used to determine the overexpression 
efficiency of MT-2A. The details of the primers, except MT-2A, adapted from Middidodi et al., (1996) 
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are shown in Table 1.  
 
Table 1. Primers for quantitative real-time PCR 






5’-CTC GAA ATG GAC CCC AAC T-3’ MT-1A NM_005946 
5’-ATA TCT TCG AGC AGG GCT GTC-3’ 
68-286 219 
5’-GCT TGT CTT GGC TCC ACA-3’ MT-1B NM_005947 
5’-AGC AAA CCG GTC AGG TAG TTA-3’ 
39-327 289 
5’-GCT TGT TCG TCT CAC TGG TG-3’ MT-1E NM_175617 
5’-CAG GTT GTG CAG GTT GTT CTA-3’ 
133-416 284 
5’-AGT CTC TCC TCG GCT TGC-3’ MT-1F NM_005949 
5’-ACA TCT GGG AGA AAG GTT GTC-3’ 
98-329 232 
5’-CTT CTC GCT TGG GAA CTC TA-3’ MT-1G NM_005950 
5’-AGG GGT CAA GAT TGT AGC AAA-3’ 
35-343 309 
5’-CCT CTT CTC TTC TCG CTT GG-3’ MT-1H NM_005951 
5’-GCA AAT GAG TCG GAG TTG TAG-3’ 
26-342 317 
5’-TCT CCT TGC CTC GAA ATG GA-3’ MT-1X NM_005952 
5’-GGG CAC ACT TGG CAC AGC-3’ 
57-207 151 
5’-GGA TCC GAT CCC AAC TGC TCC 
TGC GCC-3’ 
MT-2A NM_005953 
5’-CTC GAG TCA GGC GCA GCA GCT 
GCA CTT-3’ 
61-258 198 
5’-CCG TTC ACC GCC TCC AG-3’ MT-3 NM_005954 
5’-CAC CAG CCA CAC TTC ACC ACA-3’ 
203-527 325 
5’-CAT GGA CCC CAG GGA ATG TGT-3’ MT-4 NM_032935 
5’-GGG GTG GGA ACG ATG GA-3’ 
80-292 213 
5’-GAA GGT GAA GGT CGG AGT CAA 
CG-3’ 
Gapdh NM_032935 
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The real-time PCR reaction contains a total volume of 10 μl, consisting of a final concentration 
of 1 X QuantiTect SYBR Green PCR Master mix (Qiagen, Hilden, Germany), 0.3 μM of each of the 
primers and less or equal to 500 ng of template cDNA. The real-time PCR reaction was then loaded 
into lightcycler capillaries (Roche Applied Science, Indianapolis, IN, USA). Real-time RT-PCR 
conditions were optimized by adjusting the annealing temperature to 60 °C. PCR was performed using 
a Light Cycler (Roche Applied Science, Indianapolis, IN, USA) and a program with the following 
parameters: initial denaturation at 95 °C for 15 minutes, 45 cycles performed at 94 °C for 15 seconds, 
60 °C for 25 seconds, and 72 °C for 18 seconds. Melting curve analysis was carried out at 65 ºC for 15 
seconds to verify the specificity of the amplification reaction. Relative quantification was calculated 
using the ΔΔCT and 2–ΔΔCT method (Livak and Schmittgen 2001), where ΔCT refers to the difference 
between the CT values of the target gene and the housekeeping gene, G3PDH. The CT value is defined 
as the fractional cycle number at which the emitted fluorescence of the sample passes a fixed threshold 
above the baseline. 
 
2.6. Automated Flow Cell Sorting (FACS) 
Cells overexpressing MT-2A and the empty vector were harvested by trypsin-EDTA method and 
stored on ice prior to sorting. The cells were sorted by BD Beckinson FACSVantage machine using a 
FITC laser. The FITC threshold level was set using untransfected MCF-7 cells. The GFP positive cells 
were collected in PBS and deemed as successfully transfected cells. The cells were kept on ice for 
subsequent experiments.  
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2.7. Immunocytochemistry  
Cover slips were first treated by immersing in methanol followed by air-drying in a biosafety 
cabinet. The treated cover slips were then placed at the bottom of the multi-well plates before seeding 
the cells. After 72 h post transfection with the respective siRNAs, the coverslips with the attached cells 
were washed twice with PBS for 5 min each before fixing in 4 % paraformaldehyde for 15 min. 
Subsequently, the fixed cells were blocked with 5 % horse serum for 1 h at room temperature before 
incubation with primary mouse monoclonal anti-MT antibody at 1: 400 dilution, 4 ºC overnight. The 
cover slips were washed thrice with PBS containing 0.1 % of Tween-20 (PBS-T20) at 5 min each 
before incubating with secondary anti-mouse IgG at a dilution of 1: 200 at room temperature for 1 h. 
The cells were then washed thrice with PBS-T20 at 5 min each. Avidin Biotin Complex (ABC) solution 
which was prepared 30 min prior to usage, was added to the cells for 1 h. After washing with PBS-T20 
thrice for 5 min each, the cells were n treated with 3,3'-diaminobenzidine (DAB) in Tris Buffered 
Saline (TBS) and 1 % hydrogen peroxide for 10 min. Subsequently, cells were washed with TBS 
before rinsing with 0.1 M of acetate buffer pH 4.8. The coverslips were then counterstained with 1 % 
Methyl Green. After dehydrating the cells with increasing concentration of ethanol and Histoclear, the 
cover slips were mounted on glass slides.  
 
2.8. Growth curve analysis 
Cells were cultured for up to 72 h post siRNA transfection and analysis was conducted using 
alamarBlue (Invitrogen, CA, USA) which allows continuous monitoring of the treated cells. 
AlamarBlue was added to a concentration of 10 % (v/v) of the total volume of the medium bathing the 
cells 20 h after seeding. The samples were then incubated for 4 h at 37ºC in a 5 % CO2 humidified 
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incubator and the absorbance read at 570 nm with 600 nm as the reference wavelength using the 
Tecan2000 plate reader. Following which, the medium with alamarBlue was removed and fresh 
medium was added to the cells. The above procedure with alamarBlue was repeated 4 h before the 24 h, 
48 h and 72 h time points. The experiments were conducted in triplicates.  
 
2.9. Cell proliferation assay 
Cell proliferation was determined with the CellTiter 96® Non Radioactive Cell Proliferation 
Assay (Promega, Madison, WI). The dye solution contains a MTT tetrazolium component that is 
converted into a formazan product by living cells. At 72 h post siRNA transfection, 150 µl of dye 
solution was added to the siRNA transfected cells in a 24-well plate, containing 1000 µl of fresh culture 
medium. The plate was then incubated for 4 h at 37ºC in a humidified, 5 % CO2 atmosphere. After 
incubation, 1000 µl of Solubilization Solution/Stop Mix was added to each well to solubilize the 
formazan product. The plate was allowed to stand overnight in a humidified incubator at 37ºC. The 
absorbance was read at 570 nm with 650 nm as the reference wavelength using the Tecan2000 plate 
reader. The absorbance at 570 nm measures the maximum absorbance for the formazan product and is 
directly proportional to the number of cells used in proliferation assays.  
 
2.10. Cell adhesion assay 
Cell adhesion stripes coated with Human Collagen Type I and Human Fibronectin (Chemicon, 
Temecula, CA, USA) were hydrated with 200 µl of PBS in an incubator for at least 15 min at room 
temperature before use. PBS was then aspired from the wells. Cells treated with siRNA were 
dissociated with trypsin-EDTA method were pelleted at 2,000 rpm for 5 min at room temperature. The 
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cells were washed with serum free medium before centrifuged. The pelleted cells were then 
resuspended in 500 µl of serum-free DMEM medium. Cells were counted with a haemocytomer and 
diluted to 5 X 105 /ml. 100 µl of the cell suspension was then added to each well. Quadruplicates of 
each sample were done for both Fibronectin and Collagen Type I strips. The cells were incubated in a 
tissue culture incubator at 37ºC with 5 % CO2 atmosphere for 1 h before washing thrice with 200 µl of 
1 mM CaCl2 in PBS. 100 µl of serum-free medium was added to the cells together with 20 µl of 
MTS/PMT reagent (Pierce Biotechnology, Rockford, IL, USA) to measure cell viability. The strips 
were incubated for 1 – 3 h and readings carried out at every hour using a Tecan plate reader at 490nm. 
This experiment was performed three times independently to ensure reproducibility.  
 
2.11. Cell cycle analysis  
MCF-7 cells were transfected with siRNA or overexpression vectors as mentioned above for 72 
h and 24 h respectively. The number of cells was ensured to be at least 1 X 106 for each cell cycle 
reaction. The cell culture medium bathing the cells were aspirated and collected. The cells were then 
washed twice with warm PBS and the washes were collected before harvesting by trypsin-EDTA 
method. The harvested cells, the bathing medium and the washes were pooled together before 
centrifuging at 1,800 rpm at 4ºC for 10 min. The pelleted cells were washed twice with PBS and 
pelleted at 1,800 rpm at 4ºC for 10 min before resuspending in 1 ml of PBS. The resuspended cells 
were then fixed by adding dropwise to 4 ml of ice-cold 70 % ethanol and fixed for at least 30 min on 
ice. The fixed cells were collected by centrifuging at 1,800 rpm for 10 min at 4ºC. The pelleted cells 
were then washed once with PBS. The cells were centrifuged before suspending in propidium 
iodide/RNase solution consisting of a final concentration of 20 µg/ml of propidium iodide (Sigma 
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Aldrich, Saint Louis, MI, USA), 200 µg/ml of RNase A (Roche Applied Science, Indianapolis, IN, 
USA) solution in freshly prepared 0.1 % Triton-X in PBS. The cells were incubated for 30 min in the 
dark at room temperature before analysis. Cell cycle analysis was conducted with DAKO machine and 
BD Beckinson FACSVantage machine for the siRNA transfected cells and overexpression vector 
transfected cells. The experiment was conducted in triplicates at three independent times to ensure 
reproducibility. The cell cycle profiles were analyzed with the Summit v3.3 software 
(Dakocytomation).  
 
2.12. Cell migration assay  
Cell migration assays were carried out using Transwell polycarbonate inserts with 8.0 µm pore 
size (Corning, Acton, MA, USA). The transwell inserts were first hydrated by immersing the inserts in 
400 µl of warm DMEM containing 10 % FBS in a 24-well plate and adding 200 µl of the same culture 
medium to the upper chamber of the insert for at least 2 h prior to usage. The treated cells were 
harvested using trypsin-EDTA method and washed once in serum-free DMEM to remove any traces of 
serum before resuspending in an appropriate volume of serum-free DMEM. The number of cells were 
determined for each treatment was determined using haemocytomer and seeded at a density of 5 X 104 
cells per well in the upper chamber. The lower chamber was filled with DMEM with 20 % of FBS as 
chemo-attractant. Cells were allowed to migrate for 19 h under normal growth conditions. The inserts 
were then washed with PBS and fixed with 4 % paraformaldehyde for 10 min. The inserts were washed 
with PBS and allowed to air dry before staining with 0.5 % (w/v) of crystal violet solution for 20 min. 
The inserts were then rinsed in tap water to wash away excess crystal violet solution. Non-migratory 
cells on the upper chamber were removed with the use of a damp cotton swab. The migratory cells 
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were visualized under a microscope (Nikon SMZ 1500) at 10X magnification. Five different field 
views were taken and the cells were counted. The assay was performed in triplicates at three 
independent times to ensure reproducibility. 
 
2.13. Invasion assay  
Cell invasion assays were carried out using Matrigel inserts with 8.0 µm pore size (BD 
Biosciences, Bedford, MA, USA). The inserts were thawed to room temperature before adding 500 µl 
of warm DMEM containing 10 % FBS to the interior of the inserts and the bottom of the wells. The 
wells were left to hydrate overnight in a humidified tissue culture incubator at 37ºC with 5 % CO2 
atmosphere. After hydration, the medium was carefully aspirated without disturbing the layer of 
Matrigel Matrix on the membrane. The hydrated inserts were transferred to empty wells of BD Falcon 
24-well plates with the use of sterile forceps. The treated cells were harvested using trypsin-EDTA 
method and washed once with serum-free medium. The cells were counted using haemocytometer and 
prepared to contain a density of 2 X 105 cells/ml in the upper chamber while the wells of the BD 
Falcon 24-well plate was filled with 750 ºC l of DMEM with 20 % of FBS as chemo-attractant. The 
invasion chambers were transferred to the wells containing the chemoattractant with the use of a sterile 
forceps. Caution was taken to ensure that there was no air bubbles trapped beneath the membranes. 500 
µl of the prepared cell suspension was added to the chamber. The invasion chambers were incubated 
for 24 h in a humidified tissue culture incubator at 37ºC containing 5 % CO2. The non-invading cells 
were removed with the use of a damp cotton swab from the inserts. The inserts were then washed with 
PBS and fixed with 4 % paraformaldehyde for 10 min. The inserts were further washed with PBS and 
allowed to air dry before staining with 0.5 % (w/v) of crystal violet solution for 20 min. The inserts 
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were then rinsed in tap water to wash away excess crystal violet solution. The invading cells were 
visualized under a microscope (Nikon SMZ 1500) at 10X magnification. Five different field views 
were taken and the cells were counted. The assay was performed in triplicates at three independent 
times to ensure reproducibility. 
 
2.14. Superarray analysis  
 RNA was extracted from the cells using RNEasy Mini kit with DNase I treatment as mentioned 
above. The quantity and quality of the extracted RNA was examined using Nanodrop ND-100 
spectrophotometer (Thermo Fischer Scientific, Wilmington, USA) to ensure that the A260:A280 ratio 
of the RNA was greater than 2.0 and the A260:A230 ratio was greater than 1.7. In addition, the RT2 
RNA QC PCR Array (Superarray Bioscience, Frederick, MD, USA) was also employed to examine the 
RNA quality based on a number of RNA quality control parameters including high and low 
housekeeping gene expression levels, reverse transcription and PCR efficiency, genomic and general 
DNA contamination.  
 Once the quantity and quality of the RNA had been determined, 1.0 µg of RNA was converted 
into cDNA with the use of RT2 First Strand Kit (Cat. No. C-03, Superarray Bioscience, Frederick, MD, 
USA). Briefly, 2.0 µl of GE (5X gDNA Elimination Buffer) was added to 1.0 µg of RNA with RNase-
free water making up to a final volume of 10.0 µl of Genomic DNA Elimination mixture. The contents 
were mixed gently by pipetting before incubating at 42ºC for 5 min. The samples were then 
immediately chilled on ice for at least one minute. For each sample, the RT cocktail was prepared as 
follows:  
- 4.0 µl of 5X RT buffer 3 (BC3) 
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- 1.0 µl of Primer & External Control Mix (P2) 
- 2.0 µl of RT Enzyme mix 3 (RE3) 
- 3.0 µl of RNase-free water 
 Next, 10.0 µl Genomic DNA Elimination mixture was added to the 10.0 µl of RT cocktail. The 
samples were mixed well and incubated at 42ºC for 15 min. Following which, the samples were heated 
at 95ºC for 5 min to degrade the RNA and to inactivate the reverse transcriptase. To dilute the cDNA, 
91 µl of deionised water was added to the 20 µl of cDNA synthesis reaction and mixed well. The 
samples were either used immediately or stored at -20ºC.  
To prepare the experimental cocktail for performing real-time PCR in the array, the following 
components were prepared in a multi-channel reservoir to give a total volume of 2550 µl: 
- 1275 µl of 2X SuperArray PCR master mix 
- 102 µl of diluted first strand cDNA synthesis reaction 
- 1173 µl of deionised water 
Following so, 25 µl of the experiemental cocktail was added to each well of the PCR array with 
the use of a multi-channel pipettor. Real-time PCR was then conducted using ABI7000 with the 
conditions below:  
For each sample used for Superarray analysis, the transfection efficiency of the gene was first 
determined using real-time PCR with lightcycler capillaries (Roche Applied Science, Indianapolis, IN, 
USA). For silencing efficiency, the gene has to have a silencing efficiency of at least 75 % before 
subjecting to Superarray analysis. The normalizer used was the average of five housekeeping genes for 
each cDNA sample.  
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2.15. Immunoblot analysis  
2.15.1. Protein extraction 
Cells on the monolayer were carefully washed twice with ice-cold PBS to remove any non-adherent 
cells. An appropriate volume of M-PER with EDTA, protease inhibitor cocktail and phosphatase 
inhibitor cocktail (Pierce Biotechnology, Rockford, IL, USA) was added to the cells for 10 min with 
gentle rocking at 4ºC. The cells were then dislodged from the culture vessel with the use of a cell 
scrapper, at 4ºC. The cells were collected and the cell debris was removed by centrifuging the cell 
lysate at 13 000 rpm at 4ºC or 10 min. The protein obtained was aliquoted before storing at -80ºC. 
Protein concentration was examined before each use with Bio-rad Protein Assay Dye Reagent 
Concentrate (Bio-rad, Hercules, CA, USA). Bio-rad Protein Assay Dye Reagent Concentrate (Bio-rad, 
Hercules, CA, USA) was diluted with four parts of deionised water before use. The diluted protein 
assay reagent was then filtered through Whatman #1 filter to remove any particulates that may interfere 
with the absorbance reading. Five dilutions of the BSA standard were prepared for the microtiter plate 
assay between 0.05 to 0.5 mg/ml. Triplicates of each protein sample was done. Ten ul of each sample 
was added to separate microtiter wells. Following which, 200 µl of the diluted dye reagent were then 
added to each well and mixed thoroughly. The mixture was incubated at room temperature for at least 5 
minutes and no more than 1 h for absorbance reading at 595 nm using a Tecan microtiter plate reader.  
2.15.2 Preparation of protein sample 
Twenty µg of protein sample were boiled with 5X sample buffer containing 100 mM DTT for 
10 min before loading onto either an 8 % or 10 % SDS-PAGE gel, depending on the size of protein to 
be examined.  
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2.15.3. Preparation of resolving and stacking gel 
The SDS gel casting apparatus which comprises of the spacer plates and the outer glass plates 
were washed with water and wiped with 70 % ethanol. The resolving gel mixture is first prepared 
according to the recipe in Table 2 below, with TEMED (Bio-rad, Hercules, CA, USA) and APS (Bio-
rad, Hercules, CA, USA) being added last. The gel mixture was added to the space between the spacer 
plate and the glass plate, ensuring that no air bubble is trapped in the gel. Deionized water was then 
quickly added to the top of the resolving gel to ensure an even surface. The gel was allowed to 
completely polymerize before pouring the overlaying water. The mixture for the stacking gel was then 
prepared. Similarly, TEMED and APS were added last to prevent premature polymerization of the gel. 
Following which, stacking gel mixture was added to the top of the resolving gel and the comb was 
added into the stacking gel. The stacking gel was allowed to completely polymerize before removing 
the comb.  
 
Table 2. Recipe for the 8 % or 10 % resolving gel and stacking gel for two pieces of SDS gel. 
Resolving gel  Stacking gel 
Reagent 8 % 10 % 5 % 
Water 4600 μl 4000 μl 3400 μl 
30 % polyacrylamide 2700 μl 3300 μl 830 μl 
1.5 M Tris pH 8.8 2500 μl 2500 μl - 
1.0 M Tris pH 6.8 - - 630 μl 
10 % SDS 100 μl 100 μl 50 μl 
10 % APS 100 μl 100 μl 50 μl 
TEMED 4 μl 4 μl 5 μl 
Total 10 ml 10 ml 5 ml 
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2.15.4. SDS-PAGE 
Twenty micrograms of the each prepared protein samples were loaded to the individual wells of 
the SDS gel. Precision Plus protein prestained dual colour protein marker was also loaded to the gel for 
molecular weight prediction. The sample was subjected to electrophoresis until the bromophenol blue 
ran out from the gel.  
2.15.5. Transfer of proteins 
Proteins smaller than 100 kDa were then transferred to a PVDF membrane using either Trans-
blot SD Semi-dry Transfer cell (Bio-rad, Hercules, CA, USA) while proteins larger than 100 kDa were 
transferred using Mini Trans-blot cells (Bio-rad, Hercules, CA, USA) by wet transfer. The membrane 
was first treated with methanol before rinsing with deionised water. The membrane, filter pads and gel 
were soaked in transfer buffer before use. For semi dry transfer, transfer buffer containing 20 % 
methanol, 25 mM Tris and 192 mM glycine, pH 8.3 was used. The samples were transferred at 15 V for 
50 min using Trans-blot SD semi-dry transfer system. For wet transfer, chilled transfer buffer 
containing 10 % methanol, 25 mM Tris and 192 mM glycine was used. The samples were transferred at 
100 V at 4ºC for 1 h using the Mini Trans-blot cells. After the transfer, the membrane was then blocked 
with either 5 % Blotting-Grade blocker (Bio-rad, Hercules, CA, USA) in TBST or Superblock reagent 
(Pierce Biotechnology, Rockford, IL, USA) with 0.1 % Tween-20 for 1 h at room temperature. The 
membrane was incubated overnight at 4ºC with desired primary antibodies in its blocking reagent. The 
percentage of SDS resolving gel, type of blocking reagent and the dilution of each of the primary 
antibodies used are illustrated in Table 3. 
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Table 3. Details of immunoblotting for each specific primary antibody. 
Primary Antibody SDS Resolving Gel Blocking reagent Dilution 
Cdc25a 10 % 5 % Blotting Grade Blocker 1: 200 
uPAR 10 % 5 % Blotting Grade Blocker 1: 200 
c-Met 8 % 5 % Blotting Grade Blocker 1: 200 
ATM 8 % Superblock with 0.1 % T20 1: 100 
Chk-2 10 % Superblock with 0.1 % T20 1: 1000 
Chk-2 (P) 10 % Superblock with 0.1 % T20 1: 500 
 
The membrane was washed with TBST thrice at 10 min each before incubation with sheep-anti-
mouse IgG antibodies (Pierce Biotechnology, Rockford, IL, USA) or donkey-anti-rabbit antibodies 
(Pierce Biotechnology, Rockford, IL, USA) for 1 h at room temperature. The bands were visualized 
with Supersignal West Pico Chemiluminescent Substrate (Pierce Biotechnology, Rockford, IL, USA) or 
Supersignal West Femto Chemiluminescent Substrate (Pierce Biotechnology, Rockford, IL, USA) 
depending on the sensitivity required on CL-XPosure Film (Pierce Biotechnology, Rockford, IL, USA). 
B-actin (Bio-rad, Hercules, CA, USA) was used as the loading control.  
 
2.16. Electron microscopy 
2.16.1 Transmission electron microscopy 
The cells were grown on chamber glass slides and treated with siRNA for 48 h as previously 
mentioned. The cells were washed with PBS before fixing in 3 % glutaraldehyde (BDH, Poole, UK) 
and 2 % paraformaldehyde (BDH, Poole, UK) in Phosphate buffer (0.1 M, pH 7.4) (PB) overnight, as 
previously described (Bay et al. 1998). Briefly, osmification was carried out with 1 % osmium 
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tetroxide (Agar Scientific Ltd, Stansted, UK) for 1 h at room temperature. Samples were dehydrated in 
an ascending series of ethanol for 10 min each and embedded in araldite (Ted Pella Inc, Redding, CA, 
USA). Ultrathin sections were cut on a Reichert E Ultramicrotome and mounted on formvar-coated 
copper grids. Sections were doubly stained with uranyl acetate (BDH, Poole, UK) and lead citrate 
(BDH, Poole, UK) before examination with a Philips CM 120 BioTwin electron microscope.  
2.16.2. Scanning electron microscopy 
MCF-7 cells grown on glass slides were treated with siMT2A_1 or siNeg for 48 h. Cells were 
fixed in 3 % Glutaraldehyde in PB at pH 7.4 for 1 h. After washing with PB, cells were post-fixed with 
1 % Osmium tetroxide for 30 min. The samples were subsequently dehydrated with increasing 
concentrations of ethanol followed by drying in a Critical Point Dryer (Baltec CPD 030, Liechtenstein). 
The cells were sputter-coated with gold before viewing in a Philips XL30 SEM (FEI, Holland).  
 
2.17. Scanning transmission ion micro-tomography (STIM) 
 MCF-7 breast cancer cells were grown on the upper surface of a silicon nitride window and 
critical point dried. The cells in the STIM assembly were mounted on a computer controlled Burleigh 
Inchworm EXFO XYZ stage which has a travel of 25 mm for all axes with a 20 nm closed loop 
resolution (Van Kan and Andrew A. Bettiol 2004).  
 
2.18. Statistical analysis  
Values are presented as means ± S.E.M. An unpaired two-tailed t-test or One Way ANOVA 
MATERIALS AND METHODS 
 
    67 
followed by a post hoc Tukey test was performed using the GraphPad Prism version 4.00 for Windows. 
For comparing differences between growth curves, the Two Way ANOVA was used. p < 0.05 was 
considered significant. 
 
2.19. MT staining in invasive ductal breast carcinoma tissues 
2.19.1. Patients and tissues 
A total of 180 cases of archival breast cancers were included in the study. These samples were 
obtained from patients who had surgery at the Singapore General Hospital (SGH). The study was 
approved by the Institutional Review Board. These cases of breast invasive ductal cancer were 
diagnosed between 1998 and 2002 at the Department of Pathology, SGH. The biopsies were fixed in 10 
% formalin and embedded in paraffin for immunohistochemical studies. Patient details and tumour 
laterality were determined from accession forms while tumour size was obtained from surgical 
pathology reports. Patient follow-up was obtained from case notes and the Singapore Cancer Registry, 
National Disease Registries Office. The histological diagnosis was made on haematoxylin and eosin 
(H&E) stained slides according to standard criteria defined by the World Health Organization and 
modified by Elston and Ellis (Elston et al. 1998). None of the patients received chemotherapy or 
radiotherapy before surgery. All the samples were harvested by pathologists from the Pathology 
Department, SGH. The patient age was obtained from the pathology accession form.  
 
2.19.2. Tissue microarrays 
Invasive ductal breast cancer tissues and adjacent benign breast tissues were randomly obtained 
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from mastectomies at SGH. The preselected and marked areas were punched out from donor blocks 
and arrayed sequentially into recipient blocks using the tissue microarrayer. Three recipient blocks 
were used for this study. These blocks contained 60 tissue array punches. One tissue core was used per 
case. Benign breast tissue and irregular tissue fragments were excluded from evaluation. Each tissue 
array was 1 mm in diameter, as the 1 mm punch was used. These were mounted on glass slides coated 
with silane (3-aminopropyltriethoxysilane; Sigma Immunochemicals, USA; Cat. no. A3648), and dried 
overnight at 37°C.  
 
2.19.3. Clinicopathological parameters of patients of invasive ductal carcinomas 
 Three TMAs, namely SP07-04, SP13-04 and SP16-04, with a total 180 cases of invasive breast 
carcinoma from 1998 to 2002 were included in this study. The clinicopathological data is shown in 
Table 12.  
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Table 4. Demographic feature of invasive ductal breast cancer patients.  
 
Variable Number ( %) 
Gender  
Male 1 (0.8 %) 
Female 108 (90.8 %) 
Missing 10 (8.4 %) 
Race  
Chinese 102 (85 %) 
Malay 8 (6.6 %) 
Indian 5 (4.2 % 
Others 5 (4.2 %) 
Age range 34 to 85 years 
Mean Age 54.37 years 
Stage  
I 26 (12.3) 
II 103 (48.6) 
III 21 (9.9) 
Missing 30 (14.2) 
Histology grade  
Low (I) 25 (11.8) 
Medium (II) 76 (35.8) 
High (III) 68 (32.1) 
Not available 11 (5.2) 
DCIS association  
None 70 (33) 
Minimum 69 (32.5) 
Extensive 21 (9.9) 
Not available 8 (3.8) 
Bloomrichardson score  
3-5 22 (10.4) 
6, 7 58 (27.4) 
8, 9 56 (26.4) 
Not available 44 (20.8) 
Tubule formation  
1 11 (5.2) 
2 42 (19.8) 
3 83 (39.2) 
Not available 44 (20.8) 
Nuclear pleomorphism  
1 13 (6.1) 
2 67 (31.6) 
3 56 (26.4) 
Not available 44 (20.8) 
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Mitotic index  
1 42 (19.8) 
2 42 (19.8) 
3 52 (24.5) 
Not available 44 (20.8) 
ER status  
Negative 46 (21.7) 
Positive 107 (50.5) 
Not available 27 (12.7) 
PR status  
Negative 78 (36.8) 
Positive 75 (35.4) 
Not applicable 27 (12.7) 
Lymph node stage  
I 85 (40.1) 
II 47 (22.2) 
III 36 (17.0) 
C-erbB2 status  
Negative 109 (51.4) 
Positive 45 (21.2) 
Not available 26 (12.3) 
Treatment procedure  
Mastectomy 34  
Breast conserving surgery 152 
  
  
 This included 108 cases from female, one case from male and 10 cases with missing data. For 
ethnic distribution of the patients, 102 were Chinese, 5 were Indians, 8 were Malays and 5 cases from 
other races. The age range of these patients was found to be from 35 to 80 years, with the mean age at 
54.37 years. The tumour size of the patients ranged from 5 mm to 120 mm and the mean size was 34.33 
mm. Of the 180 cases, only 124 of the cases contain information of the stage of the tumour with 21 
cases (16.9 %) of stage 1, 90 cases (72.6 %) of stage 2 and 13 cases (10.5 %) of stage 3. Furthermore, 
70 of the cases were found not to be associated with DCIS, 69 of cases were found to have minimum 
association with DCIS and 21 cases were found to have extensive association with DCIS. There was a 
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rather uniform distribution for mitotic index with 42 cases of stage 1, 42 cases of stage 2 and 52 cases 
of stage 3. 
2.19.4. Immunohistochemical staining 
Immunohistochemistry staining for standard and TMA sections were carried out on Bond Max 
(Leica Microsystems GmbH, Wetzlar, Germany) machine with MT antibody (Dako E9). All the 
reagents used were from Leica (Leica Microsystems GmbH, Wetzlar, Germany), unless otherwise 
stated. The sections and TMA sections were first subjected to dewaxing with Bond dewax solution 
followed by washing in ethanol. The slides were then washed with Bond wash solution before heat 
activated epitope retrieval (HIER) with citrate buffer; pH 9 for 30 min. Endogenous peroxidase 
activity was blocked with Peroxidase block before washing thrice with Bond wash solution. The MT 
antibody (E9, Dako, Denmark) was diluted in primary antibody diluent (Leica Microsystems GmbH, 
Wetzlar, Germany) to a ratio of 1:50 and incubated for 15 min at ambient temperature before washing 
thrice in Bond wash buffer. The slides were then incubated with the Polymer solution for 8 min before 
washing twice in Bond wash solution. Following a wash with deionized water, the slides were 
incubated with Mixed DAB refine solution for 10 min followed by washing the slides twice with 
deionized water. The sections were then counterstained with Hematoxylin for 5 min before washing 
the excess stain with deionized water followed by Bond wash solution.  
 
2.19.5. Scoring system 
No staining or staining in <10 % of the tumour cells was taken as score of 0. Faint staining of 
>10 % of the tumour cells was regarded as score of 1+; a weak to moderate, and strong complete 
staining observed in >10 % of the tumour cells were given a score of 2+ and 3+ respectively. The 
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scoring of the immunoreactivity (IRS) was based on the sum of the product of the percentage of 
immunopositive cells and the staining intensity (0, 1, 2 or 3), yielding scores of 0 – 300. IRS Scoring 
was conducted for cytoplasmic staining (IRSCyt) and nuclear staining (IRSNu). 
 
2.19.6. Statistical analysis 
SPSS 12.0 statistical software (SPSS, USA) was used for statistical analysis. Pearson’s chi-
square and Fisher Exact test were employed to examine the significance of MT immunostaining with 

























    74 
3.1. Morphology of breast cell lines 
The breast cell lines examined included MCF-12A cells, MCF-7 cells, MDA-MB-231 cells, 
T47D cells and ZR75 cells (Figure 6). 
 
 
MCF12A      MDA-MB-231   MCF-7 
 
  
MDA-MB-435  ZR75 
 
Figure 6. Morphology of the different breast cancer cell lines. 
 
MCF-12A cell line is a non-tumorigenic epithelial cell line. MCF-7 cell line is an ER and PR 
positive epithelial shaped cell line that has low invasive capabilities in vitro (Thompson et al. 1992; 
Tong et al. 1999). MDA-MB-231 cells are ER and PR negative with epithelial-like morphology which 
appear as spindle-shaped cells. These cells have an invasive phenotype in vitro as shown in chamber 
invasion and chemotaxis assays (Thompson, et al. 1992). T-47D cell line is a breast cancer epithelial 
cell line that is ER and PR negative that is non-invasive in vitro due to its inability to invade the 
collagen fibroblast matrix. ZR-75 cell line is a ER and PR positive cell line that has epithelial-like 
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morphology and is considered as a non-invasive cell line with as it does not penetrate through the 
collagen fibroblast matrix (Thompson, et al. 1992). In general, the aggressiveness of the different 
breast cell lines ranges from the non-invasive MCF-7 cells and ZR-75 cells and less invasive T-47D 
cells, to the highly metastatic MDA-MB-231 cells.  
 The MCF-7 breast cancer cell line is the main breast cancer cell line used in this study. The 
morphology of MCF-7 breast cancer cells as visualized by high resolution microscopy is shown in 





Figure 7. High resolution microscopy pictures of MCF-7 breast cancer cells using (A) TEM, (B) SEM 
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3.2. Expression of MT in breast cell lines 
The expression of the different metallothionein isoforms were examined in the different breast 
cell lines. The expression level is presented in Figure 8 as ΔCT values. Of the several isoforms 
examined, MT-1B and MT-1G were not expressed in the various breast cell lines. MT-1H was found to 





Figure 8. Quantitative expression of MT-1and 2 isoforms using G3PDH as a housekeeping gene in 
various breast cancer cell lines, namely non-invasive breast cancer, MCF-7 cells; normal breast cells, 
MCF-12A; MDA-MB-231 cells; T47D cells and ZR-75 cells. Each column shows the ΔCT ± SE of 
each MT isoform in the corresponding breast cancer cell line. A lower ΔCT depicts a higher level of 
gene expression. 
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The specificity of the primers was verified by melting curve analysis and gel electrophoresis 
(Figure 9).  






Figure 9. Specificity of primers was verified by (A) melting curve analysis and (B) DNA gel 
electrophoresis.  
 
M    GAPDH  MT-2A 
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3.3. Transfection in MCF-7 
The transfection efficiency of RNAiFect transfection reagent in MCF-7 cells was examined 
using Cy3 labelled siNegative to ensure successful uptake of siRNA into the cells (Figure 10). The red 
fluorescence was examined using the green laser. The transfection efficiency of RNAiFect in MCF-7 
cells was found to be around 97.3 %. The percentage of fluorescent intensity was determined by the 




Figure 10. Transfection efficiency examined using Cy3 labelled siNegative at (A) 10X and (B) 40X 
magnification using fluorescent microscope. 
 
 
The various parameters for transfection such as seeding density and the amount of siRNA were 
optimized using a positive siRNA targeted against the A/C lamin gene (siAClam). The seeding density 
was also examined to be optimal at 6 X 104 of cells per well in a 24-well plate format and optimem1 
medium was the preferred medium as compared to the complete medium to dilute the siRNA prior to 
combination with RNAiFect transfection reagent (Figure 11).  
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Figure 11. Optimization of cell seeding density of MCF-7 cells with different media, namely (A) 
complete medium consisting of 10 % serum in DMEM and (B) Optimem1 reduced serum medium to 
be used in combination to the RNAiFect transfection reagent. Optimem1 gave a more consistent 
silencing efficiency with siAClamin positive control siRNA. A cell density of 6 X 104 cells was the 
selected cell seeding density prior to transfection. 
 
A preliminary time post transfection was also examined using the positive A/C lamin siRNA 
showed the knock-down efficiency from 24 - 72 h post transfection (Figure 12). The most favorable 
amount of siRNA was found to be 1.0 μg for a 24-well plate format and the optimal volume of 
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transfection reagent (μl) to amount of RNA (μg) ratio was found to be 1:6 (Figure 13).  
 







Figure 13. Optimization of transfection efficiency using AClamin positive siRNA to determine the 
optimal amount of siRNA and ratio of transfection reagent to siRNA to be used. 1.0 ug of siRNA with 
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3.4. Down-regulation of MT-2A  
The down-regulation efficiency of siMT2A was examined using two independent siRNA 
duplexes; namely siMT2A_1 and siMT2A_2. The region targeted by each siRNA targets are as shown 




Figure 14. Regions targeted by siMT2A _1 and siMT2A_2 on the MT-2A gene. 
 
The relative expression of the MT-2A gene following successful down-regulation was examined 
at 48 h and 72 h post transfection (Figure 15). The MT-2A gene was found to be successfully down-
regulated at 94 % and 96 % with siMT2A_1 and siMT2A_2 respectively at 48h. The silencing 
efficiency decreased to 76 % and 78 % for siMT2A_1 and siMT2A_2 respectively at 72h.  
RESULTS 
 






Figure 15. Manipulation of MT-2A expression in MCF-7 cells by silencing the MT-2A gene with 
siRNA. Silencing efficiency of two independent siRNA, namely siMT2A_1 and siMT2A_2, at (A) 48 
h and (B) 72 h post-transfection. Total RNA was extracted and converted to cDNA before analysis by 
Quantitative RT-PCR.  
 
 
Down-regulation of MT-2A at protein level was determined by immunocytochemistry (Figure 
16). The intensity of DAB staining in the MT-2A silenced samples was significantly lesser as compared 
to siNegative treated samples.  
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Figure 16. Immunocytochemistry with primary monoclonal anti-MT E9 antibody and DAB staining 
after treatment with (A) siMT2A_1, (B) siMT2A_2 and (C) siNegative. More intense staining is 
observed in cells treated with siNegative as compared to siMT2A_1 and siMT2A_2. Cells were 
counterstained with methyl green and imaged at magnification of 200X. 
 
Although the E9 antibody detects all MT-1 and MT-2 isoforms, MT-2A is known to be the most 
abundant isoform in MCF-7 cells. Western blotting was not employed for the detection of MT proteins 
as to-date there is no well-developed protocol for MT due to the small size (6 – 7 kDA) of this protein. 
Down-regulation of MT-2A with siMT2A_1 and siMT2A_2 was found to be independent of the other 
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Figure 17. Expression of MT isoforms in siMT2A treated (siMT2A_1 and siMT2A_2) and untreated 
MCF-7 cells. Downregulation of MT-2A was independent of other MT isoforms present in MCF-7, 
namely MT-1A, 1F, 1X and 3. This is determined by the non-significant difference in ∆CT between the 
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3.5. Morphological changes after down-regulation of MT-2A 
The morphology of MCF-7 cells after transfected with siMT2A under light microscope 
appeared to have more dead cells as compared to either untreated cells or cells treated with siNegative 
(Figure 18).  
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There appeared to be more apoptotic cells and presence of cell blebs in MCF-7 cells treated 
with siMT2A (Figure 19).  
 
Figure 19. Scanning electron micrographs of MCF-7 cells treated with siMT2A and siNegative at 48 h 
post transfection. Bar = 50 μm. Inset shows an apoptotic cell with a shrunken morphology and the 
presence of cell blebs. Bar = 5 μm.  
 
Entosis was also observed in cells that were treated with siMT2A_1 and siMT2A_2 by 
transmission electron microscopy. Entosis, or cell-in-cell invasion is a term used to describe a 
phenomenon where a whole cell is engulfed by a neighboring cell. This phenomenon was not observed 
in untreated cells or cells treated with siNegative (Figure 20). Entosis has been observed in cancer 
tissues for decades but has been recently proposed as a form of cell death and a form of tumor 
suppressor mechanism that eliminates any cell that detaches from the extracellular matrix (Overholtzer 
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Figure 20. TEM of MCF-7 cells treated with siMT-2A, siNegative and untreated cells. (A) siMT2A_1; 
(B) siMT2A_1 showing entosis (C) siMT2A_2; (D) siMT2A_2 showing entosis; (E) siNegative. 
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3.6. Specificity of MT isoforms 
Down-regulation of another MT isoform, MT-1F was carried out to examine if some of the 
phenomenon observed during the silencing of MT-2A was indeed isoform specific. This study was 
carried out using light microscopy, TEM and cell migration after verifying the knock-down of the MT-
1F gene.  
 
3.6.1. Down-regulation of MT-1F 
The relative expression of MT-1F was examined at 48 h post transfection (Figure 21). The MT-
1F gene was found to be down-regulated at 89 % and 85 % for siMT1F_1 and siMT1F_3 respectively. 
  
Figure 21. Silencing efficiency of two independent siRNA, namely siMT1F_1 and siMT1F_3 at 48 h 
post-transfection. Columns, mean (n = 3); bars, SE. 
 
Down-regulation of MT-1F using siMT1F_1 and siMT1F_3 resulted in concomitant down-
regulation of other MT isoforms present in MCF-7; namely MT-1X and MT-2A (Figure 22). siMT1F_1 
appeared to be the better siRNA for the down-regulation of MT-1F as the extend of down-regulation of 
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the other isoforms was much lesser as compared to siMT1F_3.  
 
 
Figure 22. Expression of MT isoforms in siMT1F treated (siMT1F_1 and siMT1F_3) and siNeg 
treated cells. Down-regulation of MT-1F isoform using siMT1F_1 and siMT1F_3 results in 
concomitant decrease of the other MT isoforms such as MT-1X and MT-2A.  
 
There was no obvious change in morphology in the cells under light after treatment with MT-1F 
siRNA (Figure 23).  
 
  
siMT1F    siNegative 
 
Figure 23. Light micrographs of cells treated with MT-1F siRNA (siMT1F) and Negative siRNA 
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To further examine the ultrastructural details of cells treated with siMT1F, transmission electron 
microscopy was employed. Similar to cells treated with siMT2A, several cells that were treated with 
siMT1F_1 and siMT1F_3 also displayed signs of entosis (Figure 24).  
  
 




3.7. Effect of down-regulation of MT-2A on cell proliferation 
 MT-2A was observed to have a positive effect on cell proliferation. Down-regulation of MT-2A 
in MCF-7 breast cells resulted in a decrease in the number of viable cells. Survival analysis of siMT2A 
cells from 0 h to 72 h post siRNA transfection was conducted using alamarBlue. There was a 
significant decrease in the number of siMT2A_1 cells (p = 0.0056) or siMT2A_2 cells (p = 0.0147) as 
compared to siNegative treated cells when analyzed with the two-way ANOVA (Figure 25A). There 
was no significant difference in the treatment between siMT2A_1 and siMT2A_2 when analyzed with 
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analysis using showed reduced cell proliferation at 72 h post siRNA transfection in siMT2A_1 cells (p 
< 0.001) and siMT2A_2 cells (p < 0.05) as compared to cells treated with the siNegative control 
(Figure 25B).  
 




Figure 25. Down-regulation of MT-2A decreased cell proliferation. (A) Survival curve analysis of 
siMT2A_1, siMT2A_2 and siNeg cells from 0 – 72 h post siRNA transfection was conducted using 
alamarBlue. Analysis show that treatment with siMT2A decreased cell survival. (B) Cell proliferation 
assay was conducted 72 h post siRNA transfection. There was significant decrease in the proliferation 
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 Cell cycle analysis was conducted using flow cytometry with propidium iodide staining on the 
nucleus. Both siRNAs against MT-2A demonstrated an increase in the number of cells in the sub-G1 
and G1 phase and decrease in the S and G2/M phases (Figure 26A and B). There was a slight increase 
in the percentage of cells in the sub-G1 phase in the siNegative treated cells as compared to the 
siMT2A_1 (p = 0.0067) and siMT2A_2 (p= 0.0198) treated cells. There was also a significant increase 
in the percentage of cells in the G1 phase from 71.3 % in the siNegative treated cells to 83.7 % in 
siMT2A_1 (p < 0.0001) and 74.4 % in the siMT2A_2 (p = 0.0215) treated cells. A decrease in the 
percentage of cells in the S phase was observed in the siMT2A_1 (p = 0.0002) and siMT2A_2 (p= 
0.012) treated cells as compared to the siNegative treated cells. In the G2/M phase, siMT2A_1 treated 
cells showed a significant decrease in the percentage of cells as compared to siNegative treated cells 
(7.3 % compared with 15.0 %, p = 0.0008). There was no significant difference between the untreated 








Figure 26. Down-regulation of MT-2A resulted in cell cycle G1 arrest. (A) Representative cell cycle 
profile of MCF-7 cells (control) and MCF-7 cells transiently transfected with siNegative, siMT2A_1 
and siMT2A_2. Cells were stained with propidium iodide and analyzed with FACS flow cytometry at 
72 h post-transfection. (B) Proportion of cells in various phases of cell cycle for siMT2A_1, 
siMT2A_2, siNegative and control treated cells. *** denotes p < 0.0005, ** denotes p < 0.005 and * 
denotes p < 0.05  
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3.8. Effect of down-regulation of MT-2A on cell adhesion of breast cancer cells 
 Down-regulation of MT-2A in MCF-7 cells resulted in an increased adhesiveness to cellular 
matrix. This was evident by an increase in the number of siMT2A treated cells attached on a Human 
Collagen Type I coated well as compared to siNegative treated cells after examination by MTS cell 
viability assay (p < 0.001) (Figure 27).  
 
 
Figure 27. Down-regulation of MT-2A using siMT2A_1 and siMT2A_2 resulted in an increased 
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Similarly, there was also an increase in the number of siMT2A treated cells attached on 
Fibronectin coated well (p < 0.001) (Figure 28). 
 
 
Figure 28. Down-regulation of MT-2A using siMT2A_1 and siMT2A_2 resulted in an increased 
adhesiveness to fibronectin matrix when compared to siNegative (p < 0.001). 
 
3.9. Effect of down-regulation of MT-2A on migration of breast cancer cells 
 Down-regulation of MT-2A resulted in decrease in cell migration through a polycarbonate insert 
across a 10 % serum gradient. This was shown by a decrease in the number of cells migrating through 
the polycarbonate insert in the siMT2A treated cells as compared to siNegative treated cells. Both 
strands of MT-2A siRNA showed consistent results (Figure 29A). Down-regulation of MT-2A inhibited 
more than 60 % of the cells migrating through the transwell migration chamber as only 35.95 ± 11.17 
% and 32.30 ± 9.468 % of the cells migrated through the chamber for siMT2A_1 and siMT2A_2 
treated cells respectively (Figure 29B). This phenomenon was shown to be exclusive to MT-2A as 
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demostrated by the two siRNA targeted at MT-1F, namely siMT1F_1 and siMT1F_3. There were 91.84 
± 9.422 % of siMT1F_1 treated cells and 80.55 ± 7.18 % of siMT1F_3 treated cells which migrated 
through the migration chamber (Figure 29B).  
 
A 
   




Figure 29. Down-regulation of MT-2A decreased migration of MCF-7 cells. (A) MCF-7 cells were 
treated with siMT2A_1; siMT2A_2 and siNegative. Cells which have migrated through the 
polycarbonate inserts were fixed with 4 % paraformaldehyde and stained with crystal violet. (B) MCF-
7 cells were transfected with different siRNAs; namely siNegative (sineg), siMT2A_1 (2A1), 
siMT2A_2 (2A2) and the number of cells which have migrated were counted. Columns, mean (n = 3); 
bars, SE.  
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To ensure that the effect was MT-2A specific, an experiment was also conducted using siMT1F. 
It was observed that down-regulation of MT-1F isoform by siMT1F_1 did not affect cell motility 
(Figure 30). There was no significant difference in cell motility between siMT1F treated cells when 




 siMT1F_1         siNegative 
B 
  
Figure 30. Down-regulation of MT-1F did not affect cell migration. (A) MCF-7 cells were treated with 
siMT1F_1 and siNegative. Cells which have migrated through the polycarbonate inserts were fixed 
with 4 % paraformaldehyde and stained with crystal violet. (B) MCF-7 cells were transfected with 
siNegative and siMT1F_1 (1F1) and the number of cells which have migrated were counted. Columns, 
mean (n = 3); bars, SE.  
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3.10. Invasion of MCF-7 cells 
No MCF-7 cells were found to migrate through the matrigel inserts after incubation for up to 24 
h for both siMT-2A and siNegative treated samples. A positive control was conducted using the more 
invasive MDA-MB-231 breast cancer cell line.  
  
3.11. Cloning and expression of MT-2A plasmids 
 Subcloning of MT-2A from MDA-MB-231 cells has revealed a naturally occurring deletion 
mutant which has never been reported previously. The naturally occurring deletion mutant of MT-2A 
protein was cloned and expressed using PXJ40 vector (a gift from Dr Ed Manser, Institute of Molecular 
& Cell Biology, Singapore). The sequence of MT-2A deletion mutant together with the restriction 
enzyme sites and primer regions are shown in Figure 31.  
 
A 
                                              
RE-site ok 
                            -----GFP(Vector)-------->|      
64-12           -------------------------------AGGACGACGATGACAAAGGATCCGATCCC 
64-11           ---------------TGGCCTCTTGACTACAAGGACGACGATGACAAAGGATCCGATCCC 
                                       *****   ***************************** 
                 primer-region 
64-12           AACTGCTCCTGCGCCGGCTCCTGCAAATGCAAAGAGTGCAAATGCACCTCCTGCAAGAAA 
64-11           AACTGCTCCTGCGCCGGCTCCTGCAAATGCAAAGAGTGCAAATGCACCTCCTGCAAGAAA 
                ************************************************************ 
 
64-12           AGCTGCTGCTCCTGCTGCCCTGTGGGCTGTGCCAAGTGTGCCCAGGGCTGCATCTGCAAA 
64-11           AGCTGCTGCTCCTGCTGCCCTGTGGGCTGTGCCAAGTGTGCCCAGGGCTGCATCTGCAAA 
                ************************************************************ 
                                              RE-site ok 
                          primer-region   |<-----vector 
64-12           GGGGCGTCGGACAAGTGCAGCTGCTGCGCCTGACTCGAGGCGGCCGCCCCGGGCTGCAGG 
64-11           GGGGCGTCGGACAAGTGCAGCTGCTGCGCCTGACTCGAGGCGGCCGCCCCGGGCTGCAGG 
                ************************************************************ 
                    STOP 
 
Figure 31. Sequence, restriction enzyme digestion sites and designated primer regions of the clones 
R64-11 and R64-12 of deletion mutant MT-2A (MT-2A’). 
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 Analysis by gel electrophoresis after PCR with MT-2A specific primers shows the size of the 
insert. The empty vector was shown to contain no insert (Figure 32A). The size of the insert in the 
deletion mutant, MT-2A’, was smaller than the native mutant, MT-2A (Figure 32B). The MT-2A’ 
deletion mutant contains eight amino acids lesser than the native MT-2A (Figure 33). As the MT-2A’ 
contains two less cysteine residues which are important in divalent metal ion binding, the function of 
this mutant protein will be interest to examine the role of this protein in breast cancer progression. 
A        B 
       
 
Figure 32. Gel pictures of overexpression plasmids.  
 
 
>ref|NP_005944.1|  metallothionein 2A [Homo sapiens] 
Length=61 
 
Score =  124 bits (310),  Expect = 2e-29 
Identities = 52/60 (86 %), Positives = 52/60 (86 %), Gaps = 8/60 (13 %) 
Frame = +1 
 
Query  1    DPNCSCA--------GsckckeckctsckksccsccpvgcakcAQGCICKGASDKCSCCA  156 
           DPNCSCA        GSCKCKECKCTSCKKSCCSCCPVGCAKCAQGCICKGASDKCSCCA 
Sbjct  2    DPNCSCAAGDSCTCAGSCKCKECKCTSCKKSCCSCCPVGCAKCAQGCICKGASDKCSCCA  61 
 
Figure 33. Alignment of MT-2A’ sequence with MT-2A sequence shows absence of 8 amino acids in 
the MT-2A’ (highlighted in red). 
M       MT2A’      
EV
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3.12. Overexpression of MT-2A in MCF-7 cells 
 The transfection efficiency of the plasmids into MCF-7 cells were examined using fluorescence 
microscopy as the transfected cells will fluoresce green due to co-expression of GFP in the cells 
(Figure 34A). The transfection efficiency of each vector was around 20 %, 31 % and 47 % for Mt2V, 
Mt2V’ and EV respectively (Table 5).  
 
 
Table 5. Transfection efficiency of overexpression vectors using Lipofectamine. Analysis of MT-2A, 
MT-2A’ and EV transfected MCF-7 cells was conducted using FACS by examination of the percentage 
of cells with FITC value above 101.  
 
Vector Mt2V Mt2V’ EV 
17.79 26.31 39.93 
23.69 34.25 45  % GFP 
20.23 33.46 57.01 




The expression of the MT-2A gene after transfection with the overexpression vector, Mt2V 









    Mt2V       EV 
 
 
Figure 34. Transfection efficiency of MT-2A overexpression vector using Lipofectamine. (A) 
Fluorescence of plasmid encoding for MT-2A and GFP (Mt2V) as compared with the empty vector 
(EV). (B) Comparison of MT-2A mRNA expression in cells transfected with Mt2V and EV by RT-PCR 
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3.13. Structure of MT-2A and MT-2A’ 
The structure of MT-2A and MT-2A’ generated using PyMOL are shown in Figure 35. 
 
Figure 35. Line representation for the MT2A structure (Protein Data Bank code: 4mt2). The cadmium 
and zinc ions are shown in pink and yellow respectively. (A) Native MT2A protein, and (B) Deletion 
mutant of MT2A protein. The cysteine residues highlighted in red are affected in the MT-2A’ deletion 
mutant. This diagram was generated using PyMOL. 
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The lack of two cysteine residues in the N-terminal of the protein was found to affect the overall 
structure of MT-2A’. As shown in Figure 2 previously, the two cysteine residues (highlighted in red) are 
involved in the binding of metal ions in the N-terminal. The loss of the two cysteine results will result 
in a highly probable structural alteration in the N-terminal of the protein.  
 
3.14. Effect of overexpression of MT-2A on cell proliferation 
 MT-2A overexpressing MCF-7 cells were examined with cell cycle analysis for effect on cell 
cycle progression. The Mt2V, Mt2V’ and EV treated cells were gated for to analyse only single cells 
and cells expressing GFP with FITC of at least 101 (Figure 36A). The cell cycle profile of the Mt2V 
and Mt2V’ shows the a significant decrease the percentage of cells in the G1 phase (p < 0.001) and a 
significant increase (p < 0.001) in the G2/M phase as compared to EV treated cells (Figure 36B). There 
was no significant differences between Mt2V and Mt2V’ treated cells (p > 0.05) in G1 (p = 0.5581) and 








Figure 36. Effect of overexpression of MT-2A on cell cycle progression. (A) Cell cycle profile of 
MCF-7 cells transfected with vector overexpressing MT-2A and GFP (Mt2V), MT-2A’ and GFP 
(Mt2V’) and GFP alone (EV). The cells were gated with FSC Lin / PI Lin for single cells and FITC log 
/ SSC for cells expressing GFP. (B) Bar chart of the percentage of cells in each phase for Mt2V, Mt2V’ 
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3.15. Differential effects of overexpression of MT-2A and MT-2A’ on cell migration 
 In general, there were more treated cells migrating through the polycarbonate membrane than 
controls. There were also more Mt2V treated cells migrating through the membrane as compared to 
Mt2V’ treated cells (Figure 37A). It was observed that 22.8 ± 2.267 cells migrated through the 
polycarbonate membrane for EV treated samples, 60.80 ± 3.248 cells for Mt2V’ treated samples and 
137.8 ± 9.035 cells for Mt2V treated samples (Figure 37B). Statistical analysis using One-way ANOVA 
with Tukey’s multiple comparison post test showed a significant difference between the three samples; 
EV, Mt2V and Mt2V’ (p < 0.0001). 
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Figure 37. Differential effects of overexpression of MT-2A and MT-2A’ on cell migration. (A) MCF-7 
cells were treated with EV, Mt2V’ and Mt2V and allowed to migrate through the polycarbonate inserts. 
There were significantly more MCF-7 cells overexpressing MT-2A migrating through the migration 
transwell as compared to MCF-7 transfected with EV. (B) Bar chart of the number of cells migrated 
through the polycarbonate membrane at five view points for triplicate experiment set.    
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3.16. Differential expression of cancer related genes 
 The consolidated list of cancer pathway related genes examined by Superarray technology for 
siMT2A_1 and siMT2A_2 treated samples with siNegative as control are shown in Table 6. Consistent 
differential expression of genes between the two siMT-2As included down-regulation of Chk2, IFNB1, 
GZMA, NFKB1A and PLAUR gene, with up-regulation of MTA1 and PLAU genes.  
 
Table 6. Expression of Cancer related genes using Cancer Pathway Finder to examine the genes 
induced and repressed after siMT2A_1 and siMT2A_2 treatment. p values highlighted in red indicate 
significant (p < 0.05); fold changes highlighted in magenta indicate a positive fold change greater than 
2 folds while those highlighted in blue indicate a negative fold change lesser than 2 folds.  
 
   Treatment 
   siMT2A_1 siMT2A_2 





AKT1 V-akt murine thymoma viral oncogene homolog 1 NM_005163 0.0690 1.17 0.1644 1.29 
ANGPT1 Angiopoietin 1 NM_001146 0.7798 1.18 0.5682 1.38 
ANGPT2 Angiopoietin 2 NM_001147 0.1652 1.26 0.5270 -1.12 
APAF1 Apoptotic peptidase activating factor NM_001160 0.2196 1.08 0.0283 1.09 
ATM 
Ataxia telangiectasia mutated (includes complementation 
groups A, C and D) NM_000051 0.0245 1.31* 0.4778 1.11 
BAD BCL2-antagonist of cell death NM_004322 0.4342 1.24 0.6378 1.12 
BAX BCL2-associated X protein NM_004324 0.2595 1.11 0.0538 1.25 
BCL2 B-cell CLL/lymphoma 2 NM_000633 0.0257 1.26* 0.3848 1.13 
BCL2L1 BCL2-like 1 NM_138578 0.3014 1.24 0.1931 1.31 
BRCA1 Breast cancer 1, early onset NM_007294 0.3134 -1.46 0.7870 1.10 
CASP8 Caspase 8, apoptosis-related cysteine peptidase NM_001228 0.0044 -2.01* 0.5846 -1.08 
CCNE1 Cyclin E1 NM_001238 0.1099 1.19 0.0579 1.39 
CDC25A Cell division cycle 25A NM_001789 0.0308 -2.28* 0.9979 1.00 
CDK2 Cyclin-dependent kinase 2 NM_001798 0.7866 -1.04 0.6786 1.07 
CDK4 Cyclin-dependent kinase 4 NM_000075 0.6371 1.08 0.2471 1.20 
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) NM_000389 0.0859 1.38 0.2002 1.23 
CDKN2A 
Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits 
CDK4) NM_000077 0.9975 1.00 0.0832 1.61 
CFLAR CASP8 and FADD-like apoptosis regulator NM_003879 0.0922 -1.20 0.8115 -1.02 
CHEK2 CHK2 checkpoint homolog (S. pombe) NM_007194 0.0285 -1.35* 0.0413 -1.56 
COL18A1 Collagen, type XVIII, alpha 1 NM_030582 0.0938 1.19 0.1442 1.28 
E2F1 E2F transcription factor 1 NM_005225 0.2548 -1.17 0.0586 1.38 
ERBB2 
V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog (avian) NM_004448 0.0555 1.36 0.0950 1.12 
ETS2 V-Ets erythroblastosis virus E26 oncogene homolog 2 (avian) NM_005239 0.1110 -1.34 0.9938 -1.00 
FAS Fas (TNF receptor superfamily, member 6) NM_000043 0.0306 -1.26* 0.7276 -1.04 
FGFR2 Fibroblast growth factor receptor 2 (bacteria-expressed kinase, NM_000141 0.8576 1.09 0.3572 1.48 
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keratinocyte growth factor receptor, craniofacial dysostosis 1, 
Crouzon syndrome, Pfeiffer syndrome, Jackson-Weiss 
syndrome) 
FOS V-fos FBJ murine osteosarcoma viral oncogene homolog NM_005252 0.0998 1.25 0.6376 -1.07 
GZMA 
Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated 
serine esterase 3) NM_006144 0.0007 -7.66* 0.0664 -3.13 
HTATIP2 HIV-1 Tat interactive protein 2, 30kDa NM_006410 0.9551 -1.01 0.1076 1.14 
IFNA1 Interferon, alpha 1 NM_024013 0.1225 -1.91 0.4721 1.53 
IFNB1 Interferon, beta 1, fibroblast NM_002176 0.0000 -19.48* 0.0012 -3.54 
IGF1 Insulin-like growth factor 1 (somatomedin C) NM_000618 0.4825 1.53 0.4059 1.82 
L8 Interleukin 8 NM_000584 0.0103 -2.10* 0.4459 1.21 
ITGA1 Integrin, alpha 1 NM_181501 0.7051 -1.08 0.3716 -1.22 
ITGA2 Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) NM_002203 0.7279 1.04 0.4931 1.10 
ITGA3 
Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 
receptor) NM_002204 0.7025 1.05 0.5391 1.11 
ITGA4 
Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 
receptor) NM_000885 0.9975 1.00 0.0832 1.61 
ITGAV 
Integrin, alpha V (vitronectin receptor, alpha polypeptide, 
antigen CD51) NM_002210 0.4546 1.09 0.0113 1.57 
ITGB1 
Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen 
CD29 includes MDF2, MSK12) NM_002211 0.0487 -1.18* 0.0021 1.30 
ITGB3 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) NM_000212 0.6959 -1.29 0.5580 1.61 
ITGB5 Integrin, beta 5 NM_002213 0.0206 -1.30* 0.6907 -1.04 
JUN V-jun sarcoma virus 17 oncogene homolog (avian) NM_002228 0.0578 -1.30 0.6442 -1.06 
MAP2K1 Mitogen-activated protein kinase kinase 1 NM_002755 0.8446 -1.01 0.7397 1.03 
MCAM Melanoma cell adhesion molecule NM_006500 0.3236 1.44 0.4564 1.44 
MDM2 
Mdm2, transformed 3T3 cell double minute 2, p53 binding 
protein (mouse) NM_002392 0.3206 -1.08 0.3120 1.22 
MET Met proto-oncogene (hepatocyte growth factor receptor) NM_000245 0.0364 -1.41* 0.2892 -1.13 
MMP1 Matrix metallopeptidase 1 (interstitial collagenase) NM_002421 0.0406 1.60* 0.0983 2.22 
MMP2 
Matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 
72kDa type IV collagenase) NM_004530 0.3947 -1.28 0.2916 1.32 
MMP9 
Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 
92kDa type IV collagenase) NM_004994 0.5410 -1.35 0.1385 1.37 
MTA1 Metastasis associated 1 NM_004689 0.0397 1.38* 0.0014 1.46 
MTA2 Metastasis associated 1 family, member 2 NM_004739 0.4724 1.10 0.0705 1.35 
MTSS1 Metastasis suppressor 1 NM_014751 0.0004 2.51* 0.1134 1.44 
MYC V-myc myelocytomatosis viral oncogene homolog (avian) NM_002467 0.6193 -1.06 0.3180 -1.17 
NFKB1 
Nuclear factor of kappa light polypeptide gene enhancer in B-
cells 1 (p105) NM_003998 0.1459 1.39 0.0525 1.38 
NFKBIA 
Nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha NM_020529 0.0206 -1.62* 0.0200 -1.42 
NME1 Non-metastatic cells 1, protein (NM23A) expressed in NM_000269 0.8456 -1.01 0.1792 1.11 
NME4 Non-metastatic cells 4, protein expressed in NM_005009 0.0331 1.46* 0.9218 -1.01 
PDGFA Platelet-derived growth factor alpha polypeptide NM_002607 0.2264 -1.23 0.3337 1.18 
PDGFB 
Platelet-derived growth factor beta polypeptide (simian 
sarcoma viral (v-sis) oncogene homolog) NM_002608 0.1034 1.22 0.0080 1.59 
PIK3R1 Phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) NM_181504 0.6679 1.04 0.6011 -1.10 
PLAU Plasminogen activator, urokinase NM_002658 0.0006 1.68* 0.0054 1.45 
PLAUR Plasminogen activator, urokinase receptor NM_002659 0.0030 -2.83* 0.0018 -3.58 
PNN Pinin, desmosome associated protein NM_002687 0.1606 -1.16 0.1505 1.15 
RAF1 V-raf-1 murine leukemia viral oncogene homolog 1 NM_002880 0.5647 1.06 0.3111 1.11 
RB1 Retinoblastoma 1 (including osteosarcoma) NM_000321 0.5774 1.08 0.2479 -1.28 
S100A4 
S100 calcium binding protein A4 (calcium protein, calvasculin, 
metastasin, murine placental homolog) NM_002961 0.1587 1.20 0.8133 1.04 
SERPINB5 Serpin peptidase inhibitor, clade B (ovalbumin), member 5 NM_002639 0.5460 1.11 0.8289 -1.06 
SERPINE1 Serpin peptidase inhibitor, clade E (nexin, plasminogen NM_000602 0.7286 1.06 0.0393 -1.65 
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activator inhibitor type 1), member 1 
SNCG Synuclein, gamma (breast cancer-specific protein 1) NM_003087 0.2412 1.23 0.2657 -1.18 
SYK Spleen tyrosine kinase NM_003177 0.1237 1.35 0.6371 1.09 
TEK 
TEK tyrosine kinase, endothelial (venous malformations, 
multiple cutaneous and mucosal) NM_000459 0.9975 1.00 0.0832 1.61 
TERT Telomerase reverse transcriptase NM_003219 0.0575 -1.45 0.5968 1.17 
TGFB1 
Transforming growth factor, beta 1 (Camurati-Engelmann 
disease) NM_000660 0.5310 1.05 0.0285 1.38 
TGFBR1 
Transforming growth factor, beta receptor I (activin A receptor 
type II-like kinase, 53kDa) NM_004612 0.0171 1.72* 0.1173 1.24 
THBS1 Thrombospondin 1 NM_003246 0.0320 1.28* 0.0004 -1.45 
TIMP1 TIMP metallopeptidase inhibitor 1 NM_003254 0.3711 1.05 0.5391 1.10 
TIMP3 
TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, 
pseudoinflammatory) NM_000362 0.5280 -1.36 0.2839 -1.51 
TNF Tumor necrosis factor (TNF superfamily, member 2) NM_000594 0.0033 -1.83* 0.5510 -1.09 
TNFRSF10B Tumor necrosis factor receptor superfamily, member 10b NM_003842 0.2499 -1.10 0.0918 1.12 
TNFRSF1A Tumor necrosis factor receptor superfamily, member 1A NM_001065 0.6889 1.07 0.1787 1.19 
TNFRSF25 Tumor necrosis factor receptor superfamily, member 25 NM_003790 0.5960 -1.10 0.4346 -1.13 
TP53 Tumor protein p53 (Li-Fraumeni syndrome) NM_000546 0.5348 -1.07 0.6265 -1.05 
TWIST1 
Twist homolog 1 (acrocephalosyndactyly 3; Saethre-Chotzen 
syndrome) (Drosophila) NM_000474 0.3934 1.26 0.7208 -1.16 
UCC     0.0012 -1.77* 0.3058 1.10 






    110 
The list of housekeeping genes used for the siMT2A_1 and siMT2A_2 treated samples for fold 
change calculations are shown in Table 7 and Table 8 respectively.  
 
 
Table 7. Tabulation of CT values of 6 housekeeping genes in Cancer PathwayFinder Superarray for 
normalization of ΔCT values for the various gene of interest in siMT2A_1 treated samples with respect 




Exp1 Exp2 Exp3 Exp1 Exp2 Exp3 
18SrRNA 11.82  11.43  11.54  11.88  10.94  11.35  
HPRT1 22.82  23.07  23.01  22.93  22.12  22.24  
RPL13A 20.02  19.92  19.81  21.01  20.53  21.09  
GAPD 17.20  17.01  16.90  17.18  16.61  17.09  
ACTB 16.43  16.24  16.16  16.32  15.92  16.14  
Average 17.66  17.53  17.48  17.86  17.23  17.58  
 
 
Table 8. Tabulation of CT values of 6 housekeeping genes in Cancer PathwayFinder Superarray for 
normalization of ΔCT values for the various gene of interest in siMT2A_2 treated samples with respect 




Exp1 Exp2 Exp3 Exp1 Exp2 Exp3 
18SrRNA 12.78 12.5 11.59 11.88 10.94 11.35 
HPRT1 24.01 23.68 22.67 22.93 22.12 22.24 
RPL13A 21.35 21.31 21.02 21.01 20.53 21.09 
GAPD 17.62 17.54 17.13 17.18 16.61 17.09 
ACTB 17.01 16.92 16.5 16.32 15.92 16.14 
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3.17. Differential expression of cell cycle related genes 
 The consolidated list of cell cycle related genes examined by Superarray for siMT2A_1 and 
siMT2A_2 treated samples with siNegative as a control are shown in Table 9. Several genes that were 
consistently regulated in siMT2A_1 and siMT2A_2 treated samples included up-regulation of ATM, 
BAX, CCNE1, CCNG1, CDK8, CUL1 and down-regulation of CKS1B and HERC5.  
 The list of cell cycle related genes examined in MT-2A overexpressing cells as compared to EV 
treated samples are also shown in the same (Table 9). The genes differentially expressed include down-
regulation of CCNG1, CDK4, CDKN1A and upregulation of HERC5.  
 
 
Table 9. Expression of Cell cycle related genes using Superarray to examine the induction and 
repression of genes after siMT2A_1, siMT2A_2 and Mt2V (overexpressing MT-2A) treatment. p 
values highlighted in red indicate significant (p < 0.05); fold changes highlighted in magenta indicate a 
positive fold change greater than 2 folds while those highlighted in blue indicate a negative fold change 
lesser than 2 folds.   
 
   Treatment 
   siMT2A_1 siMT2A_2 Mt2V 









ABL1   
V-abl Abelson murine leukemia viral 
oncogene homolog 1   NM_005157  0.0667 1.28 0.1644 1.15 0.0209 -1.36 
ANAPC2  Anaphase promoting complex subunit 2  NM_013366  0.0276 1.19* 0.1815 1.12 0.8847 -1.01 
ANAPC4  Anaphase promoting complex subunit 4  NM_013367  0.0230 1.26* 0.2719 1.21 0.8316 -1.04 
DIRAS3  DIRAS family, GTP-binding RAS-like 3  NM_004675  0.0117 1.30* 0.1068 1.34 0.8805 1.04 
ATM  
Ataxia telangiectasia mutated (includes 
complementation groups A, C and D)  NM_000051  0.0017 1.71* 0.0274 1.33 0.0275 -1.21 
ATR  Ataxia telangiectasia and Rad3 related  NM_001184  0.0267 1.37* 0.1179 1.15 0.3039 -1.10 
BAX  BCL2-associated X protein  NM_004324  0.0405 1.33* 0.0323 1.22 0.1956 -1.12 
BCCIP  BRCA2 and CDKN1A interacting protein  NM_016567  0.0013 1.44* 0.1352 1.11 0.0822 -1.15 
BCL2  B-cell CLL/lymphoma 2  NM_000633  0.0003 1.59* 0.1427 1.14 0.0149 -1.18 
BIRC5  
Baculoviral IAP repeat-containing 5 
(survivin)  NM_001168  0.1697 -1.30 0.1307 2.02 0.3459 -1.67 
BRCA1  Breast cancer 1, early onset  NM_007294  0.4322 -1.11 0.0219 1.43 0.0427 -1.29 
BRCA2  Breast cancer 2, early onset  NM_000059  0.0631 -1.31 0.0451 1.48 0.8147 -1.05 
CCNB1  Cyclin B1  NM_031966  0.2744 -1.14 0.3537 -1.13 0.2279 -1.11 
CCNB2  Cyclin B2  NM_004701  0.0052 -1.41* 0.0315 -1.07 0.1820 -1.17 
CCNC  Cyclin C  NM_005190  0.0001 1.67* 0.0319 1.26 0.0497 -1.22 
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CCND1  Cyclin D1  NM_053056  0.9029 -1.01 0.6314 -1.02 0.7191 -1.02 
CCND2  Cyclin D2  NM_001759  0.8610 1.13 0.4295 1.73 0.0552 1.69 
CCNE1  Cyclin E1  NM_001238  0.0024 1.78* 0.0005 1.79 0.0189 -1.30 
CCNF  Cyclin F  NM_001761  0.1532 1.17 0.0755 1.17 0.1452 -1.24 
CCNG1  Cyclin G1  NM_004060  0.0183 1.89* 0.0162 1.96 0.0122 -1.52 
CCNG2  Cyclin G2  NM_004354  0.0001 2.06* 0.1911 1.12 0.2823 -1.06 
CCNH  Cyclin H  NM_001239  0.0010 1.96* 0.8741 1.02 0.1621 -1.35 
CCNT1  Cyclin T1  NM_001240  0.0036 1.49* 0.0080 1.16 0.8353 -1.01 
CCNT2  Cyclin T2  NM_001241  0.0187 1.76* 0.1363 1.41 0.0428 -1.21 
CDC16  
Cell division cycle 16 homolog (S. 
cerevisiae)  NM_003903  0.5450 1.07 0.6508 1.02 0.6201 -1.06 
CDC2  Cell division cycle 2, G1 to S and G2 to M NM_001786  0.0012 -1.48* 0.0546 -1.28 0.9446 -1.01 
CDC20  
Cell division cycle 20 homolog (S. 
cerevisiae)  NM_001255  0.0263 -1.37* 0.1476 -1.20 0.6259 -1.07 
CDC34  
Cell division cycle 34 homolog (S. 
cerevisiae)  NM_004359  0.0018 1.65* 0.1242 1.12 0.4737 -1.08 
CDK2  Cyclin-dependent kinase 2  NM_001798  0.4838 1.08 0.3212 -1.10 0.1936 -1.15 
CDK4  Cyclin-dependent kinase 4  NM_000075  0.0012 1.38* 0.0546 1.23 0.0033 -1.64 
CDK5R1  
Cyclin-dependent kinase 5, regulatory 
subunit 1 (p35)  NM_003885  0.2495 1.14 0.4739 -1.04 0.1748 -1.18 
CDK5RAP1  
CDK5 regulatory subunit associated 
protein 1  NM_016408  0.0801 1.23 0.5340 -1.16 0.2002 -1.19 
CDK6  Cyclin-dependent kinase 6  NM_001259  0.0331 1.34* 0.3100 1.12 0.5594 -1.05 
CDK7  
Cyclin-dependent kinase 7 (MO15 
homolog, Xenopus laevis, cdk-activating 
kinase)  NM_001799  0.0462 1.49* 0.1274 1.33 0.0334 -1.26 
CDK8  Cyclin-dependent kinase 8  NM_001260  0.0035 1.64* 0.0093 1.39 0.0098 -1.16 
CDKN1A  
Cyclin-dependent kinase inhibitor 1A 
(p21, Cip1)  NM_000389  0.0115 1.66* 0.0966 1.34 0.0359 -1.57 
CDKN1B  
Cyclin-dependent kinase inhibitor 1B 
(p27, Kip1)  NM_004064  0.0903 1.28 0.9058 -1.01 0.0113 -1.37 
CDKN2A  
Cyclin-dependent kinase inhibitor 2A 
(melanoma, p16, inhibits CDK4)  NM_000077  0.8954 -1.05 0.6481 -1.20 0.3512 -1.19 
CDKN2B  
Cyclin-dependent kinase inhibitor 2B 
(p15, inhibits CDK4)  NM_004936  0.0460 1.97* 0.4294 1.22 0.3426 -1.18 
CDKN3  
Cyclin-dependent kinase inhibitor 3 
(CDK2-associated dual specificity 
phosphatase)  NM_005192  0.2340 -1.11 0.9673 1.00 0.6642 -1.03 
CHEK1  CHK1 checkpoint homolog (S. pombe)  NM_001274  0.0403 1.08* 0.0269 1.08 0.5022 -1.07 
CHEK2  CHK2 checkpoint homolog (S. pombe)  NM_007194  0.1084 -1.11 0.1460 -1.11 0.3003 1.13 
CKS1B  
CDC28 protein kinase regulatory subunit 
1B  NM_001826  0.0058 -1.58* 0.0289 -1.38 0.0179 1.12 
CKS2  
CDC28 protein kinase regulatory subunit 
2  NM_001827  0.0815 -1.17 0.4295 -1.12 0.6995 1.07 
CUL1  Cullin 1  NM_003592  0.0000 1.36* 0.0015 1.27 0.0942 -1.19 
CUL2  Cullin 2  NM_003591  0.0763 1.63 0.7610 1.09 0.4575 -1.19 
CUL3  Cullin 3  NM_003590  0.4682 1.78 0.2551 2.02 0.7628 -1.16 
DDX11  
DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide 11 (CHL1-like helicase 
homolog, S. cerevisiae)  NM_004399  0.7677 1.08 0.2747 1.64 0.6934 -1.08 
DNM2  Dynamin 2  NM_004945  0.4244 1.10 0.2912 1.05 0.0812 -1.39 
E2F4  
E2F transcription factor 4, p107/p130-
binding  NM_001950  0.0004 1.44* 0.0178 -1.12 0.6559 1.03 
GADD45A  
Growth arrest and DNA-damage-
inducible, alpha  NM_001924  0.7132 1.04 0.6085 -1.10 0.0743 -1.38 
GTF2H1  
General transcription factor IIH, 
polypeptide 1, 62kDa  NM_005316  0.0002 1.52* 0.0729 1.16 0.0544 -1.27 
GTSE1  G-2 and S-phase expressed 1  NM_016426  0.0147 -1.41* 0.3827 -1.11 0.2628 -1.14 
HERC5  Hect domain and RLD 5  NM_016323  0.0000 -6.23* 0.0006 -2.69 0.0053 1.49 
HUS1  HUS1 checkpoint homolog (S. pombe)  NM_004507  0.1632 1.16 0.8428 -1.02 0.2075 -1.14 
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KNTC1  Kinetochore associated 1  NM_014708  0.0014 -1.17* 0.0060 1.15 0.0799 -1.26 
KPNA2  
Karyopherin alpha 2 (RAG cohort 1, 
importin alpha 1)  NM_002266  0.9562 1.00 0.0567 1.10 0.1033 -1.20 
MAD2L1  
MAD2 mitotic arrest deficient-like 1 
(yeast)  NM_002358  0.0294 -1.16* 0.1113 1.11 0.4974 -1.07 
MAD2L2  
MAD2 mitotic arrest deficient-like 2 
(yeast)  NM_006341  0.0013 1.48* 0.0147 1.26 0.7278 -1.02 
MCM2  
MCM2 minichromosome maintenance 
deficient 2, mitotin (S. cerevisiae)  NM_004526  0.9204 -1.01 0.0472 1.27 0.2053 -1.19 
MCM3  
MCM3 minichromosome maintenance 
deficient 3 (S. cerevisiae)  NM_002388  0.6615 -1.08 0.3978 -1.20 0.5112 -1.06 
MCM4  
MCM4 minichromosome maintenance 
deficient 4 (S. cerevisiae)  NM_005914  0.8955 1.03 0.3068 -1.13 0.4638 -1.06 
MCM5  
MCM5 minichromosome maintenance 
deficient 5, cell division cycle 46 (S. 
cerevisiae)  NM_006739  0.6079 1.15 0.0215 2.33 0.5057 -1.35 
MKI67  
Antigen identified by monoclonal 
antibody Ki-67  NM_002417  0.1094 -1.23 0.5074 1.06 0.5092 -1.04 
MNAT1  
Menage a trois homolog 1, cyclin H 
assembly factor (Xenopus laevis)  NM_002431  0.0015 1.61* 0.4652 1.08 0.1634 -1.11 
MRE11A  
MRE11 meiotic recombination 11 
homolog A (S. cerevisiae)  NM_005590  0.2710 1.21 0.0565 -1.15 0.9540 -1.01 
NBN  Nibrin  NM_002485  0.4370 -1.10 0.0030 -1.26 0.9673 1.00 
PCNA  Proliferating cell nuclear antigen  NM_182649  0.1628 -1.16 0.1270 1.13 0.2899 -1.08 
RAD1  RAD1 homolog (S. pombe)  NM_002853  0.8500 1.03 0.1327 1.75 0.4468 -1.21 
RAD17  RAD17 homolog (S. pombe)  NM_002873  0.0791 1.36 0.1569 1.29 0.1367 -1.22 
RAD51  
RAD51 homolog (RecA homolog, E. coli) 
(S. cerevisiae)  NM_002875  0.1395 -1.48 0.2579 1.17 0.8435 -1.06 
RAD9A  RAD9 homolog A (S. pombe)  NM_004584  0.4815 -1.22 0.4299 1.61 0.1482 -1.80 
RB1  
Retinoblastoma 1 (including 
osteosarcoma)  NM_000321  0.1482 1.53 0.0276 2.05 0.7596 -1.14 
RBBP8  Retinoblastoma binding protein 8  NM_002894  0.5236 1.06 0.2857 -1.15 0.9310 -1.01 
RBL1  Retinoblastoma-like 1 (p107)  NM_002895  0.6225 -1.15 0.2928 1.45 0.1665 -1.26 
RBL2  Retinoblastoma-like 2 (p130)  NM_005611  0.0175 1.69* 0.1680 1.30 0.1912 -1.15 
RPA3  Replication protein A3, 14kDa  NM_002947  0.6580 1.14 0.0303 1.85 0.6590 1.05 
SERTAD1  SERTA domain containing 1  NM_013376  0.9852 1.00 0.3923 -1.17 0.6238 1.05 
SKP2  S-phase kinase-associated protein 2 (p45)  NM_005983  0.8617 -1.05 0.4393 -1.22 0.5553 -1.12 
SUMO1  
SMT3 suppressor of mif two 3 homolog 1 
(S. cerevisiae)  NM_003352  0.0116 1.31* 0.4784 1.04 0.7393 1.02 
TFDP1  Transcription factor Dp-1  NM_007111  0.9171 -1.02 0.0613 1.32 0.2921 -1.10 
TFDP2  
Transcription factor Dp-2 (E2F 
dimerization partner 2)  NM_006286  0.0015 1.98* 0.0251 1.49 0.2794 -1.09 
TP53  
Tumor protein p53 (Li-Fraumeni 
syndrome)  NM_000546  0.0546 1.28 0.2157 1.13 0.2877 -1.08 
UBE1  
Ubiquitin-activating enzyme E1 (A1S9T 
and BN75 temperature sensitivity 
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The list of housekeeping genes used for the siMT2A_1 and siMT2A_2 treated samples for fold change 
calculations are shown in Table 10 and Table 11 respectively.  
 
Table 10. Tabulation of CT values of 6 housekeeping genes in Cell Cycle Superarray for normalization 





Exp1 Exp2 Exp3 Exp1 Exp2 Exp3 
B2M 20.35 20.52 20.34 18.38 18.59 18.73 
HPRT1 23.72 23.83 23.59 22.83 23.00 23.11 
RPL13A 20.26 20.16 20.11 20.92 20.57 21.11 
GAPDH 16.98 17.01 17.02 17.04 16.96 17.18 
ACTB 16.34 16.28 16.27 16.23 16.12 16.41 
Average 19.53 19.56 19.47 19.08 19.05 19.3 
 
 
Table 11. Tabulation of CT values of 6 housekeeping genes in Cell Cycle Superarray for normalization 





Exp1 Exp2 Exp3 Exp1 Exp2 Exp3 
B2M 20 19.88 19.62 18.38 18.59 18.73 
HPRT1 23.56 22.89 22.63 22.83 23 23.11 
RPL13A 20.75 20.23 20.22 20.92 20.57 21.11 
GAPDH 17.14 17.06 16.99 17.04 16.96 17.18 
ACTB 16.4 16.17 16.15 16.23 16.12 16.41 
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The list of housekeeping genes used in the fold change calculations for the MT-2A overexpressing 
samples are shown in Table 12.  
 
 
Table 12. Tabulation of CT values of 6 housekeeping genes in Cell Cycle Superarray for normalization 





Exp1 Exp2 Exp3 Exp1 Exp2 Exp3 
B2M 19.65 19.47 19.81 20.13 19.8 20.2 
HPRT1 23.57 23.78 24.21 23.63 23.76 24.03 
RPL13A 21.01 20.95 21.36 21.17 21.32 21.13 
GAPDH 17.5 17.37 17.81 17.61 17.16 17.47 
ACTB 16.8 16.4 17.02 16.88 16.62 16.98 
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3.18. Differential expression of cell cycle related proteins 
The expression of several differentially expressed cell cycle related genes in Superarray were 
examined using western blotting analysis. Similar to the gene expression studies, the expression of 
ATM was found to be up-regulated after siMT2A treatment when compared to a housekeeping protein, 
beta-actin (Figure 38). Statistical analysis carried out using t-test showed a statistically significant 
difference between ATM protein levels in siNegative treated and siMT2A treated cells (p = 0.0001) 




Figure 38. Treatment of MCF-7 cells with siMT-2A induced an increase in ATM. MCF-7 cells were 
treated with siMT-2A and siNegative. Upper panel: Cell lysates were examined by Western blot 
analysis with antibodies against ATM and beta-actin. Lower panel: Relative optical density of ATM and 
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Similar to expression of cdc25A gene in siMT2A cells, the expression of cdc25A protein was 
found to be down-regulated as compared to siNegative treated cells (Figure 39). Statistical analysis 
carried out using t-test showed that the difference in cdc25a protein levels in siNegative treated and 
siMT2A treated cells was significant (p = 0.0176) while the difference in beta actin protein levels in the 




cdc25A        b-actin 
  
 
Figure 39. Treatment of MCF7 cells with siMT-2A induced a reduction in cdc25a. MCF-7 cells were 
treated with siMT-2A and siNegative. Upper panel: Cell lysates were examined by Western blot 
analysis with antibodies against cdc25a and the housekeeping protein beta-actin. Lower panel: Relative 
optical density of cdc25a and beta actin protein bands. Columns, means; n = 3; bars = SE. 
RESULTS 
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On the contrary, the expression of Chk2 protein was not differentially regulated in siMT2A cells 
(Figure 40). Statistical analysis carried out using Student’s t-test showed that the difference in non-
phosphorylated Chk2 protein levels (p = 0.1410), phosphorylated Chk2 (p = 0.5850) and beta-actin (p 
= 0.1139) protein levels in siNegative treated and siMT2A treated cells were insignificant. 
 
 






Figure 40. Treatment of MCF-7 cells with siMT-2A has no significant effects on non-phosphorylated 
(NP) and phosphorylated (P) forms of Chk2 protein. Lower panel: Relative optical density of Chk2 
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3.19. Differential expression of metastasis related proteins 
The expression of several differentially expressed metastasis related genes in Superarray were 
examined using western blotting analysis. Similar to PLAUR gene expression, uPAR protein was found 
to be down-regulated in siMT2A cells (Figure 41). Statistical analysis carried out using t-test showed 
that the difference in uPAR protein levels in siNegative treated and siMT2A treated cells was 
significant (p = 0.0145) while the difference in beta actin protein levels in the two samples was 
insignificant (p = 0.9927).  
 
                   
       uPAR      b-actin 
 
 
Figure 41. Treatment of MCF-7 cells with siMT-2A induced a reduction in uPAR. MCF-7 cells were 
treated with siMT-2A and siNegative. Cell lysates were examined by Western blot analysis with 
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Similarly, cMet protein was also found to be down-regulated in siMT2A cells when compared 
against housekeeping protein, beta actin (Figure 42). Statistical analysis carried out using t-test showed 
that the difference in c-met protein levels in siNegative treated and siMT2A treated cells was 
significant (p = 0.0362) while the difference in beta actin protein levels in the two samples was 
insignificant (p = 0.6893).  
 
 
Figure 42. Treatment of MCF-7 cells with siMT-2A induced a reduction in c-met. MCF-7 cells were 
treated with siMT-2A and siNegative. Cell lysates were examined by Western blot analysis with 
antibodies against c-met and beta-actin. 
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    121 
3.21. Expression of MT in invasive ductal breast carcinoma tissues 
 In order to examine the translational value of the in vitro studies, the expression of MT in breast 
cancer tissues was conducted. In normal breast tissue, MT stains up the myoepithelial cells of the duct 
and have been proposed to be a marker for myoepithelial cells (Jin, et al, 2002). MT was found to be 
expressed in both the nucleus and cytoplasm of the majority of the tumour cells. MT was documented 
to be expressed in the cytoplasm of the cancer cells in 122 cases (87.1 %), with only 18 cases (12.9 %) 
exhibiting no staining in the cytoplasm of the tumour cells. The percentage of MT staining in the 
nucleus was found to be relatively similar to the cytoplasm with 118 cases (84.3 %) showing positive 
MT staining and only 22 cases (15.7 %) showing absence of MT staining in the nucleus (Table 13).  
 
Table 13. Different immunoscoring methods and their cut-off values for MT staining in the cytoplasm 
and nucleus of cancer cells. 
 
Immunoscores No. of cases ( %) 
Staining of cytoplasm  
Absent 18 (12.9) 
Present 122 (87.1) 
Staining of nucleus  
Absent 22 (15.7) 
Present 118 (84.3) 
IRS of cytoplasm (IRSCyt)  
≤100 85 (60.7) 
>100 55 (39.3) 
IRS of nucleus (IRSNu)  
≤100 92 (65.7) 
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The mean values for the IRS of cytoplasmic and nuclear staining were 90.20 and 78.08 
respectively (Table 14).  
 
Table 14. Mean and median immunoscores of cytoplasm and nuclear MT staining. 
 Mean (Median) 
IRS of cytoplasmic staining  90.2 (95) 
IRS of nuclear staining 78.08 (67.2) 
 
 
Faint or low staining of MT was considered as negative staining (Figure 43).  
 
 
Figure 43. Negative MT immunostaining in both the cytoplasm and nucleus of the carcinoma. Faint 
MT staining was regarded as no staining. 
RESULTS 
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Figure 44. Categorization of MT intensity scoring for the cytoplasm and nucleus. Scoring intensity of 
1+ for (A) cytoplasm and (B) nucleus; intensity of 2+ for (C) cytoplasm and (D) nucleus; intensity of 
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The IRS of the MT staining at the cytoplasm and nucleus with cut-off at 100 for high and low 




Figure 45. IRS of cytoplasmic MT-staining. IRS of MT in cytoplasm ≤100 ranged from (A) 0 to (B) 55 




Figure 46. IRS of nuclear MT-staining. Representative examples of IRS of nucleus ≤ 100 ranged from 
(A) 0 (B) 50 (C) 100 while IRS of MT in nucleus > 100 ranged from (D) 110 to (E) 210 to (F) 250. 
A B C 
D E F 
A B C 
D E F 
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3.22. Association of MT cytoplasmic staining with clinicopathological parameters 
 The correlation of MT cytoplasmic staining with the various clinicopathological parameters is 
shown in Table 15.  
Table 15. Correlation of clinicopathological parameters with presence or absence of MT cytoplasmic 
expression in invasive ductal breast cancer patients. 
  




Total no. of cases 18 (12.86 %) 122 (87.14 %) - 
Age (means, in years) 56.47 52.93 0.226 
Tumor size (means, in mm) 41.92 33.55 0.126 
Tumor size    
≤ 30 mm 5 54 
> 31 mm 8 42 
0.251 
Staging    
1 4 17 
2 10 80 
3 2 11 
0.596 
Histological grade    
Low  14 61 
High 3 55 0.034* 
DCIS association    
None 6 52 
Minimum 10 46 
Extensive 1 18 
0.277 
Bloomrichardson score    
3 – 5 2 11 
6, 7 6 39 
8, 9 2 46 
0.235 
Tubule formation    
Low (1) 1 7 
High (2 & 3) 9 89 0.560 
Nuclear Pleomorphism    
Low (1 & 2) 9 51 
High (3) 1 45 0.040* 
Mitotic index    
Low ( 1 & 2) 9 53 
High (3) 1 43 0.043* 
ER status    
negative 2 38 
positive 14 72 0.091 
PR status    
negative 7 61 
positive 9 49 0.429 
Lymph node status    
Absent 10 70 
Present 7 41 0.791 
Lymph node stage    
Low (1) 13 55 
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C-erbB2 status    
Negative 15 73 
Positive 2 37 0.091 
 % of PCNA staining    
≤ 50 % 11 70 
> 50 % 7 51 1.000 
 
Expression of cytoplasmic MT was found to be associated with higher histological grade tumor 
(p = 0.034), higher stage of nuclear pleomorphism (p = 0.040), higher mitotic index (p = 0.043) and 
higher lymph node stage (p = 0.036) (Figure 47A-E).  
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Figure 47. Bar charts showing MT cytoplasmic expression in relation to clinicopathological 
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Legend: 
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 The representative MT staining in breast cancer tissues with the different lymph node status is 
shown in Figure 48.  
 
Figure 48. Micrographs of invasive ductal breast cancer stained with MT E9 antibodies with different 
lymph node status. (A) Low lymph node status (≤1) with no MT immunostaining. (B) High lymph 
node status at 2 with MT immunostaining. (C) High lymph node status at 3 with MT immunostaining. 
(D) Negative control with no MT E9 antibodies added.  
 
 
 IRS of MT cytoplasmic staining was banded at 100 to differentiate between low (≤100) and 
high (>100) MT cytoplasmic staining with the various clinicopathological parameters (Table 16).  
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Table 16. Correlation of Clinicopathological parameters with MT cytoplasmic expression in invasive 
ductal breast cancer patients with IRS banded at 100. 
 
MT cytoplasmic expression Variable 
≤ IRS100 > IRS100 P value 
Total no. of cases 85 (60.71 %) 55 (39.29 %) - 
Age (means, in years) 54 51.39 0.386 
Tumor size (means, in mm) 36.22 31.88 0.198 
Tumor size    
≤ 30 mm 33 26 
> 31 mm 34 16 0.238 
Staging    
1 15 6 
2 54 36 
3 9 4 
0.548 
Histological grade    
1 12 2 
2 41 20 
3 29 29 
0.023* 
DCIS association    
None 38 20 
Minimum 36 20 
Extensive 9 20 
0.340 
Bloomrichardson’s score    
3-5 11 2 
6, 7 33 12 
8, 9 20 28 
0.001* 
Tubule formation    
Low (1) 8 0 
High (2 & 3) 56 42 0.021* 
Nuclear Pleimorphism    
1 5 2 
2 38 15 
3 21 25 
0.025* 
Pleimorphism (banded)    
Low (1 & 2) 43 17 
High (3) 21 25 0.009* 
Mitotic index    
1 22 6 
2 22 12 
3 20 24 
0.016* 
Mitotic index (Banded)    
Low (1 & 2) 44 18 
High (3) 20 24 0.010* 
ER status    
negative 22 18 
positive 56 30 0.326 
PR status    
negative 38 30 
positive 40 18 0.145 
Lymph node status    
Absent 50 30 
Present 30 18 1.00 
Lymph node stage    
Low (1) 42 25 
High (2 & 3) 40 28 0.725 
C-erbB2 status    
Negative 57 31 
Positive 22 17 0.429 
 % of PCNA staining    
≤ 50 51 30 
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Higher intensity of MT staining (>100) was associated with higher histological grade, Bloom-
Richardson’s score, tubule formation, mitotic index and nuclear pleomorphism stage (Figure 49).  















































Figure 49. Bar charts showing MT cytoplasmic expression, banded at IRS 100, in relation to 
clinicopathological parameters. (A) Histological grade; (B) Tubule formation; (C) Pleiomorphism; (D) 
Mitotic index.  
 
There was no association between higher intensity of MT cytoplasmic staining and percentage 
of PCNA staining (refer to Tables 15 and 16).  
Histological grade Tubule formation 
Pleiomorphism Mitotic index 
Legend: 
 
IRSCyt ≤ 100 
 
IRSCyt > 101 
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3.23. Association of MT nuclear staining with clinicopathological parameters 
 
 The presence of MT staining in the nucleus was examined with the various clinicopathological 
parameters shown (Table 17).  
Table 17. Correlation of Clinicopathological parameters with presence or absence of MT nuclear 
expression in invasive ductal breast cancer patients. 
 




Total no. of cases 22 (15.71 %) 118 (84.29 %) - 
Age (means, in years) 56 52.87 0.233 
Tumor size (means, in mm) 41.94  33.18 0.073 
Tumor size    
≤ 30 mm 6 53 
> 31 mm 11 39 
0.114 
 
Staging    
1 5 16 
2 14 76 
3 2 11 
0.654 
 
Histological grade    
Low  15 60 
High 6 52 
0.155 
 
DCIS association    
None 9 49 
Minimum 11 45 
Extensive 2 17 
0.627 
Bloomrichardson score    
3 – 5 3 10 
6, 7 7 38 
8, 9 4 44 
0.314 
Tubule formation    
Low (1) 2 6 
High (2 & 3) 12 86 
0.285 
 
Nuclear Pleomorphism    
Low (1 & 2) 11 49 
High (3) 3 43 
0.089 
 
Mitotic index    
Low ( 1 & 2) 11 51 
High (3) 3 41 0.146 
ER status    
negative 2 38 
positive 19 67 
0.020* 
 
PR status    
negative 8 60 
positive 13 45 
0.150 
 
Lymph node status    
Absent 14 66 
Present 8 40 
1.000 
 
Lymph node stage    
Low (1) 12 56 
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C-erbB2 status    
Negative 18 70 
Positive 4 35 0.208 
 % of PCNA staining    
≤ 50 % 13 68 
> 50 % 9 49 1.000 
  
 
 There was a significant association of MT nuclear staining with presence of ER in the cancer 
patients (p = 0.020) (Figure 50). The presence of MT nuclear staining did not have any significant 

















Figure 50. Bar chart showing MT nuclear expression in relation to ER status.   
 
  
 The IRS of MT nuclear staining was banded at 100 to differentiate between low (≤100) and 
high (>100) MT nuclear staining. Similarly, low and high MT nuclear staining were examined with the 
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Table 18. Correlation of Clinicopathological parameters with MT nuclear expression in invasive ductal 
breast cancer patients with IRS banded at 100. 
 
MT nuclear expression Variable 
≤ IRS100 > IRS100 
P value 
Total no. of cases 92 (65.71 %) 58 (34.29 %) - 
Age (means, in years) 53.32 53.46 0.942 
Tumor size (means, in mm) 35.77 32.36 0.363 
Tumor size    
≤ 30 mm 33 26 
> 31 mm 37 13 0.071 
Staging    
1 15 6 
2 57 33 
3 9 4 
0.744 
Histological grade    
1 11 3 
2 43 18 
3 34 24 
0.229 
DCIS association    
None 39 19 
Minimum 37 19 
Extensive 12 7 
0.948 
Bloomrichardson’s score    
3-5 10 3 
6, 7 31 14 
8, 9 26 22 
0.186 
Tubule formation    
Low (1) 8 0 
High (2 & 3) 59 39 0.025* 
Nuclear Pleimorphism    
1 5 2 
2 37 16 
3 25 21 
0.253 
Pleimorphism (banded)    
Low (1 & 2) 42 18 
High (3) 25 21 0.109 
Mitotic index    
1 20 8 
2 22 12 
3 25 19 
0.445 
Mitotic index (Banded)    
Low (1 & 2) 42 20 
High (3) 25 19 0.308 
ER status    
negative 19 21 
positive 63 23 0.009* 
PR status    
negative 40 28 
positive 42 16 0.135 
Lymph node status    
Absent 50 30 
Present 34 14 0.337 
Lymph node stage    
Low (1) 44 23 
High (2 & 3) 44 24 1.000 
C-erbB2 status    
Negative 58 30 
Positive 26 13 1.000 
 % of PCNA staining    
≤ 50 60 21 
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 Higher MT nuclear staining was found to be significantly associated with higher tubule 
formation (p = 0.025) and presence of ER (p = 0.009) (Figure 51). The IRS of MT nuclear staining was 
examined with PCNA staining using Fisher’s exact test (refer to Table 18). MT nuclear staining was 
found to have a significant positive association with the percentage of PCNA staining (p = 0.029).  








































Figure 51. Bar charts of clinicopathological parameters with respect to MT staining banded at 
IRSNu100. Higher MT nucleus staining was found to be present in cases with (A) higher tubules 
formation; (B) negative ER status and (C) higher percentage of PCNA staining.  
   
  
Tubule formation ER status
Legend: 
 
IRSNu ≤ 100 
 
IRSNu > 101 
PCNA immunostaining ( %) 
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An example of breast cancer tissue with more than 50 % positive PCNA immunostaining is 
shown in Figure 52. 
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It is also noteworthy that MT was found to be absent in the nuclei of cells that were undergoing 
abnormal mitosis (Figure 53). In the case of abnormal mitosis, the cancer cells possess abnormal 




Figure 53. MT staining was predominantly absent in the nucleus of cells undergoing abnormal mitosis, 
indicated by green arrows.
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4.1. General discussion 
MTs have been implicated as oncogenic proteins, promoting cell proliferation in several types 
of cancers, thereby enhancing breast cancer progression (Hishikawa et al. 1999; Jayasurya et al. 2000; 
McCluggage et al. 1998; Tan et al. 1999). Clinicopathological studies have documented a relationship 
between higher aggressiveness and poorer prognosis of breast cancer with increased MT protein 
expression (Jin, et al. 2002; Oyama, et al. 1996; Sens, et al. 2001). Several studies have previously 
shown an association of expression of MT with higher tumour grade and increased nuclear 
pleomorphism (Haerslev et al. 1995). MT staining in breast cancer was also found to have a 
relationship with estrogen receptors and progesterone receptors. Previous findings from work done in 
this laboratory show that increased MT expression is related to higher histological grade and poorer 
prognosis of the cancer (Jin, et al. 2002). Expression of several biomarkers have also been examined in 
relation to the expression of MT. Several groups have found significant relationship between the 
expression of MT with other markers such as steroid receptor status, stromelysin-1, cathepsin, RCAS1, 
Ki67 (Ioachim et al. 2003; Ioachim 1999; Oyama, et al. 1996; Popiela et al. 2006). However, there is 
still a paucity of information with regard to the role of MT isoforms in tumorigenesis. Although down-
regulation of MT by anti-sense oligonucleotides in breast cancer cells have revealed the induction of 
growth arrest and apoptosis (Abdel-Mageed and Agrawal 1997; Jin, et al. 2002), the exact mechanism 
by which MT-2A affects cancer progression in breast cancer has not been well elucidated. The MCF-7 
breast cancer cell line with low invasive properties and ER and PR positive status was chosen for this 
current study where differential regulation of MT-2A was shown to have an impact on cell proliferation 
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Production of MT-2A antibodies using monoclonal technology have failed to produce MT-2A 
specific antibodies as the antibody was found to recognise other MT isoforms. This has resulted in the 
use of a general MT antibody in the examination of the MT expression in breast cancer tissue. Invasive 
ductal breast cancer was chosen for this study as this form of cancer is the most common type of breast 
cancer. To verify the phenomenon observed in the in vitro studies, analysis of MT expression in breast 
cancer TMA was conducted to find the association of MT staining with the degree of cell proliferation, 
metastasis and various clinicopathological parameters in breast cancer tissues.  
Furthermore, through cloning of the MT-2A gene for overexpressing in breast cancer cell lines, 
a naturally occurring deletion mutant, MT2A’ was detected. As a result of amplification of the MT-2A 
gene by PCR from the cDNA of MDA-MB-231 invasive breast cancer cell line, a mutant devoid of 8 
amino acids in the amino-terminal (N-terminal) of the protein was found. The 8 amino acids consisting 
of 2 cysteine residues are postulated to have an effect on the metal binding sites of the MT-2A’. 
Reconstruction of the structure of MT-2A and MT-2A’ using the Pymol software showed that absence 
of the 8 amino acids affected two metal ion binding sites at the N-terminus which could influence the 
folding conformation of MT-2A’ at the N-terminal. The deletion of the 8 amino acids, Ala – Gly – Asp 
– Ser – Cys – Thr – Cys - Ala, may even render the N-terminal of the MT-2A’ functionless.  
 
4.2. MT-2A and cell proliferation in breast cancer cells 
4.2.1. General overview of cell proliferation 
Carcinogenesis is a multi-step disease and cell proliferation has been the suggested to be one of 
the initiators of this disease. Uncontrolled cell proliferation is recognized as the core of cancer 
progression. Mitotic index, one of the early parameters used by pathologists to determine the 
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proliferation of the tumor has also been incorporated into the histological grading of the tumor. In 
cellular and in vivo assays, the uptake of thymidine which occurs during the S phase, is usually used to 
quantitate cell proliferation rate. One of the most commonly used assay is the 5-bromo-2’-deoxyuridine 
incorporation (BrdU) assay (Beresford et al. 2006). BrdU is a halogenated derivative of thymidine 
which identifies the cells that are undergoing DNA synthesis by incorporating into the newly 
synthesized DNA of the replicating cells during the S phase of the cell-cycle. Other in vitro assays such 
as alamarBlue and MTT assays have been developed to examine the number of viable cells that are 
able to reduce a colorimetric complex to elicit either a colometric change or a fluorescent signal (Kim 
et al. 2003; Ng et al. 2005). The alamarBlue assay utilizes a blue non-fluorescent dye resazurin which 
is converted to a pink and fluorescent dye resorufin in response to chemical reduction of growth 
medium as a result of cell growth. This assay enables continuous monitoring of the cell growth at 
various time-points. The absorbance signal is monitored at 570 nm and 600 nm as the reference 
wavelength. As for MTT assay, tetrazolium component of the dye is converted to a formazan product 
by living cells to produce a maximum absorbance at 570 nm following solubilization. 
In clinical applications, there has been a surge in the discovery of biomarkers that assess cell 
proliferation in cancer tissues. These include nuclear antigens, cyclins and cyclin dependant kinases 
and argyrophilic nucleolar organizer regions (AgNOR) (Mori et al. 1999). Nuclear antigens which 
include Ki67 and PCNA are closely related with cell proliferation. Ki67 is expressed as a nuclear 
protein during cell-cycle progression in all phases except the sub-G1 phase. The intensity of Ki67 is 
only examined in the nucleus of the tumor cells. A high Ki67 index was found to be associated with 
tumor grade, mitotic index and S phase fraction in flow cytometry (van Diest et al. 2004). AgNORs are 
non-histone proteins that are connected to DNA that are actively transcribed into rRNA. The amount of 
AgNORs can be determined following silver staining of the tumor tissues. NORs will seggregate 
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during mitosis with the AgNOR counts being highest in the G2 or early G1 phase of the cell-cycle. 
AgNOR staining has been correlated to DNA ploidy, tumor grade, S-phase fractions in flow cytometry 
(Beresford, et al. 2006).  
On the contrary, apoptotic index can also be determined using biomarkers such as cytokeratin, 
Bax or terminal deoxynucleotidyl transferase-mediated-biotin nick end labeling (TUNEL) (Linder et al. 
2004; Sirvent et al. 2004). 
 
4.2.2. Role of MT-2A in cell proliferation 
4.2.2.1. In vitro studies 
This present study shows a significant reduction in the number of cells with an obvious G1-
phase cell cycle arrest when the breast cancer cells were treated with MT-2A siRNA. In the growth 
curve analysis, there was a significant decrease in the proliferation of siMT2A_1 and siMT2A_2 
treated cells as compared to siNegative when examined using two-way ANOVA analysis. There was no 
difference in proliferation between siMT2A_1 and siMT2A_2 treated cells. In the proliferation assay 
using MTS at 72 h post siRNA transfection, there was a significant decrease in the number of viable 
cells for both siMT2A_1 and siMT2A_2 treated with siNegative as a control. Similarly, there was no 
significant difference between siMT2A_1 and siMT2A_2 treated cells. There was a significant increase 
in the number of cells in the G1 phase of the MT-2A suppressed cells as compared to the siNegative 
treated cells. On the other hand, breast cancer cells increased proliferation when the cells 
overexpressed MT-2A, as evidenced by a reduction in the number of cells in the G1 phase and 
enhanced G2/M phase. Cells treated with Mt2V and/or Mt2V’ had a significant decrease in the 
percentage of cells in the G1 phase and significant amplification in the percentage of cells in the G2/M 
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phases when compared to EV treated cells. There was no differences in cell cycle profile between the 
Mt2V and Mt2V’ treated cells. This indicates that the MT-2A’ deletion mutant has an equally important 
role in cell cycle progression.  
In order to better understand the molecular mechanism(s) that may result in a decrease in cell 
proliferation and a block at the G1 stage of the cell cycle, expression analysis of cell cycle related 
genes were conducted using the commercially available Superarray kit. From the gene expression study 
using siMT-2A treated cells with siNegative as a control, cdc25A was found to be significantly down-
regulated while ATM, UBE1 and CCNG1 were found to be significantly upregulated at mRNA levels. 
Gene expression analysis using Cell cycle Superarray on the MT-2A overexpressing cells reinforced 
this observation as corresponding significant down-regulations of the ATM and CCNG1 genes were 
observed. Western blotting analysis also verified the differential regulation of ATM and cdc25A at 
protein levels in siMT-2A treated cells. Both genes encode proteins belonging to the ATM-Chk2-
cdc25A pathway which is known to influence the cell cycle.  
In the early stages of checkpoint activation, DNA damage sensors are known to relay 
information to a family of phosphoinositide 3-kinase related kinases (PIKKs) (Tibbetts et al. 2000) 
which are essentially serine/threonine kinases. These proteins play essential roles in relaying early 
signals in cell cycle checkpoints. The two PIKK family members in mammalian cells are ATM and 
ATR (ATM and Rad3-related). One of the relevant substrate in response to DNA damage for both of 
these kinases is p53 (Banin et al. 1998; Canman and Kastan 1998; Tibbetts et al. 1999). In mammalian 
cells, ATM controls cell cycle arrest in G1 and G2 phases in response to DNA damage (Elledge 1996). 
In p53-dependant G1 checkpoint, phosphorylation of Ser 15 residue on p53 by ATM will eventually 
lead to its accumulation by the release of p53 from its substrate (Dumaz and Meek 1999; Freedman and 
Levine 1999). Activation of p53 will induce transcription of cyclin dependent kinase (cdk) inhibitor 
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p21 CIP1/WAF1, leading to a G1 growth arrest (Deng et al. 1995). Since ATM was found to be- up-
regulated in MT-2A suppressed cells in our present study, MT-2A could possibly act upstream of ATM 
and its substrate p53 to induce G1 growth arrest. This is supported by a previous study where MT-2A 
was reported to bind to p53 and activate its downstream target gene, p21 (Ostrakhovitch, et al. 2006).   
However, the results from the present study also indicate that MT-2A can mediate p53-
independant G1 growth arrest via ATM which regulates cdc25a phosphorylation. This is demonstrated 
by an increase in ATM mRNA levels with a corresponding increase in ATM protein levels in siMT2A 
cells in this study. Moreover, siMT2A cells showed a decrease in cdc25a levels at both mRNA and 
protein levels. In human cells, three cdc25 members, viz., cdc25A, cdc25B and cdc25C have been 
characterized (Galaktionov and Beach 1991; Nagata et al. 1991; Sadhu et al. 1990). Cdc25B and 
cdc25C mainly regulates the transition from G2 to mitosis phase through cdk1 dephosphorylation 
(Gabrielli et al. 1996; Lammer et al. 1998) whereas cdc25A is required for progression from G1 to S 
phase by phosphorylation of its primary substrate cdk2, which is essential for the DNA replication 
process (Hoffmann et al. 1994; Jinno et al. 1994). The abundance of cdc25a is regulated by the 
ubiquitin-proteasome degradation pathway in response to inhibition of DNA replication or induction of 
DNA damage (Mailand et al. 2000; Molinari et al. 1999) which is activated by ATM and ataxia 
telangiectasia-mutated and Rad3-related (ATR) proteins. ATM activates its downstream effector Chk2 
by phosphorylation at Thr68 (Ahn et al. 2000) while ATR phosphorylate Chk1 at Ser317 and Ser345 
(Zhao et al, Mol Cell Biol, 2001).  
It is posited that down-regulation of MT-2A may lead to increased expression of ATM which in 
turn regulate phosphorylation of Checkpoint homolog 2 (Chk2) and trigger the ubiquitin-proteasome 
degradation pathway for Cdc25A, thereby leading to p53 independent G1 arrest (Figure 54).  
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Figure 54. Schematic diagram of postulated pathways showing how inhibition of MT-2A expression 
affects cell proliferation. 
The Superarray data also revealed a significant up-regulation of Cyclin G1 in siMT2A cells and 
a concomitant down-regulation in MT-2A overexpressing cells. Cyclin G1 was found to be a direct 
target of p53 (Okamoto and Beach 1994) with two distinct p53 binding site (Zauberman et al. 1995). 
The up-regulation of cyclin G1 was found to be in sync with p53 via DNA damage signals (Okamoto 
and Beach 1994; Reimer et al. 1999; Zauberman, et al. 1995). Cyclin G1 can also function independent 
of p53 tumour suppressor gene as cells void of p53 were found to possess cyclin G1. (Horne et al. 1996; 
Morita et al. 1996). Cyclin G1 was found to recruit active phosphatase 2A holoenzymes to modulate 
the phosphorylation of Mdm2 (Okamoto et al. 2002). The main negative regulator of p53 is Mdm2, 
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which itself is also a target of p53 (Michael and Oren 2002). Phosphorylated Mdm2 will then inhibit 
p53, thereby regulating the levels of both Mdm2 and p53. High levels of Cyclin G1 was shown to 
mediated growth arrest independent of p53 with partial dependence on pRb and it was found to be 
down-regulated by Mdm2 via proteasome mediated degradation (Zhao et al. 2003). Furthermore, the 
regulation of cyclin G1 by p53 was found to be mediated by ATM (Ohtsuka et al. 2004). Hence it is 
postulated that MT may play a role in the regulation of ATM, thus resulting in cyclin G1 deregulation 
dependent or independent of p53 mediation, resulting in growth arrest and apoptosis. 
Furthermore, results from the Superarray study found upregulation for both Cyclin C and its 
adaptor protein, cdk8 in siMT2A cells. Cyclin C is known to bind and stabilized by CDK8 (Barette et 
al. 2001; Tassan et al. 1995). This CCNC/Cdk 8 complex has been found to phosphorylate the C-
terminal of RNA polymerase II (Rickert et al. 1996). Cdk8 in the CCNC/Cdk8 complex can regulate 
transcription by phosphorylating cyclin H in the Cyclin H/cdk7 of the general transcription initiation 
factor IIH (TFIIH), hence decreasing cell growth (Akoulitchev et al. 2000). It is proposed that MT-2A 
may act as a negative regulator upstream of Cyclin C and cdk8 as down-regulation of MT-2A leads to 
an increase in Cyclin C and Cdk8 levels and thus a decrease in cell proliferation as observed in 
siMT2A cells.  
The ubiquitin degradation pathway for the decay of cdc25A and p53 was shown to be activated 
as Superarray analysis showed upregulation of ubiquitin-activating enzyme E1 (UBE1) in siMT2A 
cells. Ubiquitination is a process that regulates the degradation of short-lived proteins in mediation of 
numerous processes such as cell cycle progression and transcriptional regulation. Covalent conjugation 
of ubiquitin to target proteins directs them for degradation. Ubiquitin pathway consists of three steps as 
reviewed by Ciechanover (Ciechanover 1994). The few steps are briefly discussed below. The first step 
involves the activation of the Gly residue in the C terminal of ubiquitin by UBE1 in an ATP dependant 
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fashion, leading to formation of an ubiquitin adenylate intermediate which leads to the binding of 
ubiquitin to the Cys residue of UBE1. The second step includes transfer of the activated ubiquitin to the 
cys residue of an ubiquitin carrier protein, UBE2. In the last step, the ubiquitin is linked to Lys residue 
of the substrate protein by ubiquitin-protein ligase, UBE3. Proteins that are ligated with polyubiquitin 
chains are usually degraded by the 26S proteasome (Coux et al. 1996) with the expenditure of ATP. 
There is usually a single polypeptide UBE1 but many species of E2 and multiple families of E3 
(Hershko and Ciechanover 1998). Activation of UBE1 in siMT2A cells is probably responsible for the 
rapid degradation of the various genes involved in cell-cycle progression such as cdc25a. Although a 
member of the ubiquitin-ligase E3, HERC5, was found to be upregulated in siMT2A cells and down-
regulated in MT-2A overexpressing cells, this probably did not affect the degradation of targeted genes. 
This deregulation of HERC5 is postulated to be a result of stress induced feedback mechanism due to 
the down-regulation of MT-2A. HERC5 has been found to be upregulated in inflammatory conditions 
and presence of LPS (Kroismayr et al. 2004), by which MT is known to exert a protectative action. 
Lastly, a slight increase in the sub-G1 phase was observed in siMT2A treated cells. The 
Superarray results show that Bax gene expression was significantly up-regulated in siMT2A cells, 
indicating a possible relationship between MT and the bcl-2 family. BAX belongs to the bcl-2 family 
protein family. It can form homodimers or heterodimer with BCL-2 and function as an apoptosis 
activator (Chipuk et al. 2008). The ratio of Bcl-2 to Bax determines survival or death following an 
apoptotic stimulus (Oltvai, et al. 1993; Zhang et al. 2008). Upon death stimulus, Bax localizes to the 
mitochondria (Knudson and Brown 2008; Wolter et al. 1997), inducing release of cytochrome c and 
activating the caspase cascade and ultimately result in to cell death (Heimlich et al. 2004; Rosse et al. 
1998). Studies have shown that p53 tumour suppressor gene is a modulator of bcl-2 and bax expression 
(Deng and Wu 2000; Miyashita et al. 1994; Miyashita and Reed 1995). It has also been demonstrated 
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that p53 and MT regulates the expression of each other (Meplan, et al. 2000; Ostrakhovitch, et al. 
2007). This intimate relationship between p53 and MT regulation may govern the expression of Bax, 
thus determining a cell’s destiny for survival or death. 
 
4.2.2.2. Clinicopathological associations of MT with cell proliferation 
The expression of MT in breast cancer tissues with respect to the various clinicopathological 
parameters was examined. As MT-2A is the most abundant MT isoform in human breast tissues, the 
effects of MT staining observed is assumed to consist mainly of MT-2A staining. The intensity of MT 
staining was found to be related to mitotic index, ER status and PCNA staining.  
This study has found an association between higher intensity of MT cytoplasmic staining with 
higher mitotic index. Mitotic index has been the first parameter used for measurement of cell 
proliferation in paraffin embedded tissue sections stained with haematoxylin and eosin by microscopy 
(van Diest, et al. 2004). This is determined by the number of mitotic bodies in a high power view field 
under light microscope. It has been found that a high mitotic index is associated with higher risk of 
cancer death and lower survival rate (Beresford, et al. 2006). There was a study which showed that the 
mitotic index is a better prognostic factor as compared to tumour size (Clayton 1991). The use of 
mitotic index as a proliferative marker had been questioned. This is due to the lack of consistency 
between different pathological laboratories and non-linear correlation of the number of mitosis with the 
rate of proliferation (van Diest et al. 1992; van Diest, et al. 2004). Irregardless of these criticisms, 
mitotic index remains as one of the more widely used and well-established method to assess cell 
proliferation in paraffin embbeded tissue sections. The data in this study indicates that MT is associated 
with mitosis in the tumour tissue and hence plays a role in cell proliferation in breast cancer.  
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MT nuclear staining was also found to be associated with ER status of the breast tissue. ER 
functions as a ligand dependant transcription factor to regulate the expression of breast cancer 
progression genes that govern cell survival, proliferation, metastasis and angiogenesis. The presence of 
ER has been shown to be an additional factor which promotes proliferation of cancer cells as estrogen 
is known to increase the growth of the ductal cells. Around 60 % of the breast tumors were found to 
contain ER (Harvey et al. 1999). The status of the hormonal receptors is also one of the important 
factors required in determining the choice of cancer therapy for the patient. The presence of ER in the 
breast tumour is an indication for possible administration of endocrine therapy. Despite so, a large 
percentage of the patients with ER positive tumors fail to respond to endocrine therapy (Sluyser 1992) 
and they eventually develop metastatic cancers which are also resistant to endocrine therapy (Dowsett 
1996). The status and level of ER was found to change with the progression of the disease (Allred et al. 
2004), and this may be the reason for the resistance. ER status is reversible by the regulation of various 
signalling molecules in the tumour (Lopez-Tarruella and Schiff 2007). The loss of ER in cancer cells is 
a possible indication that estrogen is no longer important in stimulating tumour growth, thus resulting 
in a more aggressive state of cancer that is resistant to endocrine therapy. In support of this theory, a 
higher decline in the mortility rate in patients with ER positive tumors were reported (Jatoi et al. 2007). 
The results in this study show that MT nuclear staining has a strong association with ER status, 
whereas high MT expression was related to absence of ER, which also indicates a higher aggressive 
form of tumour. This may indicate that MT is transported to the nucleus upon activation in more 
aggressive tumors to promote the growth of the cancer and protect the cancer cells from dying.  
The results also show that MT staining in the nucleus has a significant relationship with PCNA 
staining in breast cancer tissue. PCNA has been identified as one of the markers for proliferation as it is 
involved in DNA replication and repair, with its maximal activity in the S phase of the cell cycle. 
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PCNA is found to be the modulator for the switch between processive and translesional DNA synthesis 
(Haracska et al. 2004; Kannouche and Lehmann 2004). It has been found to interact with many 
proteins such as cyclin D, p21, cdk2, DNA ligase (Warbrick 2000) to regulate cell cycle progression 
and proliferation. PCNA was found to be inducible by p53 and the abundance of p53 also determines if 
PCNA will undergo DNA replication (absence of p53) or repairs (presence of p53), while low levels of 
PCNA will lead to apoptosis (Paunesku et al. 2001). In breast cancer, PCNA expression was found to 
be associated with shorter overall survival (Haerslev et al. 1996) (Biesterfeld et al. 1998) and disease 
free survival (Keshgegian and Cnaan 1995). The results demonstrated a strong association between 
higher percentage of PCNA staining with increased MT nuclear staining but not in higher MT 
cytoplasmic staining. This suggests that the expression of MT in the nucleus but not in the cytoplasm is 
potentially a proliferative marker for breast cancer and also reinforces the fact that cell proliferation is 
driven by the nuclear machinery. 
As cell proliferation is usually tightly regulated with differentiation, the study also indicates that 
MT has a close relationship with cellular differentiation. This was shown by the association of MT 
staining with the histological grade of breast cancer. Histological grade has been regarded as the 
estimation of the stage of differentiation of the tumour (Ignatiadis and Sotiriou 2008). This present 
study has found an association of higher level of MT expression with higher histological grade. 
Furthermore, MT expression also show strong associations with the different components that make up 
the histological grade; nuclear pleomorphism, mitotic index, degree of tubule formation and Bloom-
Richardson’s score. This result indicates that MT is a strong prognostic marker for breast cancer 
histological grade. The Bloom-Richardson’s system is most commonly used to determine histological 
grade. Grade 1 indicates that the tumour is well differentiated and grade 3 indicates a poorly 
differentiated tumour. It has been suggested that the nuclear component (nuclear pleomorphism and 
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mitotic index) is the most predictive for clinical outcome when combined with the modified Scarff-
Bloom-Richardson (MSBR) grading system (Le et al. 2003). Furthermore, histological grading has 
been reported to be an important factor in breast cancer treatment as the grade of the cancer was not 
found to increase with time (Roylance et al. 1999). This indicates that different tumour grades has 
different molecular origins and pathogenesis and therefore require customized treatment methods for 
the different histological stage. The data suggests that the expression of MT can be used as an aid in 
determining the type of cancer treatment to be administered. 
The clinicopathological data suggests that MT, with MT-2A being the bulk of the MT isoforms, 
plays an important role in the breast cancer proliferation and differentiation. As such, the expression of 
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4.3. MT-2A and breast cancer metastasis 
4.3.1. General overview of cancer metastasis 
Cancer metastasis involves the spreading of the malignant tumour cells from one organ to 
another. Breast cancer metastasis is the main cause of death in breast cancer patients, with the most 
common sites of breast cancer metastasis being the neighhouring organs such as lymph node, bone, 
lung, brain and liver (Chambers et al. 2002; Lu and Kang 2007; Steeg 2006). More than half of the 
breast cancers were found to develop secondary tumors in autopsy (Weigelt et al. 2005). Metastasis is a 
complicated process that involves detachment from the site of origin, migration of cancer cells, 
invasion through the basement membrane, intravastration into the lymphatic or vascular system, 
extravasation and colonization of the to target organ(s), leading to systemic metastasis. These processes 
involve intrinsic interactions with the microenvironment where the tumour resides. The orchestration of 
various genes involved in stromal-tumor interactions during metastasis controls the extent of spread of 
cancer. The risk of breast cancer metastasis have been found to have a positive association with the 
presence of lymph node metastasis, larger tumour size and tumors with higher histological grade 
(Gonzalez-Angulo et al. 2007; Rosen et al. 1989). Detection of lymph node metastasis in breast cancer 
patients has been an indicator for spread of cancer beyond its original site (Goldhirsch et al. 2001). The 
idea of sentinel lymph node examination has been a recent introduction to examine signs of metastasis 
in the lymph nodes first to receive lymphatic drainage from a tumour (Amaral et al. 2007). This 
concept has arisen due to the morbidity associated with dissection of axillary lymph nodes. The 
presence of axillary lymph node metastasis was found to be associated with a lower survival rates in 
breast cancer patients (Rivadeneira et al. 2000). The number of lymph nodes found to be involved has a 
negative relationship with the median survival of the patients (Rack et al. 2003).  
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There are found to be several markers that identify breast cancer metastasis. These include miR-
21 miRNA, Her2-neu, CXCR4, CCR7 (Cabioglu et al. 2005; Yan et al. 2008). These markers were 
found to be associated with lymph node metastasis and poorer prognosis in breast cancer.  
 
4.3.2. Role of MT-2A in cancer metastasis 
4.3.2.1. In vitro assay 
Treatment of siMT2A was shown to significantly increase cell adhesiveness to both collagen I 
and fibronectin matrix. Collagen and fibronectin are part of the non-proteoglycan matrix components 
that makes up the extracellular matrix (ECM). The results indicate that down-regulation of MT-2A in 
breast cancer cells may result in decreased adhesiveness to extracellular matrix (ECM). ECM contains 
interstitial matrix and basement membrane. The interstitial matrix is responsible for attaching the cells 
together by filling up the spaces between the cells while the basement membrane contains ECM 
molecules which bind the epithelial cells. The basement membrane is responsible for holding ductal 
epithelial cells in place in the breast, where rupture of the basement membrane triggers the switch from 
DCIS to invasive carcinoma. The data in this current study showed that MT-2A is responsible for 
promoting the decreased adhesiveness to the ECM, thus highlighting that MT-2A may be an oncogenic 
protein that positively regulates breast cancer metastasis.  
It is also demonstrated for the first time that down-regulation of MT-2A decreased the migratory 
ability of breast cancer cells, an important step in the metastasis of breast cancer. The data showed that 
down-regulation of MT-2A decreased migration of cells through the Transwell Chamber while 
overexpression of MT-2A enhanced cell migration. This further emphasizes MT-2A’s role as a 
metastasis promoting protein by enhancing cell migration following detachment from the ECM. It was 
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also observed that the MT-2A deletion mutant, MT-2A’ has a lower ability in promoting migration as 
compared to the native MT-2A. Hence it can be postulated that either the amino terminus or the number 
of metal ions that MT-2A carries is important in promoting cell migration. Although an invasion study 
was done, it was inconclusive as the control MCF cells which are known to be non-invasive did not 
invade into the matrigel. It is further shown that uPAR participates in this MT-2A mediated metastasis. 
In comparing gene expression of a subset of metastasis-related genes in MT-2A silenced cells with 
siNegative treated cells as a control, a significant down-regulation of PLAUR gene, which encodes for 
uPAR, and down-regulation of the MET gene was observed. 
The uPA system consists of the serine protease uPA, its glycolipid anchored receptor, uPAR and 
its two serpin inhibitors, plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-
2 (PAI-2). The uPA system has been shown to be implicated in various processes of cancer progression 
including tumorigenesis, cell proliferation, degradation of extracellular matrix, cell migration, cell 
adhesion, angiogenesis and intravasation (Dass et al. 2008; Estreicher et al. 1990; Hildenbrand and 
Schaaf 2009; Mazar 2008). When bound to its receptor, uPA is known to initiate the activation of 
metalloproteases (Dano et al. 2005; Ginestra et al. 1997; Le, et al. 2003) and convert plasmin to 
plasminogen (Ellis et al. 1991; Stillfried et al. 2007), hence playing an important role in metastasis and 
angiogenesis. There are significantly higher levels of uPA and uPAR in metastatic breast cancer cells as 
compared to non-metastatic breast cancer cells in vitro (Han et al. 2005; Ranson et al. 1998). In breast 
cancer tissues, overexpression of the members in the uPA system – uPA, PAI-1 and especially uPAR, 
was reportedly evident in malignant breast tumors as compared to normal or benign breast tissues 
(Jankun et al. 1993). Recent reports have shown that down-regulation of uPAR was sufficient to 
decrease the effects of cancer progression such as tumor invasion, growth and angiogenesis (Kunigal et 
al. 2007), indicating uPAR to be a primary modulator in the uPA system.  
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In this current study, MT-2A down-regulation led to a significant reduction of uPAR expression 
and also decreased the migratory ability of breast cancer cells. Although a significant level of PLAU 
was up-regulated, this could be an internal feedback mechanism by the cells to counter the effects of 
uPAR down-regulation. HGF encoded by MET has also been reported to induce increased expression 
of uPA and uPAR,  thereby regulating metastasis and angiogenesis in several cell types (Lee et al. 
2008; Moriyama et al. 1999). It is plausible that MT-2A may modulate the expression of uPAR 
receptors through HGF and thus play an important role in metastasis (Figure 55). 
 
Figure 55. Schematic diagram of postulated pathway showing how inhibition of MT-2A expression 
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4.3.2.2. Associations of MT-2A with lymph node metastasis in breast cancer patients 
The lymph node status of the patients has been used as a prognostic marker in the management 
of breast cancer. It was reported that patients with node-positive breast cancer have a worst prognosis 
as compared to node-negative cases (Dent 1996). The cancer was proposed to first spread to the 
axillary lymph nodes before to the other parts of the body via the lymphatic system (Halsted 1898). 
The involvement of lymphangiogenesis in the metastasis of breast cancer was recently reported by 
Cunnick and colleagues (Cunnick et al. 2008). The involvement of lymph node metastasis in breast 
cancer was shown to be related to a more aggressive phenotype (Jatoi et al. 1999). Furthermore, greater 
number of lymph nodes involved was also found to be a negative prognostic factor for neoadjuvant 
therapy (Botti et al. 1995; Kuerer et al. 1998). This data is the first to associate MT staining with lymph 
node status. It was shown that MT immunopositivity was found to be significantly correlated with a 
higher lymph node status. This suggests that MT may play an important role in the regulation of distant 
metastasis to other parts of the body. This further indicates the possibility of MT-2A as a biomarker in 
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5.1. Conclusions 
MT-2A appears to have a significant role in cell proliferation and metastasis in breast cancer as 
demonstrated by both in vitro and clinicopathological association studies. MT-2A expression was 
shown to increase cell proliferation in this study. The naturally occurring deletion mutant had the same 
effect on cell proliferation when compared with  native MT-2A protein. Superarray analysis indicated 
that MT-2A plausibly regulate cell proliferation via the ATM/Chk2/Cdc25a pathway. It is also possible 
that MT-2A may also regulate cell proliferation through Cyclin G1 and/or Cyclin C/Cdk8 complex. 
MT-2A could also protect breast cancer cells from cell death via regulation of Bax and/or Cyclin G1.  
In breast cancer tissues, an association of MT staining with higher degree of proliferation was 
shown by the relationship with mitotic index, ER status and PCNA staining. Specifically, expression of 
MT in the nucleus was found to be a significant phenomenon for breast cancers that has a more 
proliferative phenotype, ER-negative status and significant association with PCNA proliferation marker 
staining.   
In addition, MT-2A has been shown to be implicated in metastasis through adhesion and 
migration of the breast cancer cells. It is highly possible that these are made possible either by aiding 
the transfer of essential metal ions between the interacting partners or directly binding to the proteins in 
the postulated pathways. The detection of the naturally occurring deletion mutant, MT-2A’ with lesser 
binding sites for divalent metal ions seems to support the former hypothesis for the role of MT-2A in 
metastasis as the MT-2A’ was shown to have a lesser potency in metastasis. Furthermore, MT 
expression in the cytoplasm was found to be associated with higher lymph node status, indicating a 
relationship between MT with poorer patient prognosis and regional metastasis in breast cancer, 
validating the in vitro findings that MT-2A affects cell migration in breast cancer cells. 
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These results have verified the hypothesis in this study which is MT-2A plays important 






























Figure 56. Flow chart illustrating the role of MT-2A on breast cancer progression. 
 
One of the recent focuses in cancer therapeutic strategy is to develop molecular cancer 
therapeutics (Kuwano et al. 2003). To this end, MT-2A appears to be a promising target molecule for 
the molecular therapy of breast cancer.  
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5.2. Future studies 
The novel findings in this study will provide the groundwork for better understanding of breast 
cancer progression. This study has affirmed the role of MT in breast cancer proliferation and cell death 
from earlier studies and is the first study to show that MT-2A alone is sufficient to result in the 
fubnctional processes mentioned above. As this study has only examined a portion of the genes that are 
involved in MT-2A mediated cancer progression, it will be beneficial if a genome-wide study such as 
DNA microarray or proteomics analysis can be employed to identify more affected genes and hence 
possible interacting partners.  
Furthermore, it has been demonstrated for the first time that MT plays an important role in 
metastasis through cell adhesion and migration. This phenomenon was observed to be specific to MT-
2A alone. Additionally, MT expression in breast cancer tissues was found to have a positive association 
with lymph node status. Hence, it will be interesting to find out if MT-2A also affects the other 
components of metastasis such as invasion and angiogenesis in breast cancer. As production of MT-2A 
antibodies was found to be difficult to achieve, in-situ hybridization studies with MT-2A probes can be 
done on breast cancer tissues to analyse the expression of MT-2A to further assess the relationship of 
MT-2A in breast cancer.  
The MT silencing experiments have revealed an interesting phenomenon called “entosis”, a cell-
eat-cell phenomenon present in cells treated with either siMT2A or siMT1F but not in siNegative 
treated cells. Entosis is a non-apoptotic form of cell death which involves the internalization of one cell 
into another (Overholtzer et al. 2007). This exciting phenomenon may be exclusive to silencing of MT 
in breast cancer cells and hence open up a new avenue for further research on how the absence of MT 
triggers entosis. Moreover, the examination of related proteins such as cell-cell adhesion proteins 
consisting of cadherins can also be conducted in MT downregulated cells to further understand the 
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mechanism of entosis in breast cancer.  
In addition, animal models could also be developed to assess the functions of MT-2A in breast 
cancer with the use of a knock-out model or a model with inhibited MT-2A expression. An animal 
model is advantageous as it is able to portray the involvement of the molecule at a systemic level rather 
than at a cellular level. This is important as breast cancer is a heterogenous disease that comprises of 
many stages and may involve metastasis through the body. Furthermore, siMT2A silenced cells can 
also be introduced into an animal model to examine the motility of these cells and effect of such cells 
on distant metastasis. Interaction of MT-2A silenced cells with the extracellular matrix, vascular system 
and lymphatics can also be analyzed to have a broader picture of how MT-2A regulates breast 
carcinogenesis. 
MT has been previously reported to be a protective agent against alkylating compounds such as 
antineoplastic drugs used in breast cancer. It was also observed that several cancers with MT 
overexpression developed chemoresistance, thereby hindering the efficacy of chemotherapy. Thus, it 
will be valuable to examine the concept of inhibiting MT expression to enhance the efficacy of 
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